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Introduction
8 Chapter 1
i l  Æ  ur body is well protected against foreign invaders, also called 
pathogens, such as bacteria, viruses and fungi by a complex 
defense mechanism, the im m une system. The imm une system is 
equipped to recognize these pathogens and eliminate them , for example  
via pathogen-specific antibodies or T cells. However, the imm une system 
does not always work as it should be. In case of autoimmunity the  
imm une system has lost its tolerance against self structures and instead 
starts to attack cells, tissues and organs in the body by the devastating 
action of autoantibodies or T cells. Systemic Lupus Erythematosus 
(SLE) is a typical systemic autoim m une disease in which autoantibodies  
can lead to inflammation and damage in multiple organs and tissues, 
including the kidney.
Sy s t e m k  Lupus Er y t h e m a t o s u s
SLE is a prototype immune complex  
(type III) mediated systemic 
autoim m une disease. Autoantibodies  
are mainly targeted to nuclear con­
stituents (DNA, RNA, histones, 
nucleosomes, spliceosomes) from  
which the nucleosome is considered to 
be the main autoantigen1. These auto ­
antibodies bind to their autoantigen  
and deposit on basal membranes in 
various tissues and organs2, 3. Tissues 
and organs in the body that can be 
affected by these immune complex- 
mediated inflam m atory reactions 
include the nervous system, skin, 
joints, heart, lungs, blood vessels and 
the kidney. Clinical symptoms asso­
ciated with SLE are described in the  
criteria of the American College of 
Rheumatology (ACR criteria; table 1) 
that are used to classify SLE4, 5.
N u c l e o s o m e s
The nucleosome, is the basal structure  
of chromatin organizing more than
2 meters of DNA in the nucleus of a 
cell. The nucleosome is formed by 
an octam er of histones, containing 
tw o  copies of histone H2A, H2B, H3 
and H4. Around these core histones 
approximately 146 base pairs of DNA 
are wrapped. Histone H1 is bound to  
the DNA outside the nucleosome core 
(figure 1).
Antibodies against the nucleosome  
can be divided into three  groups: 
anti-DNA antibodies, anti-histone  
antibodies and anti-nucleosome anti­
bodies. Anti-DNA antibodies, as the 
name indicates, recognize exclusively 
DNA. The production of anti-dsDNA  
autoantibodies has long been con­
sidered serologically as the ''gold 
standard'' for SLE since they were  
found in nearly all SLE patients7. 
Anti-histone antibodies recognize in 
particular histones and are especially 
found in drug-induced lupus (DIL)8- 9. 
Anti-nucleosome antibodies recognize 
a conformational epitope comprised  
of histones and DNA10. Complexes
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Table 1. The updated revised criteria for classification of systemic lupus erythematosus by the American 
College of Rheumatology4, 5.
Criterion Definition
Malar Rash Fixed erythema, flat or raised, over the malar eminences, tending to 
spare the nasolabial folds
Discoid rash Erythematosus raised patches with adherent keratotic scaling and fol­
licular plugging
Photosensitivity Skin rash as a result of unusual reaction to sunlight
Oral ulcers Oral or nasopharyngeal ulceration
Arthritis Nonerosive arthritis involving 2 or more peripheral joints
Serositis a) Pleuritis
b) Pericarditis
Renal disorder 
Neurologic disorder 
Hematologic disorder
Immunologic disorder
a) Persistent proteinuria, or
b) Cellular casts
a) Seizures, or
b) Psychosis
a) Hemolytic anemia, or
b) Leukopenia, or
c) Lyphopenia, or
d) Thrombocytopenia
a) An abnormal titer of antibody to native DNA, or
b) Presence of antibody to Sm nuclear antigen, or
c) Positive finding of antiphospholipid antibodies
Antinuclear antibody An abnormal titer of antinuclear antibody
of nucleosomes and autoantibodies  
deposit on glomerular basement m em ­
branes (GBM) in the kidney due to an 
interaction of the negatively charged 
heparan sulfate in the GBM with the 
positively charged histones, leading 
to lupus nephritis11. Notably, in par­
ticular N-terminal histone tails can 
be altered by histone modifications, 
thus affecting structure, charge and 
immunogenicity of the nucleosome.
HiSTONE MODiFiCATiONS
Histones can be modified, especially
at the N-terminal tails. There are 8 
distinct types of possible histone 
modifications (table 2). These histone 
modifications play an im portant role 
in the regulation of transcriptional 
activation and silencing of chromatin  
domains. Many identified histone 
modifications have been linked to 
accomplish specific functions, either  
by the disruption of internucleosomal 
contact or recruitment of non-histone  
proteins12. However, a histone m odifi­
cation is not a static state but a part  
of a dynamic process that can change 
very rapidly as a result of the many 
histone modifying enzymes.
APOPTOSIS
Apoptosis is defined as the process of 
programmed cell death that can be 
induced by several intrinsic (exposure  
to irradiation, toxic chemicals or 
viral infections) and extrinsic factors  
(binding of soluble or cell-bound 
death inducing ligands to cell surface  
receptors). During apoptosis chromatin  
is degraded in mono- and oligo- 
nucleosomes by caspase-activated 
endonucleases15. Also during apop-  
tosis, the nucleosomes and other  
nuclear proteins are translocated into 
apoptotic blebs at the cell surface16- 17. 
These blebs segregate from the dying 
cell and under normal circumstances  
are removed by macrophages18.
We hypothesize that insufficient 
removal of apoptotic cells and blebs, 
and/or an deregulation of apoptosis 
in SLE contributes to the development  
of an autoim m une response against 
nuclear antigens10- 15. Released
apoptotic chromatin, including 
nucleosomes, can be found in tissues 
and plasma of SLE patients19, 20. In par­
ticular, apoptosis-induced chromatin  
modifications may contribute to the  
developm ent of autoim m unity  in SLE 
as outlined below.
HiSTONE MODiFiCATiONS iN SLE
So far, a very limited number of 
histone modifications have been linked 
to apoptosis or associated with SLE. 
Apoptosis-induced phosphorylation  
of autoantigens, like U1-70K and 
histone H3 are targets for lupus auto ­
antibodies21-23. Hypomethylation of 
DNA is another described modifi­
cation involved in the autoimmune  
response of lupus24. In addition, 
in lupus mice antibodies against 
ubiquitinated histone H2A25, 26 and 
transglutaminated histone H2B27 have 
been detected. The phosphorylation  
of histone H2B by mammalian sterile 
kinase 20 is considered as a specific
Figure 1. The nucleosome.
Double stranded DNA (grey) is wrapped around the core histones H2A, H2B, H3 and H4, two copies of each) with the 
linker histone H1 attached on the outside of the nucleosome. The N-terminal tails are protruding from the core particle6.
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hallmark for apoptosis, but is however  
not linked to SLE ye t28. We hypothesize 
that apoptosis-induced histone m odi­
fications make the nucleosome more  
immunogenic and that released apop- 
totically modified nucleosomes elicit 
an autoim m une response (figure 2).
Apoptotically-modified, therefore, 
immunogenic nucleosomes may lead 
to maturation of the most potent  
antigen presenting cells, the dendritic  
cell (DC). Simultaneously, nucleosomes 
that are modified during apoptosis are 
taken up by the DC and presented to 
histone-specific autoreactive T helper 
cells. When these T cells become acti­
vated by the DC, they activate B cells 
to d ifferentiate  to plasma cells and 
start producing anti-nucleosome, anti- 
histone and anti-DNA autoantibodies. 
The produced antibodies will bind to 
circulating nucleosomes and deposit 
on the GBM and other basement m em ­
branes, causing an inflammation.
The aim of this thesis was to identify  
apoptosis-induced chromatin modi­
fications that could drive the  
autoim m une response in SLE, leading 
to the formation of autoantibodies.
There has been a long-standing debate  
on cross-reactivity of anti-chromatin  
antibodies with several glomerular  
targets. Recent findings have lead 
to new perspectives on glomerular  
targets of anti-chromatin antibodies in 
SLE, which are reviewed and discussed 
in Chapter 2.
To discover apoptosis-induced chro­
matin modifications that could be 
the initiating antigen in SLE, we have 
generated new monoclonal anti­
bodies by using standard fusion 
techniques of SP203 myeloma cells 
with spleen cells from lupus mice to
SCOPE OF THiS THESiS
Table 2. Histone modifications and their identified functions 12, 14
H isto n e  R e sid u e  Fu n ctio n
M o d ific a tio n
Acetylation Lysine Transcription
Citrulination Arginine& Transcription- Repair
Isomerization Proline Transcription
Methylation Lysine*, Arginine# Transcription- Repair, Condensation, Replication, 
Apoptosis
Phosphorylation Serine, Threonine Transcription, Repair, Condensation, Apoptosis
Poly(ADP-ribosyl)ation Glutamate Transcription
Sumoylation Lysine Transcription
Transglutamination Lysine, Glutamine Apoptosis
Ubiquinitation Lysine Transcription, Repair
& Arginines can be enzymatically converted to citrulline
* Lysines can be mono-, di- or trimethylated
# Arginines can be monomehtylated or dimethylated in a symmetric or asymmetric way
12 C h apter 1
Figure 2. Schematic representation on the hypothesis of the development of systemic lupus erythematosus29.
generate hybridomas. By selecting 
the produced antibodies for a higher 
reactivity with apoptotic nucleosomes 
compared to non-apoptotic nucleo­
somes we aimed to select specifically 
antibodies recognizing apoptosis- 
induced chromatin modifications. This 
approach is described in Chapter 3. 
These antibodies are fur ther  selected 
for their specific reactivity with  
apoptotic cells and chromatin and 
fu r ther  characterized by analyzing 
their reactivity with (un)modified  
subnucleosomal components and 
complexes to determ ine their altered  
epitope within the nucleosome.
In addition to the developm ent of a 
new panel of monoclonal antibodies 
specific for apoptotic chromatin, we  
have also analyzed existing lupus- 
derived anti-histone autoantibodies, 
which previously have been selected
on non-apoptotic chromatin, for their  
preference to bind to apoptotic chro­
matin compared to normal chromatin. 
The epitopes of these antibodies were  
fu r ther  characterized as described in 
Chapter 4 and 5. The pathogenicity  
of the modified epitope of anti-  
histone antibody KM-2 described in 
Chapter 4 has been tested by injecting 
peptides containing the apoptosis- 
induced modification in mice. In 
control groups the corresponding non­
modified peptides were administered. 
Subsequently, disease progression 
was monitored. In addition, the effect  
of (modified) histone peptides and 
nucleosomes on DC maturation and 
DC-mediated T cell activation was 
tested. Reactivity of lupus-derived  
plasma was determined with histone 
peptides containing defined apop-  
tosis-induced modifications and the  
corresponding non-modified control
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peptides (Chapter 4 and 5). In Chapter  
5 the epitope of anti-histone antibody  
LG11-2, which was described pre­
viously, was further examined for the 
presence of apoptosis-induced histone 
modifications with the use of peptide  
ELISAs. The m om ent this modifications  
arises a fter  induction of apoptosis and 
the cellular localization were investi­
gated with the use of immune blotting  
and immunofluorescence staining. 
Lupus-derived plasma was also 
analyzed for reactivity with this apop-  
tosis-induced histone modification.
Chapter 6 describes the characteri­
zation of one of the newly generated  
antibodies that was selected on 
apoptotic nucleosomes. Random 
peptide phage display, peptide ELISAs, 
western blot analysis and im m uno­
fluorescence staining w ere  used to 
discover its epitope with possible 
apoptosis-induced modifications. This 
reactivity with this modified epitope  
was verified by blocking the histone 
modifying enzyme responsible for this 
modification using siRNA transfection. 
The reactivity of SLE-derived plasma 
was tested with the modified and non­
modified histone peptides. SLE plasma 
and kidney sections were also ana­
lyzed for the presence of this modified  
epitope within respectively the circu­
lation and glomerular depositions.
We are just beginning to understand  
the role of histone modifications and 
especially the role in apoptosis. Only 
recently, several groups, including 
ours, have discovered apoptosis-asso- 
ciated histone modifications. Finally, 
the results of the studies in this thesis 
are summarized and future perspec­
tives are discussed in Chapter 7.
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c :^ ^ ^ y s t e m ic  lupus e ry them a tosus  (SLE) is an a u to im m u n e  
disease characterized by a u to an tib od ie s  d irec ted  against 
va rious nuc lea r au toan tigens, p a rticu la rly  against th e  various 
com ponen ts  o f ch ro m a tin  such as doub le -s tranded  (ds) DNA, 
h istones, nucleosom es and rib o nu c le o p ro te in s . Lupus neph ritis  
(LN), a severe clin ica l m an ifes ta tion  o f SLE, is in general associated 
w ith  high tite rs  o f a n ti-n u c le a r a n tibod ies  especia lly  against 
ch ro m a tin , and w ith  im m u n o g lo b u lin  (Ig) and co m p lem en t 
deposits  in the  g lom eru lus .
Historically, the formation of anti­
bodies against dsDNA has been 
considered the serologic hallmark of 
SLE1, and anti-dsDNA antibodies are 
found in the majority of SLE patients2. 
In recent years, it has become clear 
that the nucleosome is the driving 
autoantigen in SLE3, and some inves­
tigators claim that the presence of 
anti-nucleosome antibodies could 
serve as a better marker for SLE than 
anti-dsDNA antibodies, since the  
form er are present in up to 90% of 
lupus patients4- 5. In SLE patients and 
in lupus-prone mice, nucleosomes can 
be found in the circulation; they are 
released from apoptotic cells and are 
present as a result of either disturbed 
apoptosis or a defective mechanism  
for clearing of apoptotic cells3.
Chromatin is basically defined as the  
entire complex of compacted DNA and 
associated proteins. The nucleosome  
is the fundam ental unit of chromatin. 
The core nucleosome particle con­
sists of 146 bp of dsDNA, wrapped  
twice around a histone octam er (2 
copies of each of the core histones 
H2A, H2B, H3, and H4)6. Antibodies  
against epitopes on the nucleosome, 
called nucleosome-specific antibodies,
have no or very low reactivity against 
individual histones or naked dsDNA. 
The formation of nucleosome-specific  
antibodies precedes the appearance  
of anti-dsDNA and anti-histone anti­
bodies as a result of epitope spreading. 
Anti-dsDNA and anti-histone anti­
bodies bind to dsDNA and histones, 
respectively, but also to nucleosomes7.
A serious topic of debate for several 
decades involves the pathogenicity, 
and especially the nephritogenicity, 
of anti-dsDNA antibodies. DNA itself 
is not immunogenic, and im m uni­
zation of mice with naked dsDNA 
leads to rapid removal, mainly through  
the liver. Nevertheless, anti-dsDNA  
antibody levels often show a high 
correlation with disease activity, 
especially in lupus nephritis, and elu­
cidating their pathogenic properties is 
thus of great interest. Therefore, the 
targets of anti-dsDNA antibodies have 
been intensively studied to gain clues 
to mechanisms that could explain the 
pathogenicity of anti-dsDNA anti­
bodies in SLE.
With  regard to the ir role in the 
developm ent of lupus nephritis, 
many investigators postulate that
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Table 1. Characteristics of reported cross-reactive epitopes for anti-double-stranded DNA antibodies*
I t • Overall charge
Cross-reactive Localization (negative/
.. point , ,epito p e positive amino acids)
Actinin- a4 Intracellular (podocytes, 
mesangial cells)
5.3 Negative (150/109)
a-enolase Intracellular 7.0 Neutral (55/55)
Extracellular domain (TECs) 4.1 Negative (2/4)
Type IV collagen# Extracellular matrix (GBM) 7.7 Positive (29/20)
Elongation factor 2 Intracellular (all cells) 6.4 Negative (114/109)
Glutamate 
receptor (NR2)
Cell surface (podocytes and 
other cells)
8.2 Positive (57/60)
Laminin Extracellular matrix (GBM) 6.7 Negative (360/341)
Myosin Intracellular (all cells) 9.4 Positive (110/147)
Ribosomal protein P1 Intracellular (all cells) 4.2 Negative (18/7)
SmD1 Intracellular (all cells) 11.6 Positive (10/26)
Cardiolipin Intracellular (all cells) ND Negative (no protein)
Heparan sulfate Extracellular matrix (GBM) ND Negative (no protein)
Phosphorylcholine Pneumococcus ND Neutral (no protein)
* TECs = tubular epithelial cells; GBM = glomerular basement membrane; ND = not defined. 
# Average of a3 , a4 , and a 5  chains.
anti-dsDNA antibodies localize in 
the glomerular basement membrane  
(GBM) due to direct cross-reactive 
binding to intrinsic glomerular  
antigens (mechanism 1), whereas, in 
our opinion, glomerular localization of 
anti-dsDNA antibodies is mediated via 
nucleosomes, which bind to heparan 
sulfate (HS) in the GBM (mechanism  
2). These tw o  hypotheses may not 
be mutually exclusive, and until 
recently, there was no unequivocal 
proof for e ither of the tw o  proposed 
mechanisms. In this review, we will 
discuss the pros and cons of each 
of these mechanisms, taking into 
account recent pertinent observa­
tions by Kalaaji et al8-10. Based on these 
findings, previous data reported in the 
l iterature are put in perspective.
CROSS-REACTiVE BINDING OF 
A N Ti-D N A  ANTIBODIES IN LUPUS 
NEPHRITIS
Since it was shown that sera from  
SLE patients were reactive with GBM 
but hardly any antibodies specific 
for glomerular components were  
found, the idea arose that anti-dsDNA  
antibodies could cross-react with  
glomerular antigens11. This concept 
was fuelled by early observations in 
studies with monoclonal anti-dsDNA  
antibodies derived from lupus-prone  
mice, which showed broad cross-reac- 
t iv ity11. Many investigators, intrigued 
by this cross-reactivity hypothesis, 
tried to obtain direct evidence and 
to discover the glomerular targets of
20 C h apter 2
Immunoglobulins in serum from lupus­
prone mice and SLE patients and 
monoclonal anti-dsDNA antibodies  
from mice with lupus from several 
experimental models have been shown 
to react with isolated glomeruli11, 
12. This binding was, in most cases, 
inhibited by dsDNA, but not by DNase 
I trea tm ent. Renal perfusion studies 
with several monoclonal mouse or 
human anti-dsDNA antibodies13 and 
intraperitoneal inoculation of anti­
dsDNA hybridomas derived from  
lupus-prone mice13-17 resulted in 
glomerular deposits. This glomerular  
binding was explained by binding of 
autoantibodies to intrinsic glomerular  
constituents. For this cross-reactivity  
of anti-dsDNA autoantibodies, various 
targets in and outside the GBM have 
been proposed (table 1). Notably, the 
listed proteins share neither common  
structural motifs comparing their  
amino acid sequences, nor common  
biochemical characteristics such as 
overall charge. At physiologic pH, 
the proposed glomerular targets are 
either positively or negatively charged. 
Furthermore, the cellular localization 
and tissue distribution of the proposed 
cross-reactive epitopes differs greatly.
The cross-reactive properties of anti­
dsDNA antibodies have been used 
to distinguish pathogenic from non- 
pathogenic anti-dsDNA antibodies18. 
The cross-reactivity of anti-dsDNA  
antibodies with non-nucleosomal 
antigens has been suggested to be 
due to 1) common structures, such 
as phosphodiester groups in phos­
pholipids, 2) molecular mimicry of 
dsDNA structures, as has been sug­
gested for a -actin in , or 3) overall
a n t i-d s D N A  a n tib o d ie s . negative charge, as in HS linked to 
proteoglycans (HSPG). W hat is the 
evidence supporting each of these 
mechanisms?
Cross-reactivity based on structures in 
common with dsDNA
Several studies have provided evi­
dence of binding of anti-dsDNA  
antibodies to cardiolipin and other  
phospholipids in micellar fo rm 19, 20. 
This cross-reactivity was explained by 
the resemblance in the structure of 
these antigens to dsDNA. The phos- 
phodiester-linked phosphate groups 
in phospholipids resemble those in the 
sugar-phosphate backbone of dsDNA. 
Another common biochemical feature  
of dsDNA and anionic phospholipids 
is the presence of negative charge. 
Subsequent to the above-mentioned  
observations, a relationship between  
the cardiolipin cross-reactivity and 
the avidity of anti-dsDNA antibodies  
was found21. Binding to cardiolipin was 
observed only in sera from SLE patients 
with anti-DNA autoantibodies with low 
avidity for DNA, whereas sera with 
high-avidity anti-DNA autoantibodies  
did not bind to cardiolipin. Moreover, 
only 6 of 55 monoclonal anti-dsDNA  
antibodies appeared to react with  
cardiolipin21. In another study, it was 
shown that histones bound strongly 
to anionic phospholipids, a fter  which 
enhanced reactivity of SLE sera toward  
cardiolipin was found22. In addition to 
histones, antibody reactivity against 
other phospholipid-binding proteins 
have been identified, which could 
explain cross-reacting anticardiolipin  
activity in sera from SLE patients23.
In summary, there is no robust bio­
chemical evidence of common  
structures between DNA and
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suggested cross-reactive targets, 
such as phosphodiester bonds, that  
could explain this binding of anti-DNA  
antibodies.
Cross-reactivity due to molecular 
mimicry of dsDNA structures
To a ttem p t to explain the reac­
tivity of anti-dsDNA antibodies with 
GBM, several groups have screened 
anti-dsDNA antibodies with random  
peptide phage display libraries in 
order to identify peptides mimicking 
the epitopes for anti-dsDNA anti­
bodies, i.e., so-called "mimotopes". 
With this technique, several m im o­
topes for dsDNA have been described 
(table 2). Interestingly, these m im o­
topes were e ither cationic or anionic, 
and did not share a common struc­
tural feature. Furthermore, structural 
homology was never observed with 
native mammalian proteins of the 
GBM or other proteins suggested to be 
cross-reactive targets of anti-dsDNA  
antibodies. Furthermore, a major 
pitfall of this method when anti-dsDNA  
antibodies are used to select dsDNA 
mimotopes is the presence of nucleo- 
somal material during the selection 
procedure, which will result in the 
identification of dsDNA binding pep­
tides rather than dsDNA m im otopes24.
In a study a ttem pting  to identify a 
dsDNA mim otope, a 10 -m er pIII peptide  
phage display library was screened 
with mouse monoclonal anti-dsDNA  
antibody R4A, which was derived  
from a non-autoim m une BALB/c 
mouse immunized with the overall 
neutrally charged phospholipid phos- 
phorylcholine25. R4A was identified  
as a mouse IgG2b anti-dsDNA m ono­
clonal antibody that causes glomerular  
deposits in non-autoim m une mouse
strains26. The mim otope identified by 
selection of phages with R4A revealed  
the DWEYS(VWLSN) motif. This motif  
contains 2 negatively charged res­
idues, which may mimic the negative 
charge of phosphate groups present 
in dsDNA, and 3 aromatic amino acids, 
which may mimic the deoxyribose  
bases in dsDNA. Because of its neg­
ative charge, the DWEYS(VWLSN) 
m otif could serve as a ligand for his­
tones within the nucleosome. Indeed, 
we have preliminary in vitro data 
demonstrating the binding of histones 
to the DWEYS(VWLSN) peptide (van 
Bavel CC, et al: unpublished obser­
vations). Immunization of mice with  
DWEYS(VWLSN) peptide on an MAP 
backbone resulted in an immune  
response with antibodies against 
dsDNA, histones, and cardiolipin. 
Most importantly, the mice developed  
SLE-like disease, with glomerular  
deposits of IgG and complement  
C3 27. Because it was thought that the  
binding of R4A to the GBM occurs 
via cross-reactivity, other proteins 
were analyzed for the presence of the  
DWEYS(VWLSN) motif. However, at 
the protein level the dsDNA mimotope  
selected by R4A shows only (very) 
partial homology with mouse and 
human type XII collagen, a-actinin,  
and the NR2A glutamate receptor, all 
proteins that normally are not present 
in the G BM 28.
Two groups independently found that  
anti-dsDNA antibodies which showed 
glomerular localization cross-reacted 
with a -actin in . Consequently, it was 
suggested that a -actin in  contained  
a molecular structure that mimics 
dsDNA17- 29.
Alpha-actinin is a twisted anti-parallel
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protein d i-m er that contains a nega­
tively charged acidic surface30. It is 
involved in crosslinking the actin 
cytoskeleton within the podocyte  
foot process to components of the  
slit diaphragm, and thus is normally  
not present in the GBM. However, 
since a pathogenic anti-DNA antibody  
could also directly bind to a -actin in  on 
mesangial cells17, it was postulated that  
this binding could lead to proliferative  
lupus nephritis. The relevance of
a -actin in  to renal pathology was 
further derived from the observation  
that in certain cases of familial focal 
segmental glomerulosclerosis, m uta ­
tions were found in the gene encoding 
for actin in -a4 , leading to altered actin 
binding31. However, it must be realized 
that these point mutations leading to 
hereditary familial focal segmental 
glomerulosclerosis do not involve 
antibodies. The cross-reactivity of 
anti-dsDNA antibodies with a-actinin
- GBM
Capillary lumen
Figure 1.
A) Schematic representation of the localization of glomerular targets for nephritogenic autoantibodies. Antibodies 
against laminin and type IV collagen bind in the glomerular basement membrane (GBM). In vivo-bound Ig and TUNEL 
staining colocalize in electron-dense deposits (EDD; gray area) in the GBM with probing antibodies for histone H1, histone 
H3, DNA, and TATA binding protein (TBP).
B) Colocalization immunoelectron microscopy of electron-dense deposits in a kidney section from an (NZW x NZB)F1 
mouse, with TUNEL staining. In electron-dense deposits, there is colocalization of in vivo-bound antibodies (5 nm gold 
particles) (green) with TUNEL staining (10 nm gold particles) (orange). Notably, TUNEL did not stain glomerular struc­
tures outside electron-dense deposits, which indicates that there was no cross-reactive binding to intrinsic glomerular 
structures.
C) Colocalization immunoelectron microscopy of electron-dense deposits in a kidney section from an (NZW x NZB)F1 
mouse, with anti-laminin staining. In electron-dense deposits, there is no colocalization of in vivo-bound antibodies (5 
nm gold particles) (green) and anti-laminin probes (10 nm gold particles) (red), whereas the GBM stained positively 
for laminin outside electron-dense deposits (adapted, with permission, from the American Society for Investigative 
Pathology9)
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was even used to distinguish between  
pathogenic and non-pathogenic anti­
bodies. Anti-dsDNA antibodies in a 
small number of patients with lupus 
nephritis bound to a-actin in , whereas  
those from SLE patients without  
renal involvement did not32, 33. The 
antibodies used were not properly  
purified, however, and may have still 
contained nucleosomal material.
In summary, the identified mimotopes  
for anti-DNA antibodies have not led 
to elucidation of a common 3 -d im en ­
sional structural m otif  that could 
explain the cross-reactive binding 
of anti-DNA antibodies to unrelated  
antigens.
Cross-reactivity due to negative charge
It is now known that the binding of 
anti-dsDNA antibodies to negatively 
charged dsDNA may be based on elec­
trostatic interactions between cationic 
amino acid residues within the third  
com plem entarity-determ in ing regions 
of the antibody and the negatively  
charged dsDNA molecule34. This sug­
gests that anti-dsDNA antibodies can 
also bind to other strongly negatively  
charged molecules, such as a-actinin  
or HS. Indeed, an early study from our 
laboratory demonstrated reactivity of 
human and mouse SLE sera with HS35. 
HS comprises many sulfate groups 
and is responsible for the majority of 
the anionic sites in the GBM. Anti-HS 
reactivity was dem onstrated in 30 of 
33 SLE patients who were  positive for 
anti-dsDNA antibodies, and this reac­
tivity could not be abolished by DNase 
I t rea tm ent. The titers of anti-HS anti­
bodies showed a significant correlation  
with titers of anti-dsDNA antibodies in 
sera both from SLE patients and from  
lupus-prone MRL-/pr//pr mice35. The
reactivity of monoclonal antibodies, 
sera, and eluted antibodies from the  
kidneys of SLE patients and lupus­
prone mice with HS or DNA could be 
inhibited in a dose-dependent manner  
by addition of dsDNA or HS, respec- 
tively35. In summary, high-avidity 
anti-DNA antibodies may bind to abun­
dantly negatively charged molecules 
such as HS
In addition, a-enolase has been postu­
lated as a renal target for anti-dsDNA  
antibodies (see table 1). Although 
a-enolase is neutrally charged, the  
extracellular domain to which anti­
bodies can bind is strongly negative, 
with a pI of 4.1. Under normal con­
ditions, a-enolase is expressed only 
in tubular cells. However, in lupus 
nephritis it has also been identified  
in the glomerulus36. Anti- a-enolase  
antibodies have been found in 20% 
of lupus nephritis patients, but their  
levels did not correlate with any 
clinical or serologic parameters, in 
contrast to an t i-C lq  and anti-dsDNA37. 
Injection of antibodies to a-enolase  
into mice did not lead to lupus-like 
glomerular disease36.
In summary, as outlined above, 
findings of several studies have sug­
gested that anti-DNA antibodies can 
directly bind to glomerular com po­
nents both in vitro and in vivo, and 
induce glomerular deposits. The 
binding of anti-dsDNA antibodies to 
glomerular targets was explained by 
the presence of structures in common  
with dsDNA, structures mimicking 
dsDNA, or just the abundant presence 
of negative charge as in dsDNA. 
Nevertheless, from these studies it 
is difficult to conclude which charac­
teristics of the anti-DNA antibodies
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are responsible for GBM-associated  
cross-reactivity.
N u c l e o s o m e - m e d ia t e d  b in d ­
in g  o f  a n t i -D N A  a n t ib o d ie s  in  
l u p u s  n e p h r it is
The nucleosome, the fundam ental unit 
of chromatin, is released from apop-  
totic cells a fter enzymatic cleavage 
of the linker dsDNA regions of chro­
matin by endonucleases. The evidence  
that apoptosis is disturbed, and/or  
removal of apoptotic material is insuf­
ficient in SLE, made the nucleosome  
an im portant candidate auto ­
antigen. Indeed, in recent years the  
nucleosome was unequivocally iden­
tified as the dominant autoantigen in 
SLE3- 4. Patients with SLE exhibit anti- 
nucleosome reactivity many years 
before the onset of disease38.
Initially, we assumed that anti-dsDNA
antibodies could cross-react with  
glomerular components, since certain  
monoclonal anti-dsDNA antibodies 
derived from lupus-prone mice bound 
to isolated HS or HSPG 35. However, 
when culture supernatants of hybri­
domas producing these anti-dsDNA  
antibodies were treated with DNase I 
and purified on a protein A-Sepharose  
column under dissociating high-salt 
conditions, the binding to HSPG was 
almost abolished 39. Strikingly, after  
this extended purification procedure, 
all previously HS-positive anti-dsDNA  
antibodies showed unaltered, or even 
enhanced, anti-dsDNA reactivity. 
The reactivity of these purified anti­
bodies with HSPG could be restored 
by addition of the effluent of the  
protein A-Sepharose column. M ore  
detailed analysis revealed that a DNA- 
histone complex, present in vivo as 
nucleosome, was bound to the unpu­
rified anti-dsDNA antibody39. Indeed, 
nucleosomes are released from dying 
cells during hybridoma culture40. Also
Table 2. Characteristics of DNA mimotopes selected by anti-DNA antibodies
Mimotope* Selecting antibody Origin of antibody Antibody Calculated Ref.
specificity# pI of
mimotope
ASPVTARVLWKASHV Polyclonal IgG Sera from SLE patients dsDNA 11.00 52
RLTSSLRYNP Polyclonal IgG Sera from SLE patients dsDNA 10.84 53
DWEYSVWLSN Monoclonal R4A BALB/c mouse 
immunized with 
phosphorylcholine
DNA 3.67 27
XXXDCTXNT OOCQL/Y/DXEMonoclonal F14.8 (NZB x NZW)F1 mouse ssDNA 4.09 54
0TGDCW/GY/GWG/
QXXCXXXX
Monoclonal J20.8 (NZB x NZW)F1 mouse ssDNA 3.80 54
XXXDCXXXXW QCXXXX Monoclonal J20.8 (NZB x NZW)F1 mouse ssDNA 3.80 54
AKYSCQKTMCYGLV Monoclonal J20.8 (NZB x NZW)F1 mouse ssDNA 8.83 54
* X = any; O = aromatic residues (F, Y, or W); 0  = hydrophobic residues (V, L, or I).
# dsDNA = double-stranded DNA; ssDNA = single-stranded DNA.
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DNase I t rea tm ent of SLE sera signifi­
cantly increased anti-DNA reactivity41, 
which suggests that anti-DNA anti­
bodies in sera are already complexed  
with dsDNA and /or nucleosomes. 
It was therefore  suggested that  
nucleosomes mediated the binding of 
anti-dsDNA antibodies to HSPG42.
Intrarenal perfusion of nucleosome- 
autoantibody complexes did indeed 
lead to strong glomerular binding, 
which was not observed after  per­
fusion of purified, nucleosome-free  
anti-chromatin antibodies. Removal 
of HS from the GBM by heparinase  
perfusion prior to the intrarenal per­
fusion of nucleosome-autoantibody  
complexes resulted in decreased 
binding to the G B M 42. Potential candi­
dates within the nucleosome for the  
binding to the anionic HS in the GBM  
are the cationic histones. Our group 
reasoned that masking of the positive 
charges would decrease binding to the  
GBM. Indeed, heparin, which is struc­
turally very similar to HS, inhibited the 
binding of complexed autoantibodies  
to HS, in a dose-dependent manner. 
Furthermore, daily subcutaneous 
administration of heparin to lupus­
prone mice prevented the deposition 
of immune complexes in the GBM and 
the developm ent of proteinuria and 
glomerular lesions43.
It was hypothesized that the binding 
of anti-dsDNA and anti-nucleosome  
antibodies to the nucleosome would  
mask part of its negative charge, which 
would facilitate the binding of posi­
tively charged regions in histones to 
the negatively charged HS in the GBM. 
On the other hand, the binding of 
anti-histone antibodies (and in some 
cases anti-nucleosome antibodies) to
the cationic histones would mask the  
positive charge, reducing deposition 
of nucleosome-immune complexes, 
as was indeed shown to be the case44. 
This nucleosome-mediated binding to 
the GBM was the reason that in both 
human and mouse lupus nephritis, 
staining with monoclonal anti-HS anti­
bodies revealed an almost complete  
absence of staining of HS in the G BM 45. 
We further showed that unmasking of 
HS by eluting the immune complexes 
from renal sections restored the  
staining of HS in the GBM 45.
Are there  nucleosomes present 
within the glomerular deposits 
that are so characteristic of lupus 
nephritis? Using extensively purified 
anti-nucleosome, anti-histone, and 
anti-dsDNA antibodies as probes in 
immunofluorescence studies, nucleo- 
somal material was indeed identified  
in these deposits in patients with  
lupus nephritis, but not in deposits 
in patients with other forms of 
glomerulonephritis, i.e., mesangio- 
capillary glomerulonephritis or 
membranous nephropathy46. This 
nucleosome-mediated binding m ech­
anism is not restricted to the kidney, 
since nucleosomal deposits were also 
found in the dermal basement m e m ­
brane in skin biopsy samples from  
patients with active lupus nephritis, 
but not in specimens from patient 
with inactive lupus nephritis or with 
parapemphigus47.
Besides HS, type IV collagen has 
been proposed as a ligand for nucle- 
osom e-m ediated binding to the GBM. 
Treatm ent of the GBM with type IV 
collagenase prevented binding, which 
could be restored only after addition  
of type IV collagen. It was suggested
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that nucleosomes bind to type IV 
collagen via the ir histone parts, anal­
ogous to the situation with HS48, 49.
In summary, given the results 
described here, it is very likely that  
the majority of the observed cross­
reactions, as discussed in the previous 
sections, are mediated by nucleosomal 
components bound to the autoanti­
bodies used for study.
In  v iv o - b o u n d  n e p h r ito g e n ic  
a u to a n t ib o d ie s  in  lu p u s  
n e p h r it is  d o  n o t  t a r g e t  
g lo m e r u la r  s t r u c t u r e s ,  b u t  
d o  t a r g e t  c h r o m a t in
As outlined above, it has been claimed 
that pathogenic anti-dsDNA anti­
bodies gain nephritogenic potential 
either by direct cross-reaction with  
intrinsic glomerular antigens such as 
laminin, type IV collagen, or a-actinin,  
or indirectly by binding in vivo to 
GBM structures via nucleosomes. We  
recently developed a novel method to 
determine, at the ultrastructural level, 
the exact glomerular localization of in 
vivo -deposited antibodies in nephritic  
(NZWxNZB)F1 mice and patients with  
lupus nephritis, by high-resolution 
imm une-electron microscopy8. Our 
data clearly dem onstrated that in vivo - 
bound antibodies could be detected  
in electron-dense deposits present 
in both the GBM and the mesangial 
matrix. This was observed in glomeruli 
from nephritic mice, but not in young  
(NZW x NZB)F1 mice before the onset 
of disease or in control mice 9. Similar 
observations were made in renal 
biopsy specimens from patients with  
lupus nephritis. Importantly, no in
v/vo-bound antibodies were observed 
outside electron-dense deposits8- 9. 
These results implied that structures 
within the GBM are not the targets for 
nephritic autoantibodies /n v/vo.
To fur ther determ ine the nature  
and biochemical composition of 
electron-dense deposits, we applied a 
double-staining electron microscopy- 
based technique using gold particles of 
different sizes50. With  this technique- 
denoted in this context "colocali­
zation imm une-electron microscopy", 
it was shown that glomerular /n v/vo- 
bound autoantibodies colocalized 
with probing experimental antibodies 
against components of chrom atin­
like dsDNA, histone H1 or H3, or the 
transcription factor TATA binding 
protein51. However, no colocalization 
of probing anti-laminin antibodies 
with /n v/vo-bound autoantibodies was 
observed, and the probing anti-laminin  
antibody stained the GBM outside the 
electron-dense deposits. These results 
dem onstrate  that chromatin is a con­
stituent of electron-dense deposits in 
lupus nephritis8.
One could argue that the experi­
mental anti-chromatin antibodies  
used for probing may cross-react 
with non-nucleosomal structures20- 
33. However, by implementing the 
TUNEL assay in conjunction with the 
detection of /n v/vo-bound antibodies, 
we dem onstrated that TUNEL-positive 
chromatin was present in e lectron­
dense deposits and colocalized with  
/n v/vo-bound autoantibodies8. Taken 
together, these results show that  
TUNEL-positive chromatin in the GBM 
and mesangial matrix is the target  
structure for nephritogenic autoanti­
bodies, which supports previously
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published data that antibodies eluted  
from nephritic kidneys are specific for  
DNA, histones, and nucleosomes, and 
not for laminin or a -ac t in in 10.
Why does chromatin bind to the 
GBM and the mesangial matrix? 
HS-mediated binding to the GBM as 
a plausible mechanism was detailed  
above. In addition, we analyzed the  
affin ity of isolated nucleosomes for  
purified constituents of the GBM, by 
surface plasmon resonance (BIAcore, 
Uppsala, Sweden). We found that  
nucleosomes possessed relatively 
high affinity for type IV collagen 
and laminin, with Kd values ranging 
from 10-8M to 10-9M 49. One may 
w onder why colocalization of chro­
matin or experimental anti-dsDNA  
antibody probes with laminin was not 
found. This can be explained by the 
hypothesis that laminin within the  
electron-dense deposits is masked 
by chrom atin-im m une complexes, 
and therefore  not accessible to anti-  
laminin antibodies, similar to the  
situation described for HS45. Elution of 
chrom atin-antibody complexes should 
lead to the reappearance of laminin, 
as we showed recently for glomerular  
HS in lupus-prone mice and patients  
with SLE45. Recent findings with  
regard to the glomerular targeting of 
autoantibodies in lupus nephritis are 
graphically summarized in figure 1.
chromatin in the GBM, and not of 
intrinsic glomerular constituents such 
as laminin. Moreover, these recent 
electron microscopy data support pre­
vious work demonstrating by other  
methods that glomerular deposition 
of anti-dsDNA antibodies in lupus 
nephritis is mediated by nucleo- 
somes339, 42, 47
However, im portant questions remain 
to be answered in order to understand  
the precise role of nephritogenic anti­
DNA antibodies and chromatin in the  
formation of electron-dense deposits 
in the GBM in lupus nephritis. What  
is the origin of the chromatin present 
in the GBM? Does it originate from  
apoptotic glomerular cells or apoptotic  
cells from the circulation? W hat is the  
molecular and cellular basis for the  
release of the nucleosomal material?  
Does this involve locally or systemi- 
cally disturbed apoptosis, reduced 
chromatin fragm entation, or reduced 
clearance of apoptotic debris? Finally, 
w hat are the relationships between  
the developm ent of autoantibodies  
in the circulation, the presence of 
electron-dense deposits in the GBM, 
proteinuria, and lupus nephritis? A 
full understanding of the underlying  
mechanisms of all of these proc­
esses may lead to concepts for new  
therapeutic modalities to treat lupus 
nephritis.
Co n c l u s ìo n s
Recent data from our group8-10, as 
summarized in figure 1, provide firm  
evidence that in lupus nephritis the  
dominant target structures for in vivo- 
bound nephritogenic autoantibodies  
are composed of TUNEL-positive
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uclear components targeted by autoantibodies is a charac­
teristic feature of the autoim m une disease systemic lupus 
erythematosus (SLE). The nucleosome, a major autoantigen, is released 
in patients with SLE as a result of a disturbed apoptosis and /o r  an insuffi­
cient clearance of apoptotic debris. During apoptosis the nucleosome is 
modified, thereby creating more immunogenic epitopes. Subsequently, 
epitope spreading will lead to the formation of autoantibodies against 
unmodified chromatin components. However, characterization of B cell 
epitopes specific for apoptotic chromatin modifications is hampered  
by the fact that the existing monoclonal antibodies (mAbs) were origi­
nally selected on non-apoptotic chromatin. Here, we describe a novel 
approach for generating mAbs from lupus mice that are specific for 
apoptosis-induced chromatin modifications.
Hybridomas were generated from pre-diseased and diseased lupus mice 
using standard fusion methods. Selection occurred on isolated apoptotic  
chromatin. Antibodies were further characterized by ELISA, western 
blot and immunofluorescence staining with apoptotic and nonapoptotic  
chromatin/cells. In addition, reactivity was determined with subnucleo- 
somal complexes and with nucleosomes treated with trypsin or DNase 
I. Finally, reactivity was determined with cells treated with the histone 
deacetylase inhibitor TSA.
Most generated mAbs appeared to be nucleosome-specific with a clear 
preference for apoptotic nucleosomes compared to normal nucleo- 
somes. Although the exact elucidation of the epitopes of these mAbs 
specific for apoptosis-associated nucleosome modifications remains a 
major challenge, the epitopes contain both DNA and histones, whereby  
the histone tails play a role in establishing the epitopes. Most impor­
tantly, the conformational epitopes of these nucleosomespecific 
antibodies seem to contain acetylated residues.
Our approach, yielding a new panel of anti-apoptotic chromatin  
antibodies, should facilitate the discovery of more apoptosis-induced 
chromatin modifications and their identification as key autoantigens in 
the pathogenesis of SLE.
N
In t r o d u c t io n
The formation of autoantibodies  
against nuclear components is 
characteristic for systemic lupus e ry ­
thematosus (SLE)1. The nucleosome  
is the main autoantigen and is 
present in the circulation of patients  
with SLE as a result of a disturbed 
apoptosis and /or an insufficient
clearance2. The core nucleosome 
particle consist of an octam er of 
histones (two copies of each H2A, 
H2B, H3 and H4) with ~146 bp of DNA 
wrapped around it. The linker histone 
H1 binds to the nucleosome w here  the  
DNA enters and leaves the nucleosome 
core. The positively charged N-terminal
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Figure 1. Hypothesis for the sequence of events in lupus graphically depicted.
Autoantibodies are formed against nucleosomes containing apoptosis-induced modifications. These initiating antigens 
are not cleared sufficiently in systemic lupus erythematosus. This leads to uptake by antigen presenting cells (APC), and 
to immunogenic presentation to autoreactive T cells, which stimulate B cells to produce autoantibodies with subse­
quently broadening of the autoantibody repertoire by epitope spreading. The produced antibodies in complex with 
chromatin deposit in basement membranes, causing inflammations as illustrated here for the kidney.
tails of the core histones protrude from  
the nucleosome and interact with the  
negatively charged DNA, controlling  
the conformation of the nucleosome3. 
These histone tails can be subjected to 
several modifications, like acetylation, 
methylation and phosphorylation, 
thereby altering the conformation of 
the nucleosome (reviewed in Wolffe
and Hayes)4. During apoptosis, the  
N-terminal tails of the histones are 
also modified, probably making them  
more immunogenic. When modified  
chromatin (i.e. DNA, histones, nucleo­
somes), or apoptotic blebs, containing 
modified antigens, are taken up by 
dendritic cells, they are presented  
in an immunogenic way to T cells5-7.
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Pathogenic autoreactive T helper cells 
that are present in lupus stimulate  
the formation of autoantibodies by B 
cells8.
Our hypothesis is that nucleosomes 
containing apoptosis-induced post- 
translational modifications (PTMs) on 
the histone tails trigger an autoimmune  
response. A fter processing of the  
antigen and formation of anti­
bodies directed against the modified  
nucleosome, epitope spreading will 
occur, which eventually leads to 
the formation of antibodies against 
unmodified nucleosomes and other  
chromatin components as well (figure  
1). These autoantibodies against chro­
matin components can be categorized 
into antibodies recognizing DNA (anti­
DNA), histones (anti-histone) and 
antibodies that specifically recognize 
nucleosomes (nucleosome-specific  
antibodies).
The M RL/lpr and (NZB/W)F1 lupus 
mouse models are often used for the  
generation of monoclonal antibodies  
(mAbs) against (components of) chro­
matin as they spontaneously develop  
an autoim m une disease that closely 
resembles human SLE, including the  
production of autoantibodies against 
chromatin and a proliferative lupus 
nephritis. So far, many mAbs against 
nuclear components have been gen­
erated including antibodies against 
DNA, histones or nucleosomes9-11. 
These mAbs have often been gen­
erated from B cells of diseased lupus 
mice with a diverse B cell repertoire,  
including B cell epitopes against 
unmodified chromatin (figure 1). 
The generation of mAbs from pre­
diseased mice could provide specific 
antibodies against initiating antigens,
containing apoptosis-induced PTMs. 
Already early in the developm ent of 
SLE12 and even before onset of the 
disease, anti-nucleosome antibodies  
have been found13. Moreover, in vivo, 
nucleosome-specific, CD4+ T cells 
were found in the spleens of lupus­
prone mice as early as 1 months of 
age, long before developm ent of other  
autoim m une manifestations8.
So far, all monoclonal anti-chromatin  
autoantibodies have been selected 
on "normal" chromatin, thereby  
introducing a negative selection for 
antibodies against modified chro­
matin. Therefore, we developed an 
approach to select mAbs from pre­
diseased lupus mice on apoptotic  
chromatin. Antibodies specific for 
apoptotic nucleosomes can be of great 
importance for the discovery of the  
composition and modification of apop­
totic nucleosomes, which in our view  
contain the initiating epitopes in SLE. 
We hereby present the results of this 
approach.
M a t e r ia l s  a n d  M e t h o d s
Isolation of (apoptotic) nucleosomes
Nucleosomes isolated from normal 
cells will be referred to as "control 
nucleosomes", whereas nucleosomes 
isolated from apoptotic cells will be 
referred to as "apoptotic nucleo­
somes". Control nucleosomes were  
obtained from 32Dcl3 cells, which 
were cultured as described pre­
viously14, and isolated according to the 
method developed by Kornberg15 with  
some modifications. Briefly, cells were  
allowed to swell for 10 min on ice in 
Dounce buffer (10 m M  HEPES-NaOH 
pH 7.9, 1.5 m M  MgCl2, 10 m M  KCl,
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0.5 m M DTT and protease inhibitors 
(Roche, Almere, the Netherlands)). 
Nuclei w ere  isolated by disrupting 
the cell membrane with the use of a 
glass Dounce tube and pestle. After  
pelleting the nuclei, they were incu­
bated with 1 U /U A260 Micrococcal 
nuclease (W orthington Biochemical 
Corporation, L a k e w o o d ,  U S A )  so 
that a fter internucleosomal cleavage 
the nucleosomes are released from  
the nucleus. The reaction was stopped 
by adding 2 m M  EDTA pH 8 and cellular 
debris was spinned down.
For the isolation of apoptotic nucleo- 
somes, apoptosis was induced by 
cold-shock (2 hours at ice followed  
by 2 hours at 37 °C) a fter  which apop­
totic nucleosomes were isolated by 
resuspending the cells in nucleosome  
releasing buffer (10 m M  Tris.HCl pH7.4, 
1 m M CaCl2 and protease inhibitors  
(Roche)). Apoptosis was determined  
by analyzing Annexin V-fluorescein  
isothiocyanate (AnV) (ITK Diagnostics, 
Uithoorn, the Netherlands) binding 
and propidium iodide (PI) staining 
with f low cytometry, as described 
previously6.
The nucleosomes used for selection 
of antibodies were isolated form  
untreated cells (3% AnV+PI-and 4% 
AnV+PI+) and apoptotic cells (89% 
AnV+PI-; 5% AnV+PI+), and were charac­
terized in ELISA and western blot for 
the presence of (apoptosis-induced) 
histone modifications.
All buffers contained 100 ng/  
ml Trichostatin A (TSA; Enzo Life 
Sciences, Raamsdonksveer, the 
Netherlands), 5 m M NaF (Sigma- 
Aldrich, Zwijndrecht, the Netherlands) 
and 1 m M  Na3VO4 (Sigma-Aldrich)
to prevent the loss of histone acety- 
lation and phosphorylation during 
isolation. All nucleosomes were stored 
in 50% glycerol (Invitrogen) at -80  °C. 
Hl-stripped chromatin was kindly pro­
vided by Dr. R. Burlingame (INOVA 
Diagnostics Inc., San Diego, California, 
USA)
Lupus mice
Pre-diseased mice (6-8 wk old 
Tnfrsf6lpr (MRL//pr) and 15 wk old 
NZBNZWF1 (NZB/W)F1) and early- 
diseased mice (14 wk old MRL//pr and 
30 wk old (N ZB /W )F1) were purchased 
from Harlan UK. All mice w ere  female. 
Albuminuria was analyzed with the  
use of Albustix (Bayer, Leverkusen, 
Germany).
Production of monoclonal antibodies
Spleen  cells f r o m  p re -d is ea se d  MRL/ 
/pr, (NZB/W)F1 mice and early-diseased 
MRL//pr, (NZB/W)F1 were fused with 
murine myeloma cells (SP2/O-Ag14)  
in 45% PEG 4 0 0 0  (Sigma-Aldrich) 
with 5% DMSO. Cells were cultured in 
96-well culture plates (Corning Costar, 
Badhoevedorp, the Netherlands) in 
RPMI-1640 Dutch modification (Gibco 
BRL, Breda, The Netherlands) supple­
mented with 10% fetal calf serum (FCS) 
(PAA Laboratories, Cölbe, Germany), 
l x  glutamax, 1 m M  pyruvate, 100 U/ml 
penicillin/streptomycin (Gibco), 1x HAT 
media supplement (Sigma-Aldrich) 
and 5% Hybridoma Enhancing Cell 
Supplement (HECS) (Sigma-Aldrich). 
After 10 days HAT Media supplement 
was replaced by HT media supplement  
(Sigma-Aldrich). A fter subcloning 
hybridomas, culture supernatants  
containing the monoclonals were  
treated with DNase I and high salt to 
remove chromatin bound to the anti­
bodies. MAbs were purified by affinity
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chromatography using a protein A 
column, as described previously16.
Screening
Hybridomas were initially screened 
on apoptotic nucleosomes in ELISA. 
Only clones that were negative in the  
anti-DNA ELISA and showed a higher 
reactivity with apoptotic chrom atin /  
cells than with control chromatin/cells  
in ELISA, western blot and im m uno­
fluorescence staining of cytospinned 
cells, w ere  selected.
ELISA
The reactivity of the supernatant  
of hybridomas was tested in a 
Maxisorp® 96-wells plate (Nunc, 
Uden, the Netherlands) coated with  
5 mg/ml nucleosomes. For screening 
of the highest reactivity with apop-  
totic nucleosomes, the supernatants  
were tested in a two-fo ld  dilution 
steps, starting with undiluted super­
natant. The histone H3 monoclonal 
antibody #3417 was used to control 
for equal chromatin coating and 
KM-2 as a positive control, specifi­
cally recognizing apoptosis-induced 
histone modifications6. For detection  
a goat anti-mouse Ig horseradish 
peroxidase-conjugated antibody
(Southern Biotechnology Associates, 
Birmingham, USA) was used using 
3,3',5 ,5 '-tetram ethylbenzid ine (SFRI 
Laboratories, Berganton, France) as a 
substrate.
Anti-DNA, anti-histone (total or 
individual histones) ELISA's w ere  per­
formed as described previously18.
The isotype of the mAbs was deter­
mined by sandwich ELISA. In brief, goat 
anti-mouse Ig (H + L) (Sigma-Aldrich) 
was first coated onto plates (Nunc) and
blocked. The culture supernatants or 
purified antibodies were added to the 
plates. Bound immunoglobulins were  
detected with peroxidaseconjugated  
goat anti-mouse IgM, IgG1, IgG2a, 
IgG2b, or IgG3, as outlined for the 
nucleosome ELISA.
Immunofluorescence staining
Cells (untreated, cold-shocked, 
camptothecin- (2 mg/ml) (Sigma- 
Aldrich) or TSA-treated (100 ng/ml)) 
were fixed with 2% (w/v) paraformal­
dehyde and permeabilized with 0.05%  
(v/v) Triton X-100. The cells were incu­
bated with the indicated primary mAbs 
and a goat anti-mouse A lexa-488  
conjugated antibody (Invitrogen, 
Breda, the Netherlands) was used for 
detection. Cells were embedded in 
VectaShield mounting medium H-1200  
containing 4 ',6-diamidino-2-phenyl-  
indole (DAPI) (Vector Laboratories, 
Peterborough, UK) and analyzed with a 
Zeiss Axio Imager M1 with an AxioCam  
MRm.
SDS-PAGE and western blot
Proteins resolved by SDS-PAGE (18%) 
were blotted as described previously19. 
Immunoblots w ere  probed with the  
indicated primary antibody and a goat 
anti-mouse Ig (H+L) antibody labeled 
with IRDye-800 (Westburg, Leusden, 
the Netherlands), and scanned with  
an Odyssey® infrared imaging system 
(LI-COR Biosciences, Lincoln, NE, USA).
Trypsin and DNase I treatment of 
nucleosomes
Nucleosomes were dialyzed over 
night against PBS to remove  
remaining protease inhibitors used 
during nucleosome isolation. Trypsin 
trea tm ent of the nucleosomes was 
performed according to Yang et al20.
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Table 1. Characteristics of newly developed antibodies selected on apoptotic chromatin
Monoclonal antibody Mouse strain Age (weeks) Isotype Epitope
BT22 MRL/lpr 6 IgM H1
BT95 MRL/lpr 14 IgG2a nucleosome
BT116 MRL/lpr 14 IgG2b nucleosome
BT124 MRL/lpr 14 IgG3 nucleosome
BT131 MRL/lpr 14 IgG3 nucleosome
BT162 MRL/lpr 14 IgG2b nucleosome
BT164 MRL/lpr 14 IgG2b H3
Briefly, trypsin-coated agarose beads 
were incubated with nucleosomes for 
O, 4, 15 and 6O minutes. A fter centrifu­
gation the supernatant containing the  
trypsin-treated nucleosomes was used 
to analyze the remaining reactivity  
with the mAbs.
Nucleosomes were treated with 1OO 
U/ml DNase I (Roche) for O, 4, 15 and 
6O minutes. Reaction was stopped by 
adding EDTA.
Blocking experiments
To discover the contribution of the 
N-terminal tails to the epitope of the 
anti-nucleosome antibodies an anti-  
nucleosome ELISA was performed with  
the addition of a blocking-step of the 
coated nucleosomes with e ither anti-  
histone antibody KM-2 (anti-H4/H2A),  
#34  (anti-H3) or LG11-2 (antiH2B), 
which mask the N-terminal histone 
tails.
Nucleosome reconstitution
Conformational epitopes of nucleo- 
somes were reconstituted by adding 
DNA to specified histones according to  
Jovelin et. al.21. Briefly, a mix of total 
histones or H2A-H2B or H3-H4 were
coated onto 96-wells plates (Nunc) 
in a concentration of 2.14 mg/ml. 
After washing and blocking, DNA was 
added in a concentration of 2.8 mg/ml 
yielding a histone-DNA ratio of 0.75, 
representative for the ratio in native 
nucleosomes.
Results
Generation of monoclonal antibodies
We have produced 38 mAbs from  
(pre-)diseased lupus mice (MRL/lpr and 
(NZB/W)F1) with a higher reactivity  
on apoptotic chromatin. Pre-diseased 
mice did not manifest albuminuria, 
whereas older mice only showed mild 
albuminuria (< 1 mg/ml). In this report  
we present 7 characteristic mAbs, 
based on anti-(apoptotic) nucleosome  
ELISA and IF staining of control and 
apoptotic cells (table 1). All these 
antibodies showed in ELISA higher 
reactivity with apoptotic nucleo- 
somes than with control nucleosomes, 
while reactivity of #34  (recognizing 
unmodified H 3 .1 /H 3 .2 )17 was identical. 
Reactivity of KM-2 (recognizing apop-  
tosis-induced tri-acetylated H4)6 was 
also higher with apoptotic chromatin
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(figure 2A). Furthermore, these anti­
bodies showed higher reactivity in 
situ  with apoptotic cells, compared to 
control cells, and in particular stained 
apoptotic blebs (figure 2B).
Identification of anti-nucleosome and 
anti-histone antibodies
Characterizing our anti-apoptotic-  
chromatin antibodies in anti-DNA, 
anti-histone and antinucleosome  
ELISAs, we found 5 nucleosome- 
specific antibodies and two  
histone-specific antibodies (BT22 and 
BT164) (figure 3A). Hardly any reac­
tivity with DNA was observed for all
antibodies. Antibodies BT95, BT116, 
BT124, BT131 and BT162 showed high 
reactivity with nucleosomes but not 
with histones, indicating that they are 
classical nucleosome-specific anti­
bodies, i.e. not reacting with isolated 
dsDNA or histones. Also western blot 
analysis suggests that BT95, BT116, 
BT124, BT131 and BT162 are anti- 
nucleosome mAbs since they show low 
or absent reactivity with denatured  
histones on western blot, unlike anti- 
histone antibodies BT22, BT164 and 
KM-2 (figure 3B). As mentioned BT164 
and BT22 appeared to be anti-histone  
antibodies since they have the highest
Figure 2. Reactivity of newly established monoclonal antibodies with normal and apoptotic nucleosomes.
A) Reactivity with apoptotic nucleosomes in ELISA. The newly developed antibodies BT22, BT95, BT116, BT124, BT131, 
BT162, BT164 show a higher reactivity with apoptotic nucleosomes (continuous line) compared to control nucleosomes 
(dotted line). Monoclonal antibody #34, which recognizes unmodified histone H3.1/H3.2, was used as a loading control 
and KM-2, which recognizes apoptosis-associated acetylated H4, was used to show the presence of apoptosis-induced 
modifications.
B) Reactivity with apoptotic cells in immunofluorescence staining. Antibodies BT22, BT95, BT116, BT124, BT131, BT162 
and BT164 show a higher reactivity in immunofluorescence staining of apoptotic cells compared to control cells. Note 
that especially the apoptotic blebs are stained by the anti-apoptotic-chromatin antibodies.
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reactivity against histones in ELISA. 
However, their reactivity is different. 
As suggested by the western blot, 
BT22 recognized histone H1, which 
is consistent with the absent reac­
tivity in the anti-nucleosomes ELISA 
with H l-stripped nucleosomes. BT164 
shows high reactivity in western blot 
with histone H3. The epitope of BT164 
on histone H3 is also accessible on 
nucleosomes, since it shows reactivity  
in the anti-nucleosome ELISA (figure 
3A).
Determination of the epitopes of 
the newly established monoclonal 
antibodies
The epitope of anti-histone antibodies  
can be determined using peptide  
ELISAs. Indeed, ELISA with coatings of 
individual histones (Roche) revealed 
that BT22 and BT164 have an epitope  
located on respectively H1 and H3 
(data not shown). Mapping the epitope  
of anti-nucleosome antibodies is less 
straightforward. To elucidate the  
epitope of the newly developed anti- 
apoptotic-nucleosome antibodies, 
several approaches were followed, 
which are detailed below.
Effect of trypsin and DNase I treatment 
on antibody reactivity
Trypsin-treatment of nucleosomes 
could reveal the participation of the  
C-and N-terminal tails in the epitopes  
of the anti-apoptotic-nucleosome  
antibodies. Trypsin cleavage sites are 
located between the histone core and 
the N-and C-terminal tails. Treatment  
of the nucleosome with trypsin leads 
to the removal of all the protruding  
tails (figure 4A). W hen the nucleo- 
somes were treated with trypsin the  
reactivity of anti-histone H3 antibody  
#34 decreased and reactivity of
anti-DNA antibody #36 remained  
almost equal. However, the reactivity  
of all BT-antibodies is much lower 
with the trypsintreated nucleosomes 
compared to untreated nucleosomes
A
^  ■ a-histone ■ a-nudeosome □ a-DNA
10000 -|
Figure 3. Reactivity of newly established monoclonal 
antibodies with histones, DNA and nucleosomes.
A) The reactivity of the anti-apoptotic-chromatin 
antibodies BT22, BT95, BT116, BT124, BT131, BT162 
and BT164 with histone, nucleosome and DNA in ELISA. 
Data are expressed as the titer (dilution where OD=0.5). 
BT22 and BT164 show highest reactivity with histones, 
indicating that they are anti-histone antibodies. BT164 
also binds to nucleosomes, whereas BT22 does not 
react with the H1-stripped nucleosomes used in this 
assay. BT95, BT116, BT124, BT131 and BT162 show the 
highest reactivity with nucleosomes, and a low or absent 
reactivity with histones and/or DNA, suggesting that they 
are nucleosome-specific antibodies.
B) The reactivity of BT22, BT95, BT116, BT124, BT131, 
BT162 and BT164 with resolved nucleosomes on western 
blot. Low or absent reactivity is observed with the anti- 
nucleosome antibodies BT95, BT116, BT124, BT131 and 
BT162, whereas the anti-histone antibody BT164 and the 
positive control mAb KM-2 show a distinct staining of, 
respectively, histone H3, and H2A and H4. Note that the 
reactivity of BT22 with histone H1 is lower than expected, 
since in ELISA a high reactivity with histone H1 is observed. 
This can be due to the lower affinity of this IgM antibody 
on western blot compared to the other antibodies with 
an IgG isotype.
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(figure 4B). Apparently, these tails 
contribute to the epitope of the newly  
developed anti-apoptotic-nucleosome  
antibodies. To investigate the role of 
DNA, the nucleosome was treated  
with DNase I. Here we observed 
similar results, a diminished reactivity  
after trea tm ent with DNase I (figure  
4B). The efficiency of DNA removal 
is illustrated by the almost complete  
loss of reactivity of the anti-DNA mAb 
#36. Apparently, the conformational 
epitopes of our new anti-nucleosome  
antibodies need both components of 
the nucleosome, i.e. DNA and histones.
Reconstitution of nucleosomal struc­
tures
Subnucleosomal structures were  
created by reconstitution experi­
ments to determ ine which 
substructure is part of the epitope  
of our anti-nucleosome antibodies. 
Reconstitution with all components  
of the nucleosome using separate his­
tones and DNA (H2A-H2B-H3-H4-DNA)  
led to high reactivity of all antibodies  
(figure 4C). The anti-nucleosome  
antibodies BT116, BT124, BT131 and 
BT162 had a higher reactivity with  
the H2A-H2B-DNA sub-nucleosomal 
particle compared to the H3-H4DNA  
particle. BT95 did not show such a dif­
ference in reactivity comparing the  
tw o  subnucleosomal particles and 
the fully reconstituted nucleosome. 
Because there is a preference for the  
fully reconstituted nucleosome con­
taining all components, these data 
suggest that the conformational epi­
topes of these nucleosome-specific  
antibodies are more complete under  
these conditions.
Effect of blocking-terminal histone tails 
on antibody reactivity
To identify the contribution of histones 
to the epitope of the anti-apoptotic-  
nucleosome antibodies, we performed  
blocking experiments in which the 
N-terminal histone tails were blocked 
with antihistone antibodies #34  (anti- 
H3), KM-2 (anti-H2A/H4) and LG11-2 
(anti-H2B). Binding of BT116 and BT124 
were inhibited for 30-45%  by anti- 
H 2A /H 4  and binding of BT131 was for 
50% inhibited by anti-H3, indicating 
participation of these histone-tails in 
the epitopes of these anti-nucleosome  
antibodies (figure 4D). In contrast, 
histone tails do not contribute to the  
epitope of BT162, since it was hardly  
blocked by the used anti-histone  
antibodies.
Effect of hyperacetylation on antibody 
reactivity
Cells treated with the histone 
deacetylase inhibitor TSA, leading to 
hyperacetylation of chromatin, could 
reveal the possible influence of acety- 
lation on the binding of these mAbs 
to the ir epitopes. The nuclear reac­
tivity of all anti-nucleosome mAbs 
with hyperacetylated cells in situ  was 
increased, similar to the increased 
staining intensity of KM-2 (recognizing 
tri-acetylated H2A/H4) (figure 5). In 
contrast, the nuclear reactivity of 
BT164, which is an anti-H3 antibody, 
was not increased after inducing 
hyperacetylation.
D iscu ss io N
In this report we present a novel 
method for the generation of mAbs 
from lupus prone mice. By selecting 
antibodies on apoptotic nucleosomes 
and not on normal chromatin, we were  
able to produce mAbs specific for
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apoptotic nucleosomes and histones. 
Previously, antibodies that have been 
generated from lupus mice appeared  
to have an epitope that contained  
apoptosis-induced modifications6, 22. 
The characterization of the epitopes  
of these antibodies pointed to the 
chosen approach. By specific selection 
on apoptotic nuclear constituents we 
can now generate panels of antibodies 
specific for apoptotic chromatin. These 
antibodies could be of great value in 
discovering apoptosis-induced m odi­
fications of nucleosomes. Because, 
of the present evidence that apop­
totic nucleosomes are the initiating  
antigen in SLE, these antibodies, gen­
erated against this inducing antigen, 
can be im portant tools to elucidate  
the pathogenesis of this autoimmune  
disease.
Since anti-nucleosome antibodies  
appear already before clinical onset of 
lupus12, 1B, we set out to generate anti­
bodies from pre-diseased lupus mice. 
It has already been described that  
early anti-nucleosome mAb display 
structural differences in the com ple­
m entary-determ ining region (CDR)B 
compared with anti-nucleosome Ab 
that appear later in the disease21. 
However, these early anti-nucleosome  
antibodies w ere  derived from MRL+/+ 
mice and had IgG isotypes. All of our 
anti-nucleosome antibodies derived 
from early-diseased MRL/lpr mice had 
an IgM isotype with a low affinity, 
which hampers epitope mapping  
and are therefore  not further  
characterized. The low affin ity  of IgM 
antibodies is illustrated by the low 
reactivity on western im m unoblot of 
the IgM anti-histone H1 antibody BT22 
derived from a pre-diseased lupus 
mice. Our anti-nucleosome antibodies
derived from older mice all had the IgG 
isotype. These mice manifested only 
mild albuminuria, so we generated  
antibodies from mice prior to overt 
clinical disease.
Our anti-apoptotic nucleosome anti­
bodies are nucleosome specific: they  
do not react with DNA or histones 
alone, but they react with a confor­
mational epitope, requiring both 
constituents of the nucleosome. 
Recognition of a predominantly  
conformational epitope within the  
(H2A-H2B)-DNA subnucleosomal
complex by anti-histone antibodies  
has been described before2B. These 
subnucleosomal complexes have also 
been proposed as a substrate for 
analysis of anti-nucleosome reactivity  
in SLE sera24, 25. Our nucleosome-spe-  
cific antibodies have a clear preference  
for fully reconstituted nucleosomes 
(H2AH2B-HB-H4)-DNA. Thus, their  
conformational epitope requires an 
entire nucleosome-particle containing 
all core histones and DNA. Similarly, 
Losman et al. also reported that 
some anti-nucleosome antibodies do 
not react with such subnucleosomal 
complexes, indicating that unique con­
formational epitopes are present on 
the native nucleosome26. Furthermore,  
the conformation of an apoptotic  
nucleosome is d ifferent from a 
"normal" nucleosome leading to the  
formation of o ther exposed epitopes27.
We have previously a ttem pted  
to determ ine the epitope of anti-  
nucleosome antibodies19. Cutting off  
the N-terminal tails of the histones 
from the nucleosome with a trypsin 
digestion did not reveal w hether  
the epitope includes histone-tails. 
Already after partial digestion most
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Figure 4. Influence of the nucleosome structure and composition on the reactivity of monoclonal antibodies.
A) Cleavage sites of trypsin are depicted in the protein structure of the individual histones H2A, H2B, H3 and H4. The 
pink parts are removed after trypsin-treatment. On the right is a representation of the 3D structure of the nucleosome, 
either untreated or treated with trypsin, which leads to the removal of the C-and N-terminal tails protruding from the 
nucleosome.
B) Treatment of nucleosomes with trypsin or DNase I leads to a decreased reactivity of the anti-apoptotic-nucleosome 
antibodies (expressed as relative reactivity) compared to untreated nucleosomes (set at 1, dotted line). Anti-histone 
antibody #34 was used as a positive control for the removal of the N-terminal tails. Anti-DNA antibody #36 was used as 
a control for equal loading after trypsin treatment and as a positive control for DNaseI treatment. These results show 
that the histone tails and DNA play an important role in the formation of the epitope of the anti-nucleosome antibodies, 
either direct as being part of the epitope or indirectly by their impact on the conformation of the epitope.
C) Anti-apoptotic nucleosome antibodies show the highest reactivity with reconstituted nucleosomal complexes 
containing all nucleosome components (H2A/H2B/H3/H4)DNA. Reactivity with subnucleosomal complexes (H2A/H2B) 
DNA or (H3/H4)DNA is lower.
D) The binding of the anti-apoptotic nucleosome antibodies to the nucleosome can be inhibited by specific anti-histone 
antibodies. Apparently, the histone tails of H2A and/or H4 are important for the epitope of antibodies BT116 and BT124, 
whereas the tail of histone H3 plays a role in the epitope of antibody BT131. Binding of BT162 is not inhibited by any of 
the used anti-histone antibodies.
reactivity with the nucleosome 
was lost. However, removal of the  
histone tails also removes many of 
the positively charged domains of
the nucleosomes, thereby altering  
the structural properties of the  
nucleosome28. Therefore, histone tails 
may be part of the epitope or may
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indirectly influence the conformation  
of the epitope. Similar results were  
obtained with DNase I treatm ent.  
Demolition of DNA leads to a com ­
pletely altered conformation of the  
nucleosome. Therefore, like histone 
tails, DNA determines and/or is part of 
the conformational epitope of these 
anti-nucleosome antibodies. W e could 
show that hyperacetylation of his- 
tones enhances the binding of certain 
anti-nucleosome antibodies BT95, 
BT116, BT124, BT131 and BT162; see 
figure 5. However, the nuclear reac­
tivity of the anti-H3 antibody BT164 
was not increased a fter inducing 
hyperacetylation.
How apoptosis-induced histone m odi­
fications that have been described so 
fa r6, 22, 29, 30 affect the structure of the  
nucleosome remains unsolved. It is 
known that acetylation of histones 
leads to a more open accessible chro­
matin structure31. Another known 
alteration of the nucleosome during 
apoptosis is the separation of the core 
histones H2A, H2B, H3, and H4 from  
the DNA32, starting with degradation
of histone H3 and H4, which are the 
main stabilizers of the nucleosome33. 
Therefore, one can speculate that  
th ese modifications facilitate further  
degradation of the nucleosome during 
apoptosis. If, as this seems the case 
in lupus, phagocytosis of apoptotic  
debris is impaired, these modifica­
tions may become immunogenic. This 
augmentation of the immunogenicity  
of nucleosomes may fur ther  result 
from apoptosis-induced abnormal 
methylated, GC-rich DNA34 or bound 
HMGB135.
We show that already in an early stage 
of lupus anti-apoptotic-chromatin  
antibodies are present. So far we  
have only partly determined the epi­
topes of these antibodies. How could 
we proceed in the elucidation of 
these epitopes? Analysis of apoptotic  
nucleosomes with mass spectrometry  
(MS) could reveal the presence of 
modifications, thereby generating can­
didate epitopes for these antibodies. 
MS of an epitope, excised or extracted  
by the antibody, could tell us what the  
epitope is, but will not illuminate the
BT95 BT116 BT124 BT131 BT162 BT164 KM2
^0
Figure 5. Effect of hyperacetylation of nucleosomes on antibody binding.
Enhanced nuclear reactivity of nucleosome-specific antibodies BT95, BT116, BT124, BT131 and BT162 with TSA-treated 
cells containing hyperacetylated chromatin compared to untreated cells (Ctrl). Anti-histone H3 antibody BT164 does not 
show an increase in reactivity with hyperacetylated cells. KM-2, an antibody against tri-acetylated histones H4 and H2A 
was used as positive control.
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structure of the epitope. Alternatively, 
epitope mapping could be performed  
by screening phage display libraries 
with the anti-apoptotic-nucleosome  
antibodies. Using an algorithm  
that compares selected amino acid 
sequences with the 3D structure of 
the nucleosome could lead to the  
discovery of the nucleosomal autoepi-  
topes36. Such an approach could also 
reveal w hat is happening during apop-  
tosis with the nucleosome.
The generation of these apoptotic-  
nucleosome-specific antibodies brings 
us one step further in the under­
standing of the effect of modifications  
on the structure and immunogenicity  
of nucleosomes and their role in SLE.
In conclusion, by using a new selection 
approach, we generated lupus-derived 
monoclonal antibodies directed 
against apoptosis modified nucleo- 
somes. Some of these mAbs are 
directed against histones, but the  
majority is nucleosome-specific and 
none of them reacted with dsDNA. 
For the nucleosome-specific mAbs all 
constituents of the nucleosome were  
mandatory. The conformational status 
of the epitope is documented by the  
loss of reactivity by approaches that  
influence the conformation of the  
nucleosome (trypsin digestion, DNase
I treatm ent).
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Î n systemic lupus erythematosus (SLE), inadequate removal of apoptotic cells may lead to challenge of the imm une system with  immunogenic self antigens that have been modified during apoptosis. 
W e undertook this study to evaluate whether apoptosis-induced histone 
modifications are targets for the imm une system in SLE.
Methods: The epitope of KM-2, a monoclonal anti-histone autoantibody  
derived from a lupus mouse, was mapped by random peptide phage 
display. The reactivity of KM-2 and plasma with (acetylated) histone H4 
(H4) peptides and with non-apoptotic, apoptotic, and hyperacetylated 
histones was determined by immunofluorescence staining, enzyme- 
linked immunosorbent assay, and western blotting.
Results: KM-2 recognized apoptosis-induced acetylation of H4 at lysines
8, 12, and 16. The majority of plasma samples from SLE patients and 
lupus mice showed higher reactivity with tri-acetylated H4 peptide 
(residues 1-22) and with hyperacetylated and apoptotic histones than 
with non-acetylated H4 peptide and normal histones. Importantly, 
administration of tri-acetylated H4 peptide to lupus-prone mice before 
disease onset accelerated the disease by enhancing mortality and aggra­
vating proteinuria, skin lesions, and glomerular IgG deposition, while  
the non-acetylated H4 peptide had no pathogenic effect. The delayed- 
type hypersensitivity response in lupus mice against the tri-acetylated  
H4 peptide was higher than that against the non-acetylated H4 peptide. 
Bone marrow-derived dendritic cells (DCs) cultured in the presence of 
hyperacetylated nucleosomes showed increased expression/production 
of CD40, CD86, interleukin-6 (IL-6), and tum or necrosis factor a  (TNFa) 
compared with DCs cultured in the presence of normal nucleosomes. 
Finally, DCs cultured in the presence of hyperacetylated nucleosomes 
were able to activate syngeneic T cells, because IL-2 production 
increased.
Conclusion: Apoptosis-induced acetylation of nucleosomes may 
represent an important driving force in the development of lupus.
IN TR oD ucTioN
The formation of autoantibodies  
against chromatin components (i.e., 
DNA, histones, and nucleosomes) 
is a major feature of systemic lupus 
erythematosus (SLE), an auto ­
antigen-driven, T cell-dependent  
autoim m une disease that affects mil­
lions of people worldwide. In SLE, the  
nucleosome is a major autoantigen1, 
and nucleosome- and histone-specific
autoreactive T cells and B cells 
have been identified. Years before  
clinical manifestation of the disease, 
anti-nuclear antibodies (ANAs) can 
be detected in the circulation of 
future SLE patients2. Anti-chromatin  
autoantibodies complexed with chro­
matin are targeted to basement  
membranes, including the glomerular  
basement membrane, which incites
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glomerular inflammation, one of the 
most serious clinical manifestations of 
SLE3, 4. Nucleosomes can be detected in 
the circulation during disease in lupus 
patients and lupus mice5, 6. There is 
evidence that in lupus, e ither aberrant  
apoptosis or reduced clearance of 
apoptotic cells or a combination of 
both leads to an overflow of the 
cleaning machinery and the presence 
of apoptotic chromatin in the circu­
lation7, 8. The contribution of aberrant  
apoptosis to the developm ent of SLE 
is supported by mouse models with 
abnormal function of factors involved 
in apoptosis, such as Fas (lpr), FasL 
(gld), Bcl-2/Bim, programmed cell 
death 1, phosphatase and tensin 
homolog, B lymphocyte stimulator, 
and TACI, leading to the formation  
of ANAs and glomerulonephritis7, 9. 
Impaired removal of apoptotic cells 
also predisposes to the developm ent of 
SLE. Mice deficient in factors required 
for proper clearance of apoptotic  
cells, such as DNase I, serum amyloid  
P/C-reactive protein, C1q, IgM, and 
Mer, develop anti-nucleosome auto ­
antibodies and glomerulonephritis7-9. 
It has been dem onstrated that the  
clearance of apoptotic material by 
phagocytes is impaired both in lupus 
mice and in patients with lupus10, 11. 
Autoantigens targeted in SLE are clus­
tered in blebs at the surface of late 
apoptotic cells12, 13. Autoantigens may 
contain apoptosis-induced modifica­
tions that constitute epitopes that  
normally are not encountered by the 
immune system when clearance of 
apoptotic cells is adequate. Apoptosis- 
induced autoantigen modifications  
include cleavage by caspases, endo­
nucleases, or granzyme B14, 15 and the 
addition or removal of covalently  
linked moieties through acetylation,
methylation, phosphorylation, ubi- 
quitination, citrullination, ADP 
ribosylation, or transglutamination15, 
16. These covalently linked m odifica­
tions have also been reported for  
nucleosomes/histones, although with  
a primary role in the context of regu­
lation of transcription17. Although it 
has been dem onstrated that apoptotic  
cells may induce a lupus-like immune  
response, nothing is known about  
apoptosis-induced chromatin m odifi­
cations as targets for autoantibodies  
in SLE18-20. Therefore, we evaluated  
w hether apoptosis-induced histone 
modifications are targets for the  
immune system in SLE.
M a t e r ia l s  a n d  M e t h o d s
Cell cultures, inhibition of histone 
deacetylases (HDAs), and induction of 
apoptosis
Jurkat or U937 cells w ere  routinely  
cultured. To inhibit HDA activity and 
induce hyperacetylation of nucleo­
somes, cells were treated with 100 
ng/ml trichostatin A (TSA; Biomol, 
Heerhugowaard, The Netherlands)  
for 16 hours. To induce apoptosis, 
cells were treated with 2 mg/ml 
camptothecin (Sigma, St. Louis, MO)  
or anti-Fas antibody diluted 1:1,000  
(Sigma) for the indicated periods 
of time. Apoptosis was determined  
by analyzing annexin V-fluorescein  
isothiocyanate (FITC) binding and 
propidium iodide staining with flow  
cytometry.
Antibodies and random peptide phage 
display epitope mapping
The epitope of KM-2, a monoclonal 
anti-histone autoantibody derived 
from an MRL/lpr lupus mouse, which
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recognizes the N-terminal tails of 
histone H2A (H2A) and H421, was 
determined by screening a 15-m er  
random peptide phage display library  
(New England Biolabs, Leusden, 
The Netherlands) according to 
the manufacturer's instructions. 
O ther antibodies used were  #34, 
which recognizes unmodified H 3.1 /  
H3.222, and antibodies specific for  
H4 acetylated at lysine 5, 8, 12, and /  
or 16, H2A acetylated at lysine 5 or
9, H2B phosphorylated at serine 14 
(Upstate Biotechnology, Huissen, 
The Netherlands), actin, caspase 3, 
and poly(ADP-ribose) polymerase 2 
(PARP-2; Santa Cruz Biotechnology, 
Heerhugowaard, The Netherlands).
Peptide, double-stranded DNA 
(dsDNA), histone, and nucleosome 
enzyme-linked immunosorbent assays 
(ELISAs)
Peptides w ere  e ither synthesized 
in Strasbourg or obtained com m er­
cially (Eurosequence, Groningen, The  
Netherlands). All peptides were ana­
lyzed for integrity and purity by high 
performance liquid chromatography  
and mass spectrometry. The reac­
tivities in ELISA of KM-2 (starting 
concentration 5 mg/ml) and plasma 
samples from M RL/lpr lupus mice 
and SLE patients (diluted 1:100) with 
coated peptides were tested as pre­
viously described23. The SLE patients  
and the local ethics com m ittee  
approved the use of patients' plasma. 
For detection, the appropriate horse­
radish peroxidase (HRP)-conjugated  
antibodies (Southern Biotechnology, 
Birmingham, AL) were used. For the  
peptide inhibition ELISA, KM-2 was 
pre-incubated in a 96-well plate with  
com petitor peptides for 1 hour and 
then transferred to Maxisorp 96-well
plates (Nunc, Uden, The Netherlands)  
coated with 2 mM non-acetylated H4 
peptide. A fter 1 hour, an appropriate  
HRP-conjugated antibody was added 
for detection. Histone, dsDNA, and 
nucleosome ELISAs were performed as 
previously described23.
Preparation of cell extracts, extraction 
of histones, isolation of nucleosomes, 
and protein determination
For analysis of histones, phosphate 
buffered saline (PBS)-washed cells 
(2 *1 0 5) were  directly dissolved in 250  
ml Laemmli buffer and boiled for 5 
minutes. Alternatively, nuclei were  
isolated from 5 *1 0 5 cells with a glass 
Dounce tube and pestle, lysed in 250  
ml lysis buffer (250 m M  NaCl, 0.1% 
Nonidet P40, 0.5 m M  dithiothreitol 
(DTT), 50 m M  HEPES (pH 7.0), 5 mM  
EDTA, 100 ng/ml TSA, 5 m M  NaF) with  
protease inhibitors (Roche, Almere, 
The Netherlands), and sonicated twice  
on ice. Subsequently, histones were  
extracted with 0.2 M H2SO4, precipi­
tated with 20% trichloroacetic acid, 
and washed with ice-cold acidified 
acetone. The pellet was dissolved in 
100 ml of 100 m M  Tris HCl (pH 8.0). 
Nucleosomes were isolated from  
normal or TSA-treated Jurkat cells as 
described previously24 and further  
purified to homogeneity by gel fil­
tration chromatography using an HR 
16 /5 0  superose 6 column (Amersham, 
Roosendaal, The Netherlands). For 
histone acetyltransferase (HAT) and 
HDA activity assays, nuclear extracts  
were prepared in lysis buffer w ithout  
DTT, NaF, and TSA. Protein content  
was determined by the bicinchoninic 
acid assay (Sigma) with bovine serum 
albumin (Sigma) as a standard.
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Sodium dodecyl sulfate-polyacryl- 
amide gel electrophoresis (SDS-PAGE), 
western blotting, and immuno­
fluorescence staining of cells
Proteins resolved by SDS-PAGE (18%) 
were transferred to nitrocellulose 
as previously described23. Equal 
loading of the resolved histones 
was checked by silver staining (Bio­
Rad, Veenendaal, The Netherlands). 
Equal transfer of histones to nitro­
cellulose was checked by ponceau S 
(Bio-Rad) staining. Blots w ere  incu­
bated with the indicated primary  
antibodies and the appropriate HRP- 
conjugated antibodies and visualized 
by using enhanced chemiluminescence  
(Amersham) and Hyperfilm x-ray films 
(Amersham). For immunofluorescence  
staining, cytospun cells were  fixed 
with 2% paraformaldehyde and per- 
meabilized with 0.5% Triton X-100. 
Cells were incubated with the indi­
cated primary antibodies followed  
by an appropriate Alexa 488-conju-  
gated antibody (Invitrogen, Breda, The 
Netherlands) for detection. Terminal 
transferase dUTP nick end labeling 
(TUNEL, Roche) and 4 ',6-diamidino-2-  
phenylindole (DAPI, Roche) staining 
were performed according to the 
manufacturer's instructions.
HAT and HDA activity assays
HAT and HDA activities were measured 
using kits from BioVision (Uithoorn, 
The Netherlands) and Biomol, respec­
tively, according to the manufacturers' 
protocols.
Mice and evaluation of albuminuria, 
delayed-type hypersensitivity (DTH), 
and IgG deposition
Eight-week-old MRL/lpr, M RL/+/+, or 
BALB/c mice (The Jackson Laboratory, 
Bar Harbor, ME) were injected
subcutaneously with non-acetylated  
H4 peptide (residues 1-22), H4 peptide  
(residues 1-22) tri-acetylated at lysines 
8, 12, and 16, or PBS. Mice received 
100 mg peptide or PBS emulsified in 
Freund's complete adjuvant and 3 
booster injections with 100 mg peptide  
in Freund's incomplete adjuvant 
at 2-week intervals. Albuminuria  
was tested using Albustix (Bayer, 
Leverkusen, Germany). DTH assay was 
performed as previously described25 in 
MRL/lpr, M R l/ +/+, B10.BR, and BALB/c 
mice. Glomerular IgG depositions 
were visualized in 2-mm frozen sec­
tions of diseased mice by staining with  
Alexa 488-conjugated anti-mouse IgG 
antibody. For each group, 50 glomeruli 
were scored for IgG depositions in 
masked sections on a scale of 0-3 by 3 
independent observers. Experimental 
handling of the animals was approved 
by the local animal ethics com mittee.
Culture and manipulation of dendritic 
cells (DCs) and mixed lymphocyte 
reaction
Bone m arrow was isolated from  
MRL/lpr mice and cultured in the  
presence of 20 ng/ml granulocyte-  
macrophage colony-stimulating factor 
(Pepro-Tech, Heerhugowaard, The 
Netherlands) to obtain imm ature DCs, 
as described previously26. On day 8 of 
the culture, we added 10, 30, or 100 
mM non-acetylated or tri-acetylated  
H4 peptide (residues 1-22) or 10 or 
30 mg/ml of normal nucleosomes 
or hyperacetylated nucleosomes. 
After 24 hours, expression of the  
DC marker CD11c and the co stim u­
latory molecules CD40 and CD86 
was evaluated by flow cytom etry  as 
previously described26, while pro­
duction of the pro inflam matory  
cytokines interleukin-6 (IL-6) and
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tum or necrosis factor a  (TNF a )  in the  
cell culture supernatant was measured 
by ELISA (eBioscience, Malden, The  
Netherlands) according to the m anu­
facturer's instructions. The ability 
of the DCs to stimulate T cells was 
determined in a syngeneic mixed lym­
phocyte reaction in 96-well plates, for  
which 2 *1 0 4 stimulator cells and 105 
responder cells (i.e. splenocytes) were  
co cultured in the presence or absence 
of non-acetylated or tri-acetylated  
H4 peptide, normal nucleosomes, or 
hyperacetylated nucleosomes. The  
production of IL-2 in the cell culture  
supernatant was used as a measure  
of T cell activation and measured by 
ELISA (eBioscience).
Statistical analysis
Data are presented as the mean ±SD. 
Statistical significance was dete r­
mined by Student's t-test. Survival 
curves were analyzed by the Kaplan­
M eier  method using SPSS 12.0 (SPSS, 
Chicago, IL) and GraphPad Prism 4.0  
(GraphPad Software, San Diego, CA).
Results
Identification of the epitope of the 
lupus mouse-derived monoclonal 
autoantibody KM-2
According to our hypothesis, apop-  
tosis-induced modifications of 
histones/nucleosomes play an 
im portant role in the initial immune  
response against chromatin in lupus. 
Previously, we showed that the lupus 
mouse-derived monoclonal au to ­
antibody KM-2 reacts in ELISA with  
both an H4 peptide (residues 1-29) 
and an H2A peptide (residues 1-20), 
which are very similar in amino acid 
sequence20, while KM-2 also reacts 
with whole H4 and H2A. Using random
peptide phage display, we mapped  
the epitope of KM-2, which yielded 
the m otif RGGLGLVNGRSLRH. Analysis 
revealed 71.4% similarity to H4 (i.e., 
residues 5-18, KGGKGLGKGGAKRH) and 
42.8% similarity to H2A (i.e., residues 
6-19, QGGKARAKAKSRSS). However, 
the positively charged lysine residues 
at positions 8, 12, and 16 (K8, K12, 
and K16), which are normally present  
in H4, were absent in the identified  
motif. This suggested that in the  
epitope for KM-2 these lysine res­
idues were uncharged and thus could 
be modified (i.e., acetylated) and 
therefore  were not selected/identified  
by random peptide phage display 
epitope mapping, which makes use of 
a bacterial host. The reactivity of KM-2 
was determ ined with (acetylated) H4 
peptides (residues 1-22). Compared  
with the non-acetylated peptide, KM-2 
showed enhanced reactivity with H4 
peptides acetylated at K8, K12, and /  
or K16, while the acetylation at K5 
reduced the binding of KM-2 (figure
IA ).  An inhibition ELISA with com ­
petitor peptides in solution, to rule 
out possible differences in coating 
efficiency, gave similar results (i.e., 
peptides acetylated at K8, K12, and /  
or K16 showed a better inhibition than 
the unmodified H4 peptide) (figure
IB).
To test w hether KM-2 could also 
react with acetylated H4 in situ, we 
stained Jurkat cells that were either  
untreated or treated with TSA, which 
is a specific HDA inhibitor resulting 
in hyperacetylation of histones. 
KM-2 staining of untreated cells 
revealed a weak, fine granular nuclear 
staining that clearly increased after  
TSA treatm ent. A similar result was 
obtained by staining with commercially
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Figure 1. Recognition of acetylated (Ac) histone H4 (H4) 
by the lupus mouse-derived autoantibody KM-2.
A) Reactivity of KM-2 with the indicated acetylated 
H4 peptides (residues 1-22) in a direct enzyme-linked 
immunosorbent assay (ELISA).
B) Inhibition of binding of KM-2 to non-acetylated H4 
peptide by acetylated H4 peptides in a competition ELISA. 
IC50 50% inhibition concentration. Values in A and B are 
the mean and SD.
C) Enhanced nuclear staining of trichostatin A 
(TSA)-treated Jurkat cells by KM-2, anti-H4-AcK8, and anti- 
H4-AcK12 (original magnification x400).
D) Enhanced reactivity of KM-2, anti-H4-AcK8, and 
anti-H4-AcK12 with equally loaded sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis-resolved 
histones (H2A and H4) that were acid-extracted from 
TSA-treated Jurkat cells. Note that the upper band repre­
sents H2A and the lower band represents H4.
available antibodies (i.e., anti-H4-  
AcK8 and anti-H4-AcK12) (Ac indicates 
acetylated) (figure 1C). In contrast, 
nuclear staining by monoclonal au to ­
antibodies to dsDNA, nucleosomes, or 
H 3.1 /H 3 .2  was not enhanced by TSA 
trea tm ent (data not shown).
Probing of resolved histones extracted  
from TSA-treated Jurkat cells with
KM-2, anti-H4-AcK8, and anti-  
H4-AcK12 antibodies also revealed an 
enhanced reactivity with H4 (figure 
1D). The reactivity of KM-2 with  
H2A was also increased upon TSA 
trea tm ent (figure 1D). Apparently, the  
region within H2A that is homologous  
to the identified epitope m otif and 
the N-terminal region of H4 includes 
one or more lysine residues that can 
be acetylated, most likely K5 and K9. 
Anti-H4-AcK5 and anti-H4-AcK16 gave 
similar results for both nuclear staining 
and western blot analysis (data not 
shown). Taken together, these data  
indicate that the primary epitope for 
the lupus mouse-derived monoclonal 
autoantibody KM-2 is located within  
the N-terminal tail of H4 and includes 
acetylated lysine residues at position 8 
and/or 12 and/or 16.
Recognition of apoptosis-induced 
histone modifications by lupus-derived 
autoantibodies
Since apoptosis-induced histone 
modifications may be targets for the  
immune system in lupus, the reac­
tivity of KM-2 was tested with histones 
that were extracted from both non- 
apoptotic and apoptotic Jurkat cells. 
Induction of apoptosis by 4 hours of 
incubation with camptothecin, a DNA 
topoisomerase I inhibitor, clearly 
enhanced the reactivity of KM-2 
with both H4 and H2A (figure 2A). 
Commercially available antibodies  
that are specific for the d ifferent  
acetylated forms of H4 or H2A also 
showed enhanced reactivity. An 
antibody specific for H2B phosphor-  
ylated at serine residue 14, which is 
a well-established apoptosis-induced  
histone modification that is also asso­
ciated with dsDNA breaks27, 28, also 
revealed enhanced reactivity with
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apoptotic H2B. In contrast, the reac­
tivity of another lupus mouse-derived  
monoclonal autoantibody, which is 
specific for unmodified H3.1/H3 . 222, 
was not different for non-apoptotic  
and apoptotic cells (figure 2A).
Immunofluorescence double staining 
of apoptotic Jurkat cells by KM-2 and 
TUNEL clearly revealed co-staining, 
especially of apoptotic blebs (figure 
2B).
The reactivity of KM-2 was also ana­
lyzed with histones extracted from  
non-apoptotic Jurkat cells and Jurkat 
cells that were apoptotic for d ifferent  
time periods. After 1 hour of incu­
bation with camptothecin or 4 hours 
after trea tm ent with anti-Fas antibody, 
the reactivity of KM-2 with H4 and 
H2A increased with a concomitant 
cleavage of PARP-2 (figure 2C) and 
caspase 3 (data not shown). Notably,
1 hour a fter induction of apoptosis 
with camptothecin, the percentage  
of apoptotic cells was still extrem ely  
low as measured by Annexin V-FITC 
staining, which indicates that apop- 
tosis-induced acetylation of H4 and 
H2A is an early event that precedes 
the reorientation of phosphatidyl-  
serine in the lipid bi-layer (figure 2C). 
The enhanced reactivity of KM-2 with  
apoptotic H4 and apoptotic H2A was 
not Jurkat cell specific and was also 
observed for the monocytic U937 cell 
line (data not shown).
W e then tested w hether apoptosis- 
induced changes in the activity of 
HATs or HDAs could serve as a mech­
anistic explanation for the observed 
hyperacetylation of apoptotic his­
tones. Determination of total HAT and 
HDA activity in both non-apoptotic
Figure 2. Recognition of apoptosis-induced hyper- 
acetylation of H4 and H2A by the lupus mouse-derived 
autoantibody KM-2.
A) Enhanced reactivity of KM-2, anti-H4-AcK5, anti- 
H4-AcK8, anti-H4-AcK12, anti-H4-AcK16, anti-H2A-AcK5, 
anti-H2A-AcK9, and an antibody to H2B phosphorylated at 
serine 14 (anti-H2B-PhS14) with sodium dodecyl sulfate­
polyacrylamide gel electrophoresis (SDS-PAGE)-resolved 
histones that were acid-extracted from Jurkat cells that 
had been induced to undergo apoptosis by 4 hours of 
incubation with camptothecin (CPT). An antibody specific 
for actin was used as an internal loading control.
B) Recognition by KM-2 of apoptotic blebs of Jurkat 
cells that stain positively by TUNEL. Staining with 
4',6-diamidino-2-phenylindole (DAPI) reveals fragmen­
tation of the nucleus. (Original magnification x 400.)
C) Concomitant cleavage of poly(ADP-ribose) polymerase 
2 (PARP-2) with enhanced reactivity of KM-2 with 
SDS-PAGE-resolved H4 and H2A extracted from Jurkat 
cells induced to undergo apoptosis by CPT and anti-Fas 
antibody for the indicated time periods. The progress 
of apoptosis was analyzed by measuring the percentage 
of cells that stained positive for annexin V-fluorescein 
isothiocyanate (AN) and propidium iodide (PI).
D) Relative histone acetyltransferase (HAT) and histone 
deacetylase (HDA) activity in non-apoptotic Jurkat cells 
and Jurkat cells in early apoptosis induced by CPT or 
anti-Fas antibody. Activities in untreated cells are set at 1. 
Values are the mean and SD. P values indicate significant 
differences compared with untreated cells. See figure 1 
for other definitions.
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and apoptotic Jurkat cells revealed  
a significantly lower HDA activity 4 
hours after induction of apoptosis 
in e ither camptothecin- or anti-Fas- 
treated cells, while total HAT activity  
was significantly increased in camp-  
tothecin-treated  cells, but not in 
anti-Fas-treated cells (figure 2D). Taken 
together, the apoptosis-induced hyper- 
acetylation of H4 and H2A in apoptotic  
cells, which is recognized by the lupus 
mouse-derived autoantibody KM-2, is 
most likely mediated by decreased HDA 
activity and /or increased HAT activity. 
To extend the findings obtained with  
the lupus mouse-derived monoclonal 
autoantibody KM-2, the reactivity of 
plasma samples from 6-9-w eek-old  
(before disease onset) and >20-week-  
old (diseased) M RL/lpr lupus mice 
with non-acetylated H4 peptide  
(residues 1-22) and the corresponding  
H4 peptide tri-acetylated at K8, K12, 
and K16 was tested in ELISA. On 
average, plasma samples from lupus 
mice before disease onset and from  
diseased lupus mice showed sig­
nificantly higher reactivity with the  
tr i-acetylated H4 peptide than with  
the non-acetylated H4 peptide (figure  
3A). For mice before disease onset and 
diseased mice, 11 of 11 plasma samples 
and 12 of 13 plasma samples, respec­
tively, showed higher reactivity with 
the tri-acetylated H4 peptide. Plasma 
samples from 6-9-w eek-o ld  (before  
disease onset) and 30-week-old  (dis­
eased) (NZB-NZW)F1 lupus mice, which 
have a different H-2 compared with  
M RL/lpr lupus mice, yielded com pa­
rable results (data not shown). We also 
tested plasma samples from 35 SLE 
patients, which revealed on average  
significantly higher reactivity with the  
tr i-acetylated H4 peptide than with  
the non-acetylated H4 peptide (figure
3A). Notably, 26 of these 35 plasma 
samples showed higher reactivity with  
the tri-acetylated H4 peptide. Plasma 
samples from M RL/+/+, B10.BR, and 
BALB/c mice and healthy individuals 
did not show any reactivity with the H4 
peptides (data not shown). Therefore, 
acetylation of H4 at lysine residues 8, 
12, and 16 seems to be im portant in 
lupus.
When acid-extracted histones from  
non-apoptotic and apoptotic Jurkat 
cells w ere  used as a coating in ELISA, a 
significant 2-fold higher average reac­
tivity of plasma samples from both 
lupus patients and mice with apop­
totic histones was found compared  
with reactivity with non-apoptotic  
histones (data not shown). We further  
visualized the reactivity of plasma 
samples from 9 SLE patients (ran­
domly selected from the cohort of 
35 SLE patients) with histones by 
probing blots of histones of normal 
Jurkat cells, TSA-treated Jurkat cells, 
and camptothecin-treated apoptotic  
Jurkat cells. This revealed that 8 of 9 
plasma samples showed higher reac­
tivity with hyperacetylated histones, 
while 9 of 9 plasma samples showed 
higher reactivity with apoptotic his­
tones compared with normal histones 
(figure 3B). In parallel, we evaluated  
the immunofluorescence staining 
of normal Jurkat cells and TSA- and 
camptothecin-treated Jurkat cells by 
these 9 plasma samples. This revealed  
more intense nuclear staining in TSA- 
treated cells for 7 of 9 plasma samples 
and intense staining of apoptotic blebs 
for 6 of 9 plasma samples compared  
with normal cells (figure 3C). The data 
from the 9 plasma samples from SLE 
patients are summarized in table 1 and 
indicate that the 6 of 9 plasma samples
60 C h apter 4
that had increased reactivity with  
the tri-acetylated H4 peptide com­
pared with non-acetylated H4 peptide  
also showed enhanced reactivity  
with apoptotic histones compared  
with normal histones in western blot 
analysis. Taken together, our data 
clearly indicate that antibodies present 
in lupus-derived plasma do recognize 
apoptosis-induced histone modifica­
tions that include histone acetylation.
Acceleration of disease developm ent  
in lupus mice by tri-acetylated H4 
peptide
To evaluate w hether  apoptosis- 
induced histone acetylation is 
im portant for the pathogenesis of 
SLE, non-acetylated or tri-acetylated  
(at K8, K12, and K16) H4 peptide  
(residues 1-22) was subcutane­
ously administered to lupus-prone  
M RL/lpr mice before disease onset, 
H-2-matched control M RL/+/+ mice, or 
H-2-mismatched BALB/c mice, while 
PBS-injected mice served as controls. 
Administration of H4 peptide, either  
acetylated or non-acetylated, to 
M RL/+/+ or BALB/c mice did not result 
in anti-dsDNA, anti-histone, and anti- 
nucleosome reactivity in plasma, nor 
did it result in proteinuria. However, 
administration of the tri-acetylated  
H4 peptide to lupus-prone MRL/lpr  
mice before disease onset resulted in
Figure 3. Recognition of apoptotic histones and acetylated histones by lupus-derived plasma samples.
A) Reactivity of plasma samples (given in absolute optical density [OD] values measured at 450 nm) from 6-9-week-old 
(before disease onset) MRL/lpr lupus mice (n=11), >20-week-old diseased MRL/lpr lupus mice (n=13), and systemic lupus 
erythematosus (SLE) patients (n=35) with non-acetylated H4 peptide (residues 1-22) and the corresponding H4 peptide 
tri-acetylated at K8, K12, and K16. Horizontal lines indicate the mean. P values were obtained by Student's paired t-test.
B) Reactivity of plasma from 9 SLE patients with resolved histones extracted from Jurkat cells cultured without addition 
or with TSA or camptothecin (CPT).
C) Immunofluorescence staining of Jurkat cells cultured without addition or with TSA or CPT by plasma from 9 SLE 
patients. Note that apoptotic blebs are intensely stained after induction of apoptosis. A pool of plasma samples from 
healthy individuals was used as a control (C). Semi-quantitative scoring of the blots and immunofluorescence staining 
is summarized in table 1. (Original magnification x 400.) DAPI= 4',6-diamidino-2-phenylindole (see figure 1 for other 
definitions).
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Table 1. Different anti-chromatin reactivities of plasma samples from 9 patients with lupus nephritis*
Patiënt SLEDAI Anti-dsDNA Anti- Anti-histone Anti-H4 peptide Anti-H4 peptide Immunofluorescence Western blot analysis 
score, antibody nucleosome antibody titer, (non-acetylated) (tri-acetylated) staining of Jurkat cells of Jurkat cells
0-105 titer,
units/ml
antibody titer, 
units/ml
units/ml antibody titer, 
units/ml
antibody titer, 
units/ml
No TSA CPT No TSA CPT
1 16 400 18 7 40 70 + ++ ++ ++ +++ +++
2 20 218 1200 83 50 100 ++ + + ++ ++ +++
3 22 75 220 9 50 120 + ++ ++ ++ +++ +++
4 20 689 1400 11 70 70 + ++ ++ + ++ ++
5 10 72 220 8 50 80 - + + - + +
6 18 29 11 7 50 70 - + + - + +
7 28 643 1000 50 70 70 + + + + ++ ++
8 14 29 15 8 90 60 + ++ + + ++ ++
9 6 15 8 7 40 60 + ++ ++ + ++ ++
C 0 0 0 0 0 0 - - - - - -
* All patients had biopsy-proven lupus nephritis (International Society of Nephrology/Renal Pathology Society class III or IV [see ref. 53]) with proteinuria (range 2.2-11.9 
gm/24 hours) and normal or impaired renal function (serum creatinin range 58-203 jxmoles/litre). A pool of plasma samples from healthy individuals was used as a control 
(C). SLEDAI = Systemic Lupus Erythematosus Disease Activity Index (see ref. 54). No = no treatment of the cells
t Anti-double-stranded DNA (anti-dsDNA), anti-nucleosome, anti-histone (using total histone mix as substrate), and non/acetylated and tri-acetylated (at K8, K12, and K16) 
histone H4 (H4) peptide (residues 1-22) titers in plasma were determined by enzyme-linked immunosorbent assay.
t  Semi quantitative analysis of immunofluorescence staining (of Jurkat cells cultured without treatment or with trichostatin A [TSA] or camptothecin [CPT]) by plasma as 
shown in figure 3C. Note that staining of blebs was scored after induction of apoptosis.
§ Semi quantitative analysis of western blots of resolved histones (extracted from Jurkat cells cultured without treatment or with TSA or CPT) probed with plasma as shown 
in figure 3B.
enhanced m ortality  compared with  
t rea tm en t with the non-acetylated  
H4 peptide or PBS (figure 4A). 
Furthermore, the developm ent of 
proteinuria and progression of skin 
lesions were  significantly accelerated  
and affected more mice in the group 
treated with the tr i-acetylated peptide  
than in the PBS- or non-acetylated  
peptide-treated  groups (figures 4B 
and C). The severity of skin lesions was 
more pronounced in the group that  
received the tr i-acetylated peptide. 
The titers of anti-dsDNA, anti-histone, 
anti-nucleosome, anti-H4-AcK8,
anti-H4-AcK12, and anti-H4- AcK16 
antibodies in plasma samples from  
16-week-old mice did not differ sig­
nificantly between the 3 groups (data 
not shown). In lupus, glomerular 
IgG deposition is associated with 
the developm ent and severity of 
proteinuria. Scoring on a scale of 0-3 
revealed a mean ± SD glomerular 
IgG deposition index of 2.1 ± 0.2 for 
the tri-acetylated peptide-treated  
group, which was significantly higher 
(P < 0.01) than those for the non- 
acetylated peptide- and PBS-treated 
groups (1.3 ± 0.1 and 0.8 ± 0.2, respec­
tively). Taken together, these data 
indicate that administration of the  
tri-acetylated H4 peptide, which cor­
responds to the apoptosis-induced 
epitope for the lupus mouse-derived  
autoantibody KM-2, significantly 
accelerates disease developm ent in 
M RL/lpr lupus-prone mice.
Maturation of DCs by hyperacetylated 
nucleosomes and activation of T cells
To evaluate w hether the acceleration  
of disease developm ent by the tri- 
acetylated H4 peptide was associated 
with a d ifferent cellular response, 
we deployed a DTH reaction.
Sixteen-week old M RL/lpr mice pre­
treated with the non-acetylated  
peptide, the tri-acetylated peptide, or 
PBS received either the non-acetylated  
or the tr i-acetylated H4 peptide in the  
left or right ear, respectively, and ear 
swelling was subsequently measured
Figure 4. Acceleration of disease in MRL/lpr lupus mice 
by tri-acetylated H4 peptide.
Shown are the results of treatment of 8-week-old MRL/ 
Ipr lupus mice with non-acetylated H4 peptide (residues 
1-22) (n=7), H4 peptide (residues 1-22) tri-acetylated 
at lysine residues 8, 12, and 16 (n=11), or phosphate 
buffered saline (PBS) as a control (n=6).
A) Administration of the tri-acetylated H4 peptide results 
in enhanced mortality of animals compared with adminis­
tration of the non-acetylated H4 peptide or PBS (P<0.01).
B) Administration of the tri-acetylated H4 peptide aggra­
vates proteinuria compared with administration of the 
non-acetylated H4 peptide or PBS (P<0.05).
C) The tri-acetylated H4 peptide induces earlier and more 
severe skin lesions compared with the non-acetylated H4 
peptide or PBS (P< 0.05). See figure 1 for other definitions.
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after  24 hours. In all MRL/lpr groups, 
ear swelling induced by the tri-  
acetylated peptide was significantly 
greater than that induced by the  
non-acetylated peptide (figure SA). 
Apparently, MRL/lpr mice pre-treated  
with PBS alone already showed a 
higher DTH response against the tri-  
acetylated peptide than against the 
non-acetylated peptide, while pre­
trea tm ent with the tri-acetylated  
peptide did not fur ther increase the 
DTH response against this peptide. 
There was no significant DTH reac­
tivity against the tri-acetylated and 
non-acetylated H4 peptides in M RL/+/+ 
mice, non-autoim m une H-2-matched  
B10.BR mice, and H-2-mismatched  
BALB/c mice (figure SA).
Next, we wondered w hether the tri- 
acetylated H4 peptide could induce 
maturation of DCs and specific T 
cell reactivity. DCs from 1S-week-  
old MRL/lpr mice were incubated for 
24 hours with non-acetylated or tri-  
acetylated H4 peptide or with normal 
nucleosomes or hyperacetylated  
nucleosomes. This revealed that only 
the culture with hyperacetylated  
nucleosomes resulted in DC m atu­
ration as measured by increased 
expression of the co-stimulatory mol­
ecules CD40 and CDS6 (figure SB) 
and increased production of the pro- 
in flam m atory cytokines IL-6 and TNFa  
(figure SC) compared with that in DCs 
incubated with medium alone. The H4 
peptides had no effect on DC m atu­
ration (data not shown), while normal 
nucleosomes had a minor effect  
(figures SB and C). Finally, we per­
formed a syngeneic mixed lymphocyte  
reaction using DCs and splenocytes 
from 1S-week-old MRL/lpr mice co­
cultured in the absence or presence
of non-acetylated or tri-acetylated  
H4 peptide or normal nucleosomes or 
hyperacetylated nucleosomes. Only 
hyperacetylated nucleosomes were  
able to induce a DC-mediated T cell 
response as measured by IL-2 pro­
duction, whereas normal nucleosomes 
(figure SD) or H4 peptides (data not 
shown) failed to induce IL-2 secretion. 
In summary, hyperacetylation of 
nucleosomes results in DC maturation  
and subsequent T cell activation, which 
may explain our findings. However, we  
could not dem onstrate  a syngeneic T 
cell response against the tri-acetylated  
H4 peptide, which may require more 
sensitive methods.
D iscuss ioN
We dem onstrate  that lupus-derived  
autoantibodies show enhanced reac­
tivity with acetylated histones from  
either apoptotic cells or cells treated  
with an HDA inhibitor. O ther groups of 
investigators also have reported that 
lupus-derived sera react with apop­
totic histones; however, the nature  
of these histones was not further  
evaluated29. We found that apoptosis- 
induced acetylation of histones was 
mediated by changes in HDA and/or  
HAT activity. Both apoptosis-induced 
histone deacetylation and acetylation  
have been described30-34, which may 
be explained by differences in applied 
experimental approaches. In recent 
studies, it has been shown that HAT­
mediated hyperacetylation of histones 
is associated with dsDNA breaks35. In 
the present study, we have charac­
terized and applied a sensitive tool 
that was provided by nature itself 
(i.e., a lupus-derived monoclonal au to ­
antibody) to analyze apoptosis-induced
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Figure 5. Maturation of dendritic cells (DCs) by hyperacetylated nucleosomes and activation of T cells.
A) Higher delayed-type hypersensitivity (DTH) response of 16-week-old MRL/lpr lupus mice against the triacetylated H4 
peptide than against the nonacetylated H4 peptide in all groups, irrespective of the pretreatment received. Age-matched 
MRL/+/+, B10.BR, or BALB/c mice did not show any significant DTH response against the triacetylated or nonacetylated H4 
peptides. Phosphate buffered saline injections alone gave an average ear swelling of 0.22 mm.
B) Expression of costimulatory molecules CD40 and CD86 in bone marrow-derived DCs from 15-week-old MRL/lpr mice 
after 24-hour incubation with medium alone (no addition) or in the presence of 10 or 30 mg/ml normal nucleosomes 
(N) or hyperacetylated nucleosomes (HAN). Only hyperacetylated nucleosomes led to increased expression of CD40 and 
CD86 by DCs (P<0.01 versus DCs without addition).
C) Secretion of the proinflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor a  (TNFa) by DCs after 
24-hour incubation with medium alone or in the presence of 10 or 30 mg/ml normal nucleosomes or hyperacetylated 
nucleosomes. Only hyperacetylated nucleosomes led to increased expression of IL-6 and TNF_by DCs (P<0.01 versus DCs 
without addition).
D) IL-2 production in syngeneic cocultures of DCs and splenocytes in the presence of 10 or 30 mg/ml normal nucleosomes 
or hyperacetylated nucleosomes. Only hyperacetylated nucleosomes led to IL-2 production. Splenocytes or DCs alone in 
the absence or presence of nucleosomes or hyperacetylated nucleosomes did not produce IL-2 (data not shown). See 
figure 1 for other definitions.
histone acetylation. Treatment of cells 
by HDA inhibitors such as TSA may 
lead to apoptosis, while HDA inhib­
itors and other inducers of apoptosis 
act synergistically36, 37. The apoptosis- 
inducing capacity of HDA inhibitors  
is explained by the effect of histone 
hyperacetylation on the expression 
of genes operative in apoptotic
pathways or the cell cycle38, since 
hyperacetylation of histones leads to 
a transcriptionally active and acces­
sible chromatin structure39. Notably, 
trea tm ent of lupus-prone mice with  
HDA inhibitors ameliorates disease40, 
41. The beneficial effect of systemically  
administered HDA inhibitors, including 
TSA, to M RL/lpr lupus-prone mice was
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explained by a reduced expression 
of certain cytokines by peripheral 
blood mononuclear cells. We show 
that administration of a defined tr i­
acetylated H4 peptide is pathogenic in 
lupus-prone mice. Apparently, the sys­
temic administration of HDA inhibitors 
to lupus-prone mice does not lead to 
an enhanced release of apoptosis- 
derived hyperacetylated histones into 
the circulation and may even induce 
anti- in flam m atory  effects. Other  
apoptosis-induced histone modifica­
tions include de-ubiquitination of H2A, 
transglutamination of H2B, and phos­
phorylation of H2A, H2A.X, H2B, and 
H3 at d ifferent residues42. Apoptosis- 
induced phosphorylated proteins have 
been dem onstrated to be targets for 
SLE-derived sera; however, histones 
were not evaluated43. As far as we 
know, apoptosis-induced methylation  
(or demethylation) or citrullination of 
histones has not yet been assessed. 
This latter modification is of par­
ticular importance, since antibodies 
specific for citrullinated autoantigens  
are predictive for the developm ent of 
rheumatoid arthritis44. Until now, none 
of the abovementioned apoptosis- 
induced histone modifications has 
been identified as a target of autoanti­
bodies in SLE.
Several nucleosomal and /or histone T 
cell epitopes have been identified for 
both lupus mice and lupus patients 
in H1, H2A, H2B, H3, and H4 45. In all 
studies, however, the T cell response 
was measured by presenting a panel 
of unmodified histone peptides, which 
could have prevented the identif i­
cation of T cell epitopes containing 
modifications. Apoptosis-associated 
histone modifications that may be 
located within the identified lupus
T cell epitopes include de-ubiquiti-  
nation of H2A at position 119 and 
phosphorylation of H2B at S14 27- 46. 
Notably, the primary epitope m otif we  
have identified for KM-2 in H4 (res­
idues 5-18) partially overlaps with a T 
cell epitope in H4 (residues 14-28) in 
human lupus47, and, as we show here, 
the overlapping region contains K16, 
which can be acetylated during apop­
tosis. In a syngeneic test system that 
consisted of bone marrow-derived  
DCs and splenocytes, we were able 
to dem onstrate  DC maturation and 
subsequent T cell activation upon 
incubation with hyperacetylated  
nucleosomes, whereas normal nucleo- 
somes had no clear effect. Previously, 
it has been described that normal 
nucleosomes, although at higher 
concentrations than we used here, 
are also able to mature DCs24. We  
failed to dem onstrate  a specific T cell 
response against the non-acetylated  
or tri-acetylated H4 peptide (res­
idues 1-22) in our in vitro system, 
which may be explained by inefficient  
processing and /or presentation of the  
peptides by DCs or by the use of insuf­
ficiently sensitive methods to detect  
a T cell response in vitro. It has been 
shown that administration of apop-  
totic cells results in the developm ent  
of anti-nucleosome antibodies and 
proteinuria in both normal and lupus 
mice18-20. In the present study, we  
show that administration of an H4 
peptide tri-acetylated at K8, K12, and 
K16 accelerates disease development  
in lupus-prone mice before disease 
onset, as measured by increased 
mortality, the increased deposition 
of glomerular IgG, and more severe 
proteinuria and skin lesions. However, 
we could not dem onstrate  d iffer­
ences in anti-dsDNA, anti-nucleosome,
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anti-histone, anti-H4-AcK8, anti- 
H4-AcK12, or anti-H4-AcK16 antibody  
titers a fter  immunization with the tri-  
acetylated H4 peptide. This may be 
explained by high-affinity binding of 
arising antibodies to tissues such as 
the glomerulus. Moreover, the patho­
genesis of lupus may be independent  
of anti-dsDNA or anti-nucleosome  
antibody t iters48, 49.
The DTH response in lupus mice 
against the tri-acetylated H4 peptide  
was higher than that against the  
non-acetylated peptide and was 
independent of the pre -treatm ent  
of mice with PBS, non-acetylated H4 
peptide, or tri-acetylated H4 peptide. 
The presence of apoptosis-derived  
endogenous tri-acetylated H4 in the  
M RL/lpr lupus background may explain 
why the DTH response against the tri-  
acetylated H4 peptide was already  
present in non-immunized mice and 
was not enhanced a fter  immunization  
with the tri-acetylated peptide. In 
contrast to MRL/lpr lpus-prone mice, 
control MRL/+/+ mice and BALB/c mice 
treated with the tri-acetylated peptide  
failed to develop autoim m unity  and 
disease. In addition, control MRL/+/+ 
mice, non-autoim m une H-2-matched  
B10.BR mice, and non-autoimm une  
H-2-mismatched BALB/c mice did not 
show a DTH response against either H4 
peptide. Therefore, a cellular response 
to the tri-acetylated H4 peptide was 
found in only the lupus-prone MRL/lpr  
mouse.
How can we explain the pathogenic  
nature of the tr i-acetylated H4 peptide  
in lupus-prone MRL/lpr mice? It may 
be due to the absence of tolerance  
for the apoptosis-induced acetylation  
m otif15, 16. An inefficient processing
of the apoptosis-induced acetylation  
m otif in lupus mice, a change in the 
co-stimulatory capacity/activity of 
antigen-presenting cells, or epitope  
spreading to even more pathogenic  
epitopes may be other possible con­
tributing factors50. In conclusion, 
we show that the tri-acetylated H4 
peptide, which carries the apoptosis- 
associated acetylation motif, incites 
a vigorous response in a lupus-prone  
background. We are currently inves­
tigating whether, in addition to  
apoptosis-induced histone acetylation, 
other apoptosis-induced histone modi­
fications or combinations of histone 
modifications (i.e., a "histone code" 
for apoptosis) exist that are pathogenic  
and targets for lupus-derived autoanti­
bodies17, 51. For diagnostic purposes, 
the reactivity of sera from SLE patients 
with apoptosis-induced modifications  
may be "missed" when non-apoptotic  
cells are used as a substrate (e.g., in 
HEp-2 ANA staining). Indeed, our data 
revealed an enhanced nuclear staining 
or staining of apoptotic blebs by 5 of 
9 plasma samples from SLE patients. 
In addition to diagnosis, it would be 
of interest to determ ine in patients  
w hether antibodies specific for apop- 
tosis-induced histone or nucleosome 
modifications are predictive for the 
developm ent of SLE and /or exacerba­
tions of the disease.
Finally, the apoptosis-induced histone 
motifs that are targets for the immune  
system in lupus could be applied in 
tolerizing strategies52. In conclusion, 
we have shown that lupus-derived 
autoantibodies recognize apoptosis- 
induced histone modifications, in 
particular histone acetylation, and that  
an H4 peptide carrying an apoptosis- 
induced acetylation m otif accelerated
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disease developm ent and severity in 
lupus-prone mice before disease onset. 
Furthermore, we could demonstrate  
maturation of DCs and DC-mediated  
T cell activation by hyperacetylated  
nucleosomes. Therefore, the challenge 
of the imm une system by apoptosis- 
induced chromatin modifications may 
be an im portant initial event that leads 
to disruption of the balance between  
tolerance and auto im m unity  and the 
formation of pathogenic chromatin  
autoantibodies in SLE.
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ucleosomes have been identified as a key autoantigen in 
systemic lupus erythematosus (SLE). Nucleosomes are present 
in the circulation due to a disturbed apoptosis and /or an insufficient 
clearance in SLE. During apoptosis, histones can be modified, thereby  
making them  more immunogenic. Recently, w e  showed the importance  
of apoptosis-induced acetylation of histone H4 in the pathogenesis of 
SLE. The lupus-derived antibody LG11-2 was previously shown to react 
with the N-terminal tail of histone H2B, which contains amino acid 
residues that can be modified including phosphorylation of serine 14, 
known to occur during apoptosis. Here, w e  evaluate w hether apoptosis- 
induced histone modifications on H2B exist that are targeted by LG11-2 
or lupus-derived plasma.
Methods: Immunofluorescence staining and western immunoblot  
analysis of control, apoptotic and Trichostatin A-treated cells/chromatin  
was performed with monoclonal antibody LG11-2. Reactivity of LG11-2 
and plasma from lupus mice and SLE patients with acetylated and/or  
phosphorylated H2B peptides was determined in competition ELISA.
Results: LG11-2 showed enhanced reactivity with apoptotic and hyper- 
acetylated H2B compared to normal H2B. This enhanced reactivity was 
due to the acetylation of lysine 12 in H2B. This modification was also 
recognized by autoantibodies from pre-diseased lupus mice, but to a 
lesser extent by plasma of diseased lupus mice and lupus patients.
Conclusions: The apoptosis-induced acetylation on H2BK12 is a target 
for autoantibodies in SLE. Since the anti-H2BK12ac reactivity was mainly 
found in pre-diseased lupus mice, this epitope seems important in the  
early phase of the anti-chromatin autoim m une response with subse­
quent epitope spreading to unmodified H2B.
N
In t r o d u c t io n
One of the characteristic features  
of Systemic Lupus Erythematosus  
(SLE) is the formation of anti-nuclear  
antibodies, including anti-histone  
antibodies. Nucleosomes, composed 
of an octam er of core histones with 
DNA wrapped around, are a major 
autoantigen in SLE. Nucleosomes are 
released into the circulation due to a 
disturbed apoptosis and /or insuffi­
cient clearance of apoptotic material 
in SLE1. Histone modifications take
place mainly at the N-terminal tails 
of the histones, thereby adjusting 
the structure and function of chro­
matin. According to the histone 
code hypothesis distinct (combinations 
of) histone modifications are related  
to specific chrom atin-related functions 
and processes2. Histone modifications  
play, for example, a role in gene tran ­
scription, DNA repair, mitosis, meiosis, 
developm ent and most likely in apop­
tosis. The first identified histone
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modification linked to apoptosis 
was the phosphorylation of serine 
14 on histone H2B that is catalyzed 
by the mammalian sterile 20 kinase 
( M s t l ) 3, 4. O ther identified modifi­
cations linked to apoptosis include 
the SLE-associated tri-acetylation  
of histone H4, as we described pre­
viously 5 and the recently identified  
phosphorylation of threonine 45 on 
histone H36. We and others hypoth­
esized that histone modifications  
set during apoptosis make released 
apoptotic nucleosomes more im m u­
nogenic, leading to an immunogenic  
presentation by antigen presenting 
cells, which ultimately could result 
in autoantibody production. Hence, 
characterization of epitope specificity 
of autoantibodies in SLE could reveal 
histone modifications that occur spe­
cifically during apoptosis.
Initially, the epitope of the lupus- 
derived antibody LG11-2 was roughly 
mapped in the N-terminal tail of 
histone H2B (amino acids (aa) 6-18) 
using peptide ELISAs 7. Furthermore, 
the epitope of LG11-2 seems accessible 
at the surface of the nucleosome8, 9. 
The amino-terminal tail of histone H2B 
appears to be essential for chromatin  
condensation10, and, as mentioned, 
the phosphorylation of serine 14 on 
H2B is linked to apoptosis3, 4 and also 
to double strand DNA breaks11.
Importantly, the epitope of LG11-2 is 
located within an identified lupus T 
cell epitope12. Furthermore, LG11-2 has 
been used for the detection of apop-  
totic nucleosomes in ELISA and binds 
to apoptotic blebs13, 14. Moreover, it has 
been shown that apoptotic material 
can activate dendritic cells and subse­
quently T cells, while administration of
apoptotic cells or dendritic cells loaded 
with apoptotic material induces/ 
enhances autoantibody production15,
16.
Autoantigen modifications set during 
apoptosis seem im portant in these  
immunogenic processes17. Therefore, 
LG11-2 with an epitope in H2B encom ­
passing a potential apoptosis-modified  
residue, is an interesting candidate to 
further characterize. In this report, we  
evaluate w hether apoptosis-induced  
modifications on H2B occur that are 
targeted by the lupus-derived auto ­
antibody LG11-2 and by plasma from  
lupus mice and SLE patients.
M e t h o d s
Cell cultures and induction of apopto- 
sis
Jurkat cells were cultured in com ­
plete medium (RPMI 1640 Dutch 
modification, 10% fetal calf serum, 
1% penicillin-streptomycin, 1% glu- 
tamax, 1% pyruvate). To inhibit histone 
deacetylases, cells were treated  
with 100 ng/ml Trichostatin A (Enzo 
Life Sciences, Raamsdonksveer, the  
Netherlands). Apoptosis was induced 
by treating cells with 2 mg/ml campto-  
thecin (Sigma, Zwijndrecht, the  
Netherlands). Apoptosis was 
determined by analyzing Annexin 
V-fluorescein isothiocyanate (FITC) 
(ITK Diagnostics, Uithoorn, the  
Netherlands) binding and Propidium  
Iodide (PI) staining with flow  
cytometry, as described previously5.
Antibodies and plasma
LG11-2 is a monoclonal anti-histone  
autoantibody derived from a non­
immunized MRL/lpr mouse, which
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recognizes a.a. 6-18 in the N-terminal 
tail of H2BX O ther antibodies used 
are monoclonal antibody (mAb) #34  
recognizing unmodified H 3 .1 /H 3 .218, 
KM-2 recognizing apoptosis-asso- 
ciated acetylation of H4 and H2A5 
and antibodies specific for H2BK12ac 
(Abcam, Cambridge, UK), H2BS14p 
(Upstate Biotechnology, Huissen, 
the Netherlands), phosphorylated  
serines (Sigma), and actin (Santa 
Cruz Biotechnology, Heidelberg, 
Germany). Plasma was collected from  
pre-diseased (6-10 wk) (n=32) and dis­
eased (14-22 wk) (n=23) MRL/lpr  mice 
as approved by the local animal ethics 
com m ittee. SLE (n=26), rheumatoid  
arthritis (RA) (n=23) and systemic scle­
rosis (SSc) (n=24) patients' plasma was 
collected at the Radboud University 
Nijmegen Medical Centre, which was 
approved by the local ethics com ­
mittee. All SLE patients had > 4 ARC 
criteria and had biopsy proven lupus 
nephritis. A pool of plasma from 10 
healthy controls was included as addi­
tional control.
Enzyme-linked immunosorbent assays 
(ELISA)
The reactivity in ELISA of LG11-2 (5 
mg/ml) and plasma samples from  
MRL/lpr mice and SLE, RA and SSc 
patients and healthy controls (diluted 
1:100) with d ifferent H2B peptides  
(aa 1-18) was tested as described 
previously19. The peptides were syn­
thesized by the peptide synthesis 
facility of the CNRS in Strasbourg  
and analyzed for integrity and purity. 
For the peptide competition ELISA, 
LG11-2 was pre-incubated in a 96-well 
plate (Corning Costar, Badhoevedorp, 
the Netherlands) with com petitor  
peptides for 2 hours at room te m ­
perature and then transferred onto
Maxisorp 96-well plates (Nunc, Uden, 
the Netherlands) already coated with  
2 mM unmodified H2B peptide. After
2 hours of incubation, an appro­
priate HRP-conjugated antibody  
(Southern Biotechnology Associates, 
Birmingham, USA) was added and the 
reaction was started by addition of 
3,3 ' ,5 ,5 '-tetram ethylbenzidine (SFRI 
Laboratories, Berganton, France). 
Notably, the unmodified peptide was 
coated overnight at 4 °C in 0.05 M 
carbonate buffer, pH 9.6 and the 
plates were blocked with PBS con­
taining 0.05% (v/v) Tween-20 and 1% 
(w/v) bovine serum albumin (BSA) 
(Sigma-Aldrich).
Preparation of cell extracts, extraction  
of histones and protein determination
Cell extracts were prepared by lysing 
non-apoptotic and apoptotic cells in 
extract lysis buffer (ELB) (250 mM  
NaCl, 50 m M  Hepes pH 7.0, 5 mM  
EDTA, 0.1% (v/v) Igepal, 0.5 m M  dithi- 
othreitol, 100 ng/ml trichostatin A 
(TSA), 5 m M  NaF, 1 m M  Na3VO4 and 
with a mixture of protease inhibitors 
(Roche, Almere, the Netherlands) and 
sonicating twice on ice.
Histones were extracted with 0.2 
M H2SO4, precipitated with 20%  
trichloroacetic acid, and washed with  
ice-cold acidified acetone. The pellet  
was dissolved in 100 m M  Tris HCl (pH 
8.0). Subsequently, protein content  
was determined by the bicinchoninic 
acid assay (Sigma- Aldrich) with BSA as 
standard.
Sodium dodecyl sulfate-polyacryl- 
amide gel electrophoresis (SDS-PAGE), 
western immunoblotting
Proteins resolved by SDS-PAGE (18%)
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were transferred to nitrocellulose as 
previously described19. Transfer to 
nitrocellulose was confirmed with  
Ponceau S Red staining (Sigma-Aldrich). 
Equal loading of the resolved histones 
was measured by Krypton infrared 
staining according to the manufac­
turer's protocol (Pierce, Etten-Leur, 
the Netherlands). Immunolots were  
incubated with the indicated primary  
antibodies and the appropriate HRP- 
conjugated antibodies (Southern  
Biotechnology Associates) and 
visualised by using enhanced chemi-  
luminescence (Pierce) and Hyperfilm  
x-ray films (Amersham Pharmacia 
Biotech Benelux, Roosendaal, 
the Netherlands) or stained with  
IRDye800-conjugated antibodies
(Westburg, Leusden, the Netherlands) 
for detection, and analyzed with the 
Odyssey® infrared scanner (LI-COR 
Biosciences, Lincoln, NE, USA).
Immunofluorescence staining of cells
Cytospinned cells were  fixed with 2% 
(w/v) paraformaldehyde and permea-  
bilized with 0.05% (v/v) Triton X-100. 
Cells were  incubated with the indi­
cated primary antibodies followed by 
an appropriate Alexa 4 8 8 -  or Alexa 
594-conjugated second antibody  
(Invitrogen, Breda, the Netherlands)  
for detection. TUNEL (Roche) and 
4,6-diamidino-2-phenylindole (DAPI) 
(Invitrogen) staining was performed  
according to the manufacturer's  
instructions.
Statistical methods
Significance for the reactivity of sera 
with the H2B peptides was determined  
by Kruskal-Wallis and M ann-W hitney  
U test using Graphpad Prism V.4.0 
(GraphPad Software, Inc., San Diego, 
California, USA). A p value < 0.05 was 
regarded as significant.
A
u n m o d ifie d  - 1 
K S ac-| 
K12ae-I 
K 1 5 a c  - 1 
$14p - 1 
K5j s  S l4 p - 1 
K12JC S14p - 1 
K15JC S14p - 1 
10
Figure 1. The lupus-derived autoantibody LG11-2 preferably binds to H2B acetylated at K12.
A) Reactivity of the lupus-derived antibody LG11-2 with different H2B peptides. The reactivity was measured in a peptide 
competition ELISA in which unmodified H2B (aa 1-18) peptide was coated. LG11-2 was pre-incubated with unmodified 
or modified H2B peptides, after which its reactivity to the coated unmodified H2B peptide was determined. Binding 
of LG11-2 to unmodified H2B peptide (1-18) is most efficiently inhibited by a H2B peptide acetylated at K12. Peptides 
phosphorylated at S14 and/or acetylated at K5 and K15 are far less efficient competitors compared to unmodified H2B 
peptide and the peptide acetylated at K12. IC50 values are defined as the amount (expressed in nM) of competitor 
peptide required to inhibit the maximal LG11-2 binding to coated unmodified H2B peptide by 50%.
B) Immunofluorescence double staining of LG11-2 (green) and anti-H2BS14p (red) on apoptotic (induced by CPT) Jurkat 
cells did not reveal a significant co-localization as depicted in the merge by yellow. These in situ data confirm the peptide 
ELISA data in panel A. The images are representative for numerous observations.
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Results
Identification of a modification in the 
epitope of the lupus mouse-derived 
monoclonal autoantibody LG11-2
Possible modifications within the 
epitope of the lupus-derived au to ­
antibody LG11-2, originally found to  
react with  histone H2B7, were eval­
uated by determining the reactivity  
of LG11-2 with synthetic histone H2B 
peptides (aa 1-18) in a peptide inhi­
bition ELISA. Unmodified H2B peptide  
was coated onto the plates and LG11-2 
was pre-incubated with each of the  
(modified) H2B peptides prior to incu­
bation with the coated unmodified  
peptide. The reactivity of LG11-2 pre­
incubated with the modified peptides  
was compared to the reactivity of
LG11-2 pre-incubated with  unmodified  
H2B peptide. We observed that LG11-2 
binding to the coated unmodified H2B 
peptide was much stronger inhibited 
by the H2B com petitor peptide  
acetylated on lysine 12 (figure 1A) 
than by the unmodified peptide or 
peptides acetylated at other positions 
(H2BK5, H2BK15). This result indicates 
that LG11-2 preferably recognizes 
histone H2B acetylated on lysine 12. 
Remarkably, all the H2B com petitor  
peptides that contain a phosphorylated  
serine 14, known to be associated with  
apoptosis, showed a much lower inhi­
bition compared with the unmodified  
H2B peptide (figure 1A). Notably, even 
the peptide with for LG11-2 favourable  
acetylation of K12 in combination  
with phosphorylation of S14 was not 
able to inhibit the binding of LG11-2
Figure 2. The lupus-derived autoantibody LG11-2 preferably recognizes hyperacetylated and apoptotic histones.
A) LG11-2 shows on western immunoblot an enhanced binding to histones extracted from cells treated with trichostatin 
A (TSA) or camptothecin (CPT) compared to normal (control) cells. Antibody-antigen concentrations were optimalized to 
maximally visualize differences in reactivity between control, hyperacetylated and apoptotic histones.
B) LG11-2 shows an enhanced binding to apoptotic (CPT) and hyperacetylated (TSA) Jurkat cells compared to normal 
(control) cells. LG11-2 staining is visualized in green and DAPI in the pseudo-colour red in the merged images. Antibody 
concentration was optimalized to maximally visualize differences in reactivity between control, hyperacetylated and 
apoptotic histones.
C) Immunofluorescence double staining of LG11-2 (green) and anti-H2BK12ac (red) on TSA treated cells revealed a signif­
icant co-localization as indicated by yellow in the merge.
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to the unmodified H2B peptide. In situ 
immunofluorescence double staining 
with anti-H2B phosphorylated at S14 
and LG11-2 did not reveal any co-local­
ization (figure 1B), supporting the fact 
that the epitope of LG11-2 and phos­
phorylated H2BS14 are not identical.
In summary, LG11-2 preferably binds 
to H2B acetylated at K12. Apoptosis- 
associated phosphorylation of serine 
14 in H2B, alone or in combination with  
acetylation, is inhibitory for binding of 
LG11-2 to H2B and, therefore, is cer­
tainly not a part of its epitope.
Apoptosis-associated acetylation of 
histone H2B
LG11-2 shows almost no reactivity 
with extracted histones from normal 
cells, while this reactivity was clearly 
increased with hyperacetylated and 
apoptotic histones, extracted from  
respectively TSA- or CPT-treated 
cells (figure 2A). This enhanced reac­
tivity of LG11-2 was also observed 
in immunofluorescence staining of 
cells treated with TSA or CPT (figure 
2B). These data support the com pe­
tition ELISA result that acetylation of 
histone H2B is part of the epitope of 
LG11-2. This was fur ther strengthened  
by double staining with LG11-2 and 
anti-H2BK12ac on TSA-treated cells, 
containing hyperacetylated chromatin, 
that revealed in the merge a sound 
co-localization (figure 2C). Hence, the  
acetylation of lysine 12 recognized by 
LG11-2 is increased during apoptosis. 
Immunofluorescence staining of apop-  
totic Jurkat cells with LG11-2 showed 
an enhanced staining of Annexin 
V-positive and overall TUNEL-negative 
cells (data not shown), suggesting that  
acetylation of H2BK12 occurs early 
during apoptosis.
The dynamics of acetylation of H2B 
at K12 after induction of apoptosis 
was fur ther studied by western immu-  
noblot analysis of histones extracted  
from untreated (time point 0) and 
apoptotic cells. These data were  
related to other apoptotic events like 
Annexin V binding/Propidium Iodide 
staining, phosphorylation of H2B at 
S14, and acetylation of H4 and H2A. 
The increase in acetylation of H2BK12, 
as probed with LG11-2, the increase in 
phosphorylation of H2BS14, as probed 
with anti-H2BS14p and anti-a-phos-  
phoserine all coincided, and appeared  
about 4 hours a fter  induction of 
apoptosis (figure 3). Probing with
Figure 3. Dynamics of acetylation of H2B at K12 and 
other apoptosis-associated chromatin modifications 
during apoptosis.
Acetylation at H2BK12 was analyzed by LG11-2 staining, 
phosphorylation at H2BS14 by anti-H2BS14p and anti- 
phosphoserine. Apoptosis-associated acetylation of H4 
and H2A was probed by the lupus-derived autoantibody 
KM-2.The progress of apoptosis was analyzed by measuring 
the % positivity for Annexin V-FITC binding (AnV+) and 
Propidium Iodide (PI) staining with flow cytometry. 
a-actin staining was used as control for loading of equal 
amounts of protein. Acetylation of H2B at K12 (LG11-2 
staining) occurs 4 hours after induction of apoptosis at the 
same time as apoptosis-induced hyperacetylation of H4/ 
H2A (KM-2 staining) and phosphorylation of H2B at S14 
(anti-H2BS14p and anti-phosphoserine staining) appear 
This coincides with the increase of the amount of early 
apoptotic cells (AnV+) while the number of late apoptotic 
cells (AnV+/PI+) are still low.
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an antibody specific for unmodified  
histone H3 revealed no differences  
(not shown)5. The same observation  
was made for apoptosis-associated 
acetylation of H4 and H2A as probed 
with the lupus-derived autoantibody  
KM-2, as we recently reported5. The  
state of apoptosis was analyzed by 
Annexin V binding and Propidium 
Iodide staining in f low cytometry, 
which revealed that the apoptosis- 
associated chromatin modifications  
are early events, in predominantly  
early apoptotic cells (not shown). In 
summary, acetylation at K12 of H2B 
is associated with apoptosis and its 
appearance coincides with other apop-  
tosis-associated histone modifications  
like phosphorylation of S14 in H2B and 
acetylation of H4 at K8, K12 & K16.
Acetylation of H2BK12 in SLE
To test the relevance of the apoptosis- 
associated acetylation of H2BK12 
for SLE we analyzed the reactivity of 
plasma from (pre)diseased lupus mice 
and SLE, RA and SSc patients with (un)
modified H2B peptides and protein. 
The prevalence of autoantibodies to 
the H2B protein and unmodified H2B 
peptide was 2-fold higher in diseased 
mice and SLE patients compared to 
pre-diseased mice (data not shown). 
Plasma from RA, SSc patients and 
healthy controls did not show any 
reactivity with the H2B peptides (data 
not shown), indicating an exclusive 
reactivity of this epitope for SLE 
patients. Plasma with positive reac­
tivity for the H2B peptide (1-18) was 
tested in an inhibition ELISA with the 
unmodified H2B (1-18) and acetylated  
peptide (H2BK12ac). The reactivity of 
autoantibodies to H2BK12ac compared  
to unmodified H2B peptide was similar 
in the group of diseased mice and in 
patients with active SLE (figure 4). 
Plasma of pre-diseased mice showed 
a significant higher reactivity with  
H2BK12ac compared to unmodified  
H2B peptide. These findings indicate 
that antibodies formed before  
manifestations of disease prefer­
entially recognize the acetylated
Figure 4. Reactivity of plasma of lupus mice and SLE patients with acetylated and non-acetylated H2B peptide.
Only plasma that reacts with complete H2B were tested in a competition ELISA in which non-acetylated H2B peptide 
(aa 1-18) was coated, and plasma (32 pre-diseased lupus mice, 23 diseased lupus mice and 26 SLE patients) were 
pre-incubated with non-acetylated H2B peptide or H2B peptide acetylated at K12. Plasma from pre-diseased (6-10 
wks) MRL/lpr lupus mice show a higher reactivity with the H2B peptide (1-18) acetylated at K12, compared to the 
non-acetylated H2B peptide. In contrast, the reactivity of plasma of diseased lupus mice and SLE patients with the 
acetylated H2B peptide was similar to the unmodified H2B peptide. 1/IC50 values are defined as 1 divided by the amount 
(expressed in nM) of competitor peptide necessary to inhibit the maximal antibody binding by 50%. * P<0.05.
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epitope in H2B (H2BK12ac), while if 
disease progresses the reactivity to 
unmodified H2B becomes equal.
D is cu s s io n
We dem onstrate that the lupus- 
derived antibody LG11-2 preferably  
reacts with H2B acetylated at lysine 
12, which is form ed during apoptosis, 
located within the epitope of LG11-2 
as mapped with unmodified peptides 
previously7.
The higher reactivity of LG11-2 with  
apoptotic histones supports previous 
findings where LG11-2 was shown to 
react with apoptotic blebs and nucleo- 
somes13, 14.
We previously showed that hyper- 
acetylation of histone H4 and H2A 
is also associated with apoptosis5. It 
is not clear yet w hat the function of 
histone acetylation is during apop­
tosis. Histone acetylation neutralizes 
positively charged residues, thereby  
reducing the affin ity of the histone 
tails for the negatively charged DNA20 
21. This results in an open, more  
accessible, chromatin structure. 
Indeed, acetylation of H2BK12 affects  
interactions around residue S1422. 
Chromatin fragmentation is a hallmark  
of apoptosis, and it is likely that  
during apoptosis histone acetylation  
increases the susceptibility of chro­
matin for cleavage.
The formation in lupus of autoanti­
bodies like LG11-2, recognizing an 
acetylated form of histone H2BK12, 
suggests that this modification  
could be of importance in the patho­
genesis of SLE. Others previously
dem onstrated that the reactivity of 
SLE sera with apoptotic histones is 
enhanced23. We recently showed also 
enhanced reactivity of lupus-derived 
autoantibodies with hyperacetylated  
and apoptotic histones5. We found 
that tri-acetylation of H4 at K8, 12 
and 16 was associated with apoptosis 
as probed with another lupus-derived 
autoantibody, KM-2. Administration  
of tri-acetylated H4 peptide accel­
erated disease developm ent and 
severity in MRL/lpr mice and syn­
geneic T cells were activated by DC's 
matured by hyperacetylated nucleo- 
somes5. In the present study we  
show that predominantly sera from  
pre-diseased lupus mice contain auto ­
antibodies that recognize acetylated  
H2B at K12 and not non-acetylated  
H2B. When disease progresses both 
in lupus mice and patients the reac­
tivity to H2B acetylated at K12 equals 
that to unmodified H2B. Therefore, 
this apoptosis-related acetylation  
of H2B at K12 could be im portant in 
the initial phase of the disease, due 
to the absence of tolerance for the  
apoptosis-induced acetylation m otif17, 
24. In face of a defective removal 
of apoptotic material in SLE1, these  
apoptosis-induced neo-epitopes are 
recognized by the immune system. 
Subsequently, through epitope  
spreading the immune response 
is also directed at the unmodified  
H2B protein. This mechanism of an 
autoim m une response initially induced 
by modified-autoantigens followed by 
epitope spreading has been described 
for various autoantigens like (cyclic) 
citrullinated peptides and ribonuclear 
proteins25-28.
We postulate that hyperacetylation  
of histones may act as an initial
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trigger in the autoim m une response 
in SLE. O ther groups suggest a role 
for hypoacetylation in SLE. However, 
in these studies only acetylation of 
chromatin in non-apoptotic CD4+ T 
cells was investigated. The observed 
hypoacetylation probably reflects a 
gene expression profile of T cells in 
SLE. This is most likely not related to 
our finding of apoptosis-associated 
hyperacetylation of histones as auto ­
antigens in SLE29, 30. Treatm ent with 
the histone deacetylase inhibitor  
TSA, which normally results in hyper- 
acetylation of chromatin, led to a 
decrease in autoantibody levels, 
glomerular immune depositions and an 
amelioration of glomerulonephritis29, 
31. This study is not in contrast with our 
finding that apoptosis-induced hyper- 
acetylation of histones is im portant in 
the pathogenesis of SLE, since many 
(downstream) pathogenic processes 
are affected by systemic inhibition of 
HDAC.
We show that acetylation of H2B at K12 
and phosphorylation of H2B at S14 both 
influence the binding of LG11-2 con­
siderably, but with opposite effects. 
Apoptotic chromatin is considered 
to be phosphorylated at H2BS14 and 
LG11-2 does not bind to phospho- 
rylated H2BS14, but, seemingly in 
paradox, has an enhanced binding 
to apoptotic chromatin. Previously, 
it was shown that phosphorylation  
of H2BS14, and not acetylation of 
H2BK12, exclusively increases during 
apoptosis. This may be explained by 
the omission of deacetylase inhibitors  
by these authors during the isolation 
of the histones as we did, which pre­
vents the loss of histone acetylation 4. 
Nevertheless, our western immunoblot  
analysis could suggest that acetylation
of H2B at K12 and phosphorylation  
at S14 occur simultaneously about
4 hours a fter  induction of apop-  
tosis. However, with this technique a 
mixture of histones from whole cells 
with different chromatin domains and 
a mixture of cells with d ifferent stages 
of apoptosis are analyzed in one lane. 
Therefore, we suggest that acetylation  
of H2B at K12 and phosphorylation of 
H2B at S14 can be consecutive events, 
and, therefore, these modifications  
may not be simultaneously present in 
the same chromatin (micro) domains.
In conclusion, the acetylation of H2B 
at K12 is associated with apoptosis. 
Antibodies to apoptosis-induced 
acetylation of H2B at K12 are predom i­
nantly present in the initial phase of 
the disease, while during development  
of the disease the levels of 
autoantibodies to acetylated and non- 
acetylated H2B are similar. Therefore, 
apoptosis-induced acetylation of 
K12 in H2B seems im portant in the  
initiation of autoim m unity  against 
chromatin in SLE.
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Î n systemic lupus erythematosus (SLE) apoptotic chromatin is present extracellularly, which is most likely the result of a disturbed apoptosis and/or an insufficient removal. Released chromatin, modified during 
apoptosis, activates the im m une system, resulting in the formation of 
autoantibodies. In this study w e aimed to identify apoptosis-induced  
histone modifications that play a role in SLE. W e started with the charac­
terization of a lupus-derived monoclonal antibody, BT164, that we  
recently established by selection employing apoptotic nucleosomes. 
Methods: BT164 was analyzed by ELISA, western blot and im m uno­
fluorescence staining, using chromatin, cells and renal sections. Random  
peptide phage display and peptide inhibition ELISA was used to precisely 
identify the epitope of BT164. The reactivity of plasma from lupus mice 
and SLE patients with the epitope of BT164 was investigated in peptide 
ELISA.
Results: The epitope of BT164 was mapped in the N-terminal tail 
of histone H3 (27-KSAPAT-32) and included the apoptosis-induced  
tri-methylation of K27. Furthermore, siRNA-mediated silencing of 
histone demethylases in cultured cells resulted in hypermethylation  
of H3K27 and an increased nuclear reactivity of BT164. This apoptosis- 
induced H3K27me3 is a target for autoantibodies in lupus patients and 
mice, and is present in plasma and in glomerular deposits.
Conclusion: In addition to previously identified acetylation of histone H4, 
H2A and H2B, we now show that tri-methylation of histone H3 on lysine
27 is induced by apoptosis and associated with autoimmunity in SLE. 
This finding is important for understanding the autoim m une response in 
SLE and for the development of translational strategies.
In t r o d u c h o n
SLE is an autoim m une disease that is 
characterized by the formation of au to ­
antibodies against nuclear antigens, for  
which the nucleosome is considered as 
a major autoantigen.1 The nucleosome  
is comprised of an octam er of two  
copies of histones H2A, H2B, H3 and 
H4 with 146 bp of DNA wrapped  
around it. In SLE, these nucleosomes 
are released from apoptotic cells that  
are not removed due to an insufficient 
clearance.2- 3 This leads to the presence 
of chromatin (i.e. DNA, histones,
nucleosomes) in the circulation and 
tissues.4 During apoptosis chro­
matin can be modified, and several 
apoptosis-induced modifications have 
been described, amongst them  the  
phosphorylation of H2B on serine 
14, considered as a hallmark for 
apoptosis.5 In addition to the phos­
phorylation of serine 14 on histone 
H2B, the phosphorylation of serine
28 and threonine 45 and methyl-  
ation of lysine 27 on histone H3 have 
been related to apoptosis.5-7 Several
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apoptosis-associated histone modifi­
cations have been identified that are 
targeted by lupus autoantibodies, like 
specific acetylation of histone H4, H2A 
and H2B as we showed recently.8- 9
Apoptosis-induced modifications may 
enhance the immunogenic potential 
of chromatin- most likely initiated 
by ligation of specific receptors on 
antigen presenting cells. Thereafter, 
the modified chromatin will be 
ingested, digested and presented in 
an immunogenic way by antigen pre­
senting cells.8- 10-12 Recently- we have 
shown that dendritic cells (DC) can be 
activated in particular by apoptotic  
blebs containing histones with apop-  
tosis-associated hyperacetylation- or 
by isolated hyperacetylated nucleo- 
somes.8- 11- 12 Importantly- we identified  
a mixed Th1/Th17  response induced 
by apoptotic b leb-matured DC.11
In our hypothesis- a fter  activation 
by mature DC- autoreactive T helper 
cells specific for these apoptosis-asso- 
ciated chromatin modifications will 
stimulate B cells to produce autoanti­
bodies. Finally- the autoantibodies  
will form immune complexes with 
circulating chromatin and deposit  
in basement membranes like the 
glomerular basement m em brane in 
the kidney- thereby inciting severe 
glomerulonephritis .13
Recently- we have established a 
panel of new monoclonal antibodies  
derived from lupus-mice by selection 
on apoptotic chromatin. One of these 
monoclonal autoantibodies- BT164- 
preferentially binds to apoptotic chro­
matin and in preliminary experiments  
has been identified as an anti-histone  
H3 antibody (van Bavel et al.- in
In this study we aim to map the  
exact epitope of BT164 and in par­
ticular to identify the presence of 
apoptosis-associated modifications. 
Furthermore, we evaluate w hether  
this modified epitope is targeted by 
autoantibodies from SLE patients and 
lupus mice.
M e t h o d s
Plasma
Plasma from 24 SLE patients with 
biopsy proven lupus nephritis (ISN 
class III or IV), 16 SLE patients w ithout  
lupus nephritis, 12 rheumatoid  
arthritis (RA) and 12 systemic sclerosis 
(SSc) patients were  collected at the  
Radboud University Nijmegen Medical 
Centre and Erlangen University, which 
was approved by the local ethics com ­
mittees. All SLE patients had > 4 ARC 
criteria.
Plasma was collected from 18 pre­
diseased (6-10 wk) and 28 diseased 
(14-22 wk) MRL/lpr mice as approved  
by the local animal ethics com mittee.
Cell culture & apoptosis induction
HeLa, Jurkat and 32Dcl314 cells were  
routinely cultured in complete DMEM  
or RPMI-1640 DM medium (Invitrogen, 
Breda, The Netherlands). Apoptosis 
was induced by trea tm ent with 4 |ag/ 
ml camptothecin (CPT) (Sigma-Aldrich, 
Zwijndrecht, the Netherlands) for 
indicated periods. The progress of 
apoptosis was determined by Annexin 
V-fluorescein isothiocyanate (FITC) and 
propidium iodide (PI; ITK Diagnostics, 
Uithoorn, The Netherlands) staining 
and analyzed with flow cytometry.
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Antibodies
BT164 is a lupus-derived mAb that  
was recently established by selection 
on apoptotic chromatin (van Bavel et 
al., in preparation). The lupus-derived 
mAb antibody #34, specifically recog­
nizes unmodified H 3 .1 /2 .15 Antibodies  
against methylated H3K27 were pro­
vided by Dr. A. Peters and described 
previously.16 Anti-H3S28p, anti- 
H3K18ac, anti-H3K23ac (Invitrogen), 
anti-H3K27ac (Abcam, Cambridge, 
UK), and anti-EHS laminin, that is anti- 
laminin-1 were purchased.
Preparation of cell extracts, histones & 
immunoprecipitation
Preparation of cell extracts, extraction  
of histones and protein determination  
was described previously.8, 9
For imm unoprecipitation, cell extracts  
of apoptotic cells were incubated with  
BT164. A fter 2 hours, immune com ­
plexes w ere  catched by anti-mouse  
IgG agarose beads (sigma-Aldrich). 
After 5 washing steps, imm unopre-  
cipitated proteins were denatured  
by heating and resolved by SDS-PAGE 
(18%) gel electrophoresis, essentially 
as described.17
Isolation of chromatin from plasma
One mg of purified BT164 was cova­
lently coupled to 1 ml (bed volume) 
of CNBr-activated Sepharose 4B. The 
column was loaded with by circulating 
6 ml plasma of SLE patients or controls 
for 16 hours. Chromatin was eluted 
with 50 m M  citrate buffer pH 2 with 
1M NaCl.
Western blot
Proteins resolved by SDS-PAGE were  
blotted as previously described.18 
Immunoblots were incubated with
the indicated primary antibodies and 
the appropriate IRDye800-conjugated  
antibodies (Westburg, Leusden, the 
Netherlands) for detection, and ana­
lyzed with the Odyssey® infrared  
scanner (LI-COR Biosciences, Lincoln, 
NE, USA).
Random peptide phage display
Random peptide phage display with the 
12-m er Ph.D.-12 Phage Display Peptide 
Library kit (New England Biolabs, 
Ipswich, UK) was used to determ ine  
the epitope of BT164 according to 
manufacturers' protocol. A fter three  
panning and amplification rounds with  
decreasing antibody concentrations, 
individual clones were picked for iso­
lation of ssDNA with the Qiagen Spin 
M 13 kit (Qiagen) according to the 
manufacturers' protocol. Phage ssDNA 
was sequenced on the 3730 Sequence 
Analyzer (Applied Biosystems, Foster 
City, USA) according to the Sanger 
method and aligned using ClustalW2.
Peptide (inhibition) ELISA
Peptide (inhibition) ELISA was per­
formed as described previously.9 
BT164 (150 ng/ml) was pre-incubated  
with the indicated com petitor pep­
tides and subsequently transferred  
to a Maxisorp® 96-well plate (Nunc, 
Uden, the Netherlands) coated 
with 0.1 mM unmodified H3(23-34)  
peptide. Peptides H3(18-37), H3.3(18-  
37), H3S28p(18-37), H3(23-34), 
H3K27ac(23-34), H3K27me1(23-34), 
H3K27me2(23-34) & H3K27me3(23-34)  
were synthesized in our laboratories in 
Strasbourg or obtained commercially.
Immunofluorescence staining
Cells or 2 mm frozen sections of mouse 
kidneys were fixed with 2% (w/v) 
paraformaldehyde and permeabilized
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with 0.05% (v/v) Triton X-100, blocked 
with 2% (w/v) BSA, and subsequently  
incubated with the primary antibody. 
Appropriate Alexa 488 -  or Alexa 
594-labeled secondary antibodies  
(Invitrogen) were  used for detection.  
All cells and sections were em bedded  
in VectaShield mounting medium  
H-1200 containing the DNA stain 
4',6-diamidino-2-phenylindole (DAPI) 
(Vector Laboratories, Peterborough, 
UK).
siRNA transfection
HeLa cells were transfected with siRNA 
specific for the histone demethylases  
JMJD3 and UTX, or control siRNA 
(Applied Biosystems, Nieuwerkerk  
a/d IJsel, the Netherlands) with  
Oligofectamine (Invitrogen) according 
to manufacturers protocol. Briefly, 54 
pmol siRNA or 1.08 m l oligofectamine  
were each diluted in 135 ml serum­
free O pti-M E M  (Invitrogen). After
5 minutes of incubation, siRNA was 
gently mixed with oligofectamine for 
20 min. The culture medium from the  
wells was replaced with the 270 ml 
transfection mix. Cells were analyzed 
48 hours after  transfection.
Statistical analysis
Statistical analysis was pe r fo rm ed  
by M a n n -W h itn e y  U- and the  s tu ­
den ts ' t - te s t  using Graphpad Prism 
V.4.0 (GraphPad Software, Inc., San 
Diego, California, USA). A P value < 
0.05 was regarded significant.
Results
The lupus-derived monoclonal 
antibody BT164 preferentially recog­
nizes apoptotic chromatin
BT164 has been selected for its higher
A 1.5
i  1.0
O LO
§ 0 .5
o.oj------T— - --------- ------,— ,----------
1 10 100 
antibody dilution
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#34
— — - KM-2
8% 46% AnV+/P|-
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Figure 1. Higher reactivity of lupus-derived mAb BT164 
with apoptotic chromatin.
A) BT164 shows a higher reactivity with apoptotic 
nucleosomes (dashed line) in ELISA compared to control 
nucleosomes (continuous line).
B) BT164 shows an increased immunofluorescent 
staining with apoptotic cells compared to control cells. 
DAPI = blue, BT164 = green and anti-H2BS14p = red. 
Furthermore, the epitope of BT164 appears to be translo­
cated to the surface of apoptotic blebs as most staining in 
the apoptotic cell is observed in the blebs. Apoptosis was 
induced by camptothecin.
C) An enhanced reactivity of BT164 with apoptotic 
histone H3 on western blot is observed already 4 hours 
after induction of apoptosis. As a control, #34 recognizing 
non-modified histone H3, is used as a probe. With #34 
no difference between control and apoptotic histones is 
observed, and equal loading is demonstrated. Apoptosis- 
associated tri-acetylation of H4 as probed by KM-2 also 
increases in apoptotic extracts as reported previously.8 
The rate of apoptosis is measured by staining with 
Annexin V (AnV) and Propidium Iodide (PI). AnV-positive/ 
PI-negative cells represent early apoptotic cells; 
AnV-positive/PI-positive cells represent late apoptotic 
cells.
—control
—apoptotic
92 Chapter 6
reactivity with apoptotic nucleosomes 
in ELISA compared to control nucleo­
somes (figure 1A). This enhanced  
reactivity was also observed with 
apoptotic cells and blebs (figure 1B). 
It appeared that BT164 in particular 
stained apoptotic cells and blebs 
that also stained positively with anti- 
H2BS14p, the latter antibody defining 
an established apoptosis-induced  
histone modification.5 Western blot 
analysis revealed an increased staining 
by BT164 of histone H3 isolated form  
apoptotic cells (46% AnV+/PI-; 17% 
AnV+/PI+) compared to H3 isolated from  
normal cells (8% AnV+/PI-; 5% AnV+/ 
PI+) (figure 1C). Inhibition of apoptosis 
by Z-VAD-FMK prevented the induction 
of the epitope of BT164 (data not 
shown). This finding with BT164 pref­
erentially reacting with apoptotic H3 
was similar to the previously identified  
apoptosis-induced hyperacetylation  
of H4 as defined by the lupus-derived 
mAb KM-2, whereas the reactivity of 
antibody #34, specific for unmodified  
H3.1 /3 .2  was not affected by apop­
tosis (figure 1C).8 Apparently, BT164 
recognizes an epitope within histone 
H3 that is modified during apoptosis.
Fine mapping the epitope of BT164
To map the exact epitope of BT164, 
we performed random peptide phage 
display. A fter 3 panning rounds, a con­
sensus was obtained, with sequence  
IAAPAS/T corresponding to amino  
acids (a.a.) 27-KSAPAT-32 from histone 
H3 (figure 2A). However, the lysine 
on position 27, was never identified  
in the selected random peptide  
expressing phage clones. The iden­
tified amino acids on position 27 in 
the isolated clones were in general 
neutrally charged, indicating that this 
lysine residue is probably neutralized
by post-translational histone modifica­
tions, and the most likely candidates 
are acetylation or methylation (figure 
2A). Note that these post-translational 
modifications are not synthesized 
in the bacterial random peptide  
expressing system, thus explaining the 
presence of neutrally charged residues 
mimicking methylated K27.
Peptide inhibition ELISAs were  con­
ducted, in which the binding of 
BT164 to coated non-modified H3 
peptide (23-34) was tested a fter  pre­
incubation with defined modified  
and non-modified H3 peptides. We  
observed a significant decreased 
binding of BT164 with the coated 
unmodified H3 peptide only when  
inhibited with peptides containing 3 
methyl-groups on lysine 27 (figure 2B). 
H3 peptide acetylated on lysine 27, or 
phosphorylated on serine 28, or the 
non-modified H3.3 variant (alanine 
at position 31 is replaced by a serine) 
did not inhibit binding to unmodified  
H3 peptide. These findings indicate a 
preferential binding of BT164 to in par­
ticular the H3 peptide tri-m ethylated  
at lysine K27.
BT 164 preferentially reacts with 
tri-methylated H3K27 in situ
Histone H3K27 methylation is carried  
out by histone methyltransferase EZH2 
as part of the polycomb complex PCR2. 
The site-specific demethylases for 
H3K27, UTX and JMJD3, which catalyze  
dem ethylation of the tri- and di-m eth-  
ylated form to the mono-m ethylated  
H3K27 have been recently dis­
covered.19-22 To induce a possible 
hypermethylation of histones in situ, 
we applied siRNA-mediated gene 
silencing of the histone H3K27me2  
and -m e3 specific demethylases UTX
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Figure 2. Fine mapping of the epitope of BT164.
A) The epitope of BT164 as mapped with random peptide phage display. Depicted is the alignment of several clones with 
the amino acid sequence of histone H3 (27-KSAPAT-32). The consensus of all sequences is IAAPAS. The lysine on position 
27, which can be modified, is never found in any sequence.
B) BT164 recognizes methylated H3K27 with a preference for tri-methylated H3K27 as shown by inhibition ELISA. The 
amount of peptide necessary to inhibit the binding of BT164 to coated H3 peptide (23-34) shows that tri-methylation of 
H3K27 gives the strongest inhibition. H3 peptides acetylated at K27, phosphorylation at S28 and the H3.3 variant peptide 
do not inhibit the binding of BT164 at all.
C) BT164 has a higher nuclear reactivity with cells containing hypermethylated chromatin. Immunofluorescence staining 
of cells transfected with siRNA of H3K27 specific histone demethylases UTX and JMJD3, which results in hypermethylation 
of H3K27, shows an increased staining of BT164 (left panel) and anti-H3K27me3 (right panel). Because UTX and JMJD3 
are H3K27me2 and -me3 specific demethylases, blocking these enzymes leads to a decreased amount of H3K27me1, as 
is revealed by staining with anti-H3K27me1 (middle panel).
and JMJD3 in HeLa cells. Subsequently, 
we stained these manipulated cells 
with BT164 and antibodies specific for 
H3K27me1 and H3K27me3 (figure 2C). 
Nuclear staining by BT164 was strongly 
increased in cells transfected with  
siRNA specific for the demethylases  
UTX and JMJD3 compared to cells 
transfected with control siRNA (figure  
2C left panels). As expected, nuclear 
staining by an anti-H3K27me3 antibody
was also increased in cells transfected  
with UTX/JMJD3 siRNA (figure 2C right 
panels), while nuclear staining by anti-  
H3K27me1 was decreased (figure 2C 
middle panels).
In addition, we found that im m uno­
fluorescence double staining of 
apoptotic cells with BT164 and anti­
bodies against methylated H3K27 
(mono- di- and tri-methylation),
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acetylated H3K27, phosphorylated  
H3S28 and #34  (anti-H3.1 /H3.2) only 
revealed co-localization with anti­
bodies against methylated histone 
H3K27 (figure 3A). W e also performed  
imm unoprecipitation experiments  
with BT164 using apoptotic chromatin  
as input. Probing of blots of resolved 
imm unoprecipitates with BT164, anti-  
H3K27me3 and anti-H3K27ac only 
revealed precipitated bands with  
BT164, as expected, and with anti-  
H3K27me3, but not with anti-H3K27ac  
(figure 3B). Apparently, methylated  
histone H3 in apoptotic chromatin is 
predominantly precipitated by BT164. 
Taken together, all these in situ data 
are in agreem ent with the peptide  
inhibition ELISA data, indicating that  
histone H3 tri-m ethylated  at K27 is the  
preferred epitope of BT164.
Methylation of histone H3 in SLE
The immunogenicity of apoptotic chro­
matin containing tri-m ethylated  H3 at 
K27 is in part dictated by its release and 
presence in the circulation and other  
tissues. W hen we analyzed kidney sec­
tions of control mice (MRL+/+) and lupus 
mice (MRL//pr) by staining with BT164, 
a nuclear staining was observed in 
both mice, as expected. However, only 
in lupus mice a glomerular staining of 
BT164 outside nuclei was observed, 
as visualized by co-staining with anti-  
laminin (figure 4A). Using an affinity  
purification column with BT164 we  
were also able to specifically isolate 
chromatin containing tr i-m ethylated  
H3 at K27 from plasma of SLE patients  
as probed with BT164 (figure 4B). 
Plasma from controls did not contain  
any chromatin. Therefore, the epitope  
of BT164, methylated histone H3, 
seems to be present in extracellular  
chromatin deposited in the glomerular
A  Ab BT164 Merge
Figure 3. BT164 specifically stains and precipitates 
H3K27me3.
A) BT164 (green) immunofluorescence staining colocalizes 
(yellow) only with antibodies against methylated H3K27 
(red). No colocalization is observed with antibodies (red) 
directed against other possible modifications present in 
the epitope of BT164. Also antibody #34 that recognizes 
unmodified H3, does not show colocalization with bT164.
B) BT164 immunoprecipitates apoptotic tri-methylated 
histone H3K27. Apoptotic chromatin immunoprecipi- 
tated with BT164 is recognized by BT164, as expected, 
and by the anti-H3K27me3 antibody, while precipitated 
chromatin does not contain acetylated H3K27 since no 
staining is observed with anti-H3K27ac.
basement mem brane in diseased lupus 
mice, and in the circulation of patients  
with SLE.
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Figure 4. H3K27me3 is present in glomerular deposits, in plasma and is recognized by lupus autoantibodies.
A) Extracellular glomerular staining of kidney sections of MRL/lpr lupus mice by BT 164. In MRL+/+ mice is only a nuclear 
staining of the glomerular cells is observed. In MRL/lpr mice extracellular staining is observed, which colocalizes with 
anti-laminin-1 staining expressed in the glomerular basement membrane. In the merge the colocalization of BT164 
(green) with the nuclei (DAPI) and laminin-1 (red) is visualized.
B) Tri-methylated H3 (15 kDa) is present in the plasma form SLE patients, but not in controls. Plasma from a SLE patient 
or control (C) was affinity purified with a BT164 column. The eluate was resolved by SDS-PAGE, blotted and probed with 
BT164. Molecular weight is indicated in kDa.
C) Higher reactivity with the H3 peptide tri-methylated on K27 compared to non-modified H3 peptide of 13/18 plasma 
from pre-diseased lupus mice, 24/28 plasma from diseased lupus mice, 17/24 plasma from SLE patients with lupus 
nephritis, and 13/16 plasma from SLE patients without lupus nephritis . Plasma from control patients with rheumatic 
arthritis (RA) or systemic scleroderma (SSc) do not show (enhanced) reactivity with the tri-methylated peptide H3 
peptide. Plasma from healthy control humans and mice do not show any reactivity with either peptide (data not shown). 
*P< 0.05; **P <0.01; ***P<0.001
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We further investigated the relevance  
of apoptosis-associated methylation  
in SLE by analyzing the reactivity of 
plasma with the epitope of BT164 in 
peptide ELISA. We used plasma from  
pre-diseased and diseased lupus mice, 
from SLE patients with lupus nephritis  
and w ithout lupus nephritis, and from  
control patients with RA and SSc . The  
reactivity of the majority of plasma 
from (pre)diseased lupus mice and 
SLE patients, with or w ithout lupus 
nephritis, was significantly higher with 
the tr i-m ethylated  H3 peptide com ­
pared to the control peptide, whereas  
almost no reactivity was observed 
with plasma from control disease 
patients (RA and SSc) (figure 4C). In 
addition, there  was a significant higher 
reactivity, with either H3 peptide, of 
plasma from diseased mice compared  
to plasma from pre-diseased mice. 
Plasma from healthy control humans 
and mice do not show any reactivity  
with e ither H3 peptide (data not 
shown). These findings indicate that  
autoantibodies derived from lupus 
plasma, preferentially recognize the  
apoptosis-associated tr i-methylation  
of H3 at K27, compared to the non- 
methylated H3K27.
DISCUSSION
We recently established the lupus- 
derived monoclonal antibody BT164 
that was specifically selected on apop-  
totic chromatin. In the current study, 
using different approaches, we iden­
tified the exact epitope of BT164 in 
histone H3 (a.a. 27-32). Importantly, 
recognition of apoptosis-induced tri-  
methylation on lysine 27 (H3K27me3) 
is an im portant characteristic of this 
lupus-derived autoantibody.
The association of tri-methylation  
of H3K27 with apoptosis has been 
described very recently also by 
others.7 The mechanisms and conse­
quences of apoptosis-specific histone 
H3K27 methylation are not known 
yet. Tri-methylation of lysine residues 
neutralizes positive charge, which may 
induce changes in chromatin structure  
required for facilitating the process 
of apoptosis. Notably, methylation of 
histone H3K27 is commonly associated 
with repression of genes that may be 
linked to condensation of chrom atin.16, 
23, 24 Kim et a/. showed that methylation  
of H3K27 by the histone methyltrans-  
ferase WHISTLE is im portant for the 
induction of caspase 3-m ediated  
apoptotic cell death .25 Epigenetically, 
enhanced histone H3K27 methylation  
is found in CD4+ T cells of lupus mice26, 
which coincides with the decreased 
acetylation of histone H3 in lupus 
prone mice and SLE patients.26, 27 
Finally, methylation of H4K20 also has 
been related to apoptosis.28
Previously, sera from SLE patients 
have been found to react with the  
N-terminal tail of histone H329, 30 and 
recently the epitope of another lupus 
derived monoclonal antibody, #34, has 
also been mapped in the N-terminal  
tail of histone H3 from a.a. 28 -33 .15 
In contrast to these B cell epitopes, 
histone H3-specific T cell epitopes  
have been identified ,so far, mainly 
outside the N-terminal tail of H3.31-33
This study shows that methylated  
histone H3 is a target for lupus 
autoantibodies. Apparently, the apop- 
tosis-associated tr i-m ethylation of 
H3K27 seems to be associated with  
increased immunogenic potential of 
apoptotic chromatin, similar to the
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specific acétylation patterns we have 
recently described for H2A, H2B and 
H4.8- 9 It is conceivable that a pattern  
of combined chromatin modifications  
associated with apoptosis specifi­
cally ligates to receptors on antigen 
presenting cells, like the DC, thereby  
activating these cells resulting in 
an immunogenic presentation. The 
predominant staining of BT164 of 
apoptotic blebs indicates that the 
tr i-m ethylated  histone H3K27 is trans­
located during apoptosis from the 
nucleus to apoptotic blebs, which 
is consistent with reports on the 
presence of autoantigens in apoptotic  
blebs.34, 35 Notably, we have recently  
shown that apoptotic blebs containing 
apoptosis associated histone modifi­
cation, induce maturation of DC and 
subsequently activation of Th1 and 
Th17 T cells.11, 12
The enhanced reactivity of autoanti­
bodies present in the plasma from  
lupus mice and patients with the 
tr i-m ethylated H3K27 peptide com ­
pared to the non-modified peptide  
was specific for SLE, since there was 
hardly any reactivity from plasma 
of RA and SSc patients, and healthy 
controls. Furthermore, released apop-  
tosis-induced methylated histone H3 
was present in glomerular deposits 
in lupus mice and not in non-lupus 
mice. Importantly, we could show 
the presence of apoptosis-induced  
methylated histone H3 in the plasma 
of patients with SLE, but not in 
controls. Apparently, apoptosis-asso- 
ciated H3K27 methylation is a target  
for the immune system leading to the 
production of autoantibodies, which 
deposit with apoptotic chromatin in 
the glomerular capillary filter. These 
chromatin deposits are an im portant
feature for lupus nephritis.36 It shows 
that in SLE modified apoptotic chro­
matin is released that triggers the  
immune system.
Peptides, or combinations of pep­
tides, containing apoptosis-induced  
modifications associated with SLE, 
like specific acetylation of H2A, H2B, 
H48, 9, and methylation of H3 (this 
study), could lead to the development  
of novel diagnostic and prognostic 
approaches. Furthermore, application 
of such peptides with apoptosis- 
induced modifications can even lead 
to tolerance against these im m uno­
genic key autoantigens in SLE37, 38
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Summary & future perspectives
V V V V
Su m m a r y
Systemic lupus erythematosus is an 
autoim m une disease with clinical 
manifestations in various organs, 
including the kidneys. SLE is a multifac­
torial disease and in its pathogenesis 
environmental, hormonal and genetic  
factors play a role. Therefore, a single 
main pathogenic factor explaining the 
disease has not been identified and, 
therefore , a specific cure for SLE is 
not available. As a consequence, the 
therapy for SLE patients is deem ed to  
a general suppression of the immune  
system. Central in the developm ent of 
SLE is the early formation of antibodies 
to a myriad of nuclear autoantigens. 
The identification and characterisation  
of these initiating nuclear autoantigens  
in SLE could enhance the mecha­
nistic understanding of the underlying 
cause of the disease. Understanding  
of "initiating autoantigens" could 
facilitate the developm ent of more  
specific therapeutic  options for SLE. 
One of the major autoantigens in SLE 
is the nucleosome, which consists of 
146 base pairs of double stranded 
DNA wrapped around an octamer  
of histones. The nucleosome can be 
modified during apoptosis, which is 
deregulated in SLE, and is released 
into the circulation due to a disturbed 
removal of apoptotic material, thereby  
creating the possibility to induce an 
immune response. In this thesis, we  
addressed w hether apoptosis-induced 
histone modifications could be a 
target for lupus autoantibodies.
Since decades there is a debate on the 
targets for lupus autoantibodies and 
the nephritogenicity of these 
autoantibodies. There are tw o
hypotheses for the pathogenicity  
of autoantibodies in the glomerulus  
leading to lupus nephritis. One 
hypothesis assumes cross-reactive 
binding of anti-nucleosome and anti­
DNA antibodies to intrinsic glomerular  
antigens (mechanism 1). The other  
hypothesis proposes binding of au to ­
antibodies via nucleosomes to heparan 
sulfate in the glomerular basement 
m embrane (GBM, mechanism 2). 
In Chapter 2, the pro's and con's of 
these tw o  hypotheses are discussed 
in the context of recent observa­
tions from Rekvig's laboratory, which 
favour the second mechanism. These 
recent findings show that anti-nucle-  
osome, anti-DNA and anti-histone  
antibodies co-localize with chromatin  
in glomerular deposits and not with 
intrinsic glomerular proteins, like 
laminin. Although many reports have 
shown cross-reactivity of anti-chro­
matin autoantibodies with glomerular  
components, these results can be 
questioned because the used anti­
bodies were not properly purified 
and, therefore, were in complex with  
chromatin, such as nucleosomes. 
Consequently, the observed "direct, 
cross-reactive, binding" can be 
explained by nucleosome-mediated  
binding to glomerular structures, in 
particular the GBM.
In Chapter 3, we describe the gen­
eration of monoclonal antibodies  
(mAbs) from lupus mice by selection 
for a higher reactivity with apop- 
totic chromatin compared to normal 
chromatin in ELISA. We envisaged 
that this approach could reveal 
the apoptosis-specific targets for
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these lupus-derived autoantibodies. 
Following this approach, we were  able 
to generate several mAbs specific for  
apoptotic nucleosomes and /or  his- 
tones. These antibodies also showed 
increased reactivity with apoptotic  
cells and blebs as determined by 
immunofluorescence staining. The  
majority of selected mAbs were  
nucleosome-specific w ithout any 
reactivity with histones or DNA as 
determined in ELISA. We could not 
exactly identify the conformational 
epitopes of these nucleosome-specific  
antibodies. Nevertheless, with experi­
ments using trypsin and DNAse I, 
which respectively cleave the free  
N-terminal histon tails and DNA, we  
showed that both the N-terminal 
histone tails and the DNA were cru­
cially involved in the formation of 
the epitope. The involvement of the  
N-terminal tails in the epitopes of 
these nucleosome-specific mAbs was 
confirmed by blocking experiments  
with anti-histone antibodies specific 
for the N-terminal histone tails. We  
found also an increased reactivity of 
these nucleosome-specific mAbs with  
nucleosomes after  induction of hyper- 
acetylation of chromatin, indicating 
that the conformational epitopes  
contain acetyl-groups that are formed  
during apoptosis.
In Chapter 4, the identification of 
the epitope of the lupus-derived 
mAb KM-2 was described. Using the  
random peptide phage display tech­
nique, we localized the epitope in 
the N-terminal tail of histone H4. 
The epitope of KM-2 contained three  
lysines at position 8, 12 and 16, that  
were acetylated. This tri-acetylated
epitope arises within hours after  
induction of apoptosis with campto-  
thecin or anti-FAS in d ifferent cell 
types. Tri-acetylated histone H4 
appeared to be a target for lupus 
autoantibodies from both lupus mice 
and SLE patients. The tri-acetylated  
histone H4 peptide was pathogenic  
after injection in lupus-prone mice, 
while the non-acetylated H4 peptide  
was not pathogenic. The tri-acetylated  
H4 peptide accelerated the disease 
compared to mice treated with a 
unmodified peptide, as revealed  
by more severe glomerular and 
skin lesions and enhancement of 
proteinuria and mortality. Importantly, 
hyperacetylated nucleosomes were  
able to stimulate syngeneic T cells via 
DC maturation in a mixed lymphocyte  
reaction more efficiently than normal 
nucleosomes.
In Chapter 5, we describe the identif i­
cation of another apoptosis-associated 
histone modification as defined by 
the anti-histone H2B antibody LG11-2. 
Previously, the epitope of LG11-2 was 
mapped in histone H2B (amino acids 
6-18). Notably, within this epitope  
phosphorylated serine 14, is con­
sidered to be specific for apoptosis. 
However, for LG11-2 we have identified  
acetylated lysine 12 as the preferred  
epitope, while phosphorylation of S14 
was inhibitory as revealed by peptide  
inhibition ELISA. As determined by 
im m unoblotting acetylation of lysine 
12 occurs at a similar time point 
after apoptosis-induction as phos­
phorylation of serine 14. It could be 
that separate chromatin domains 
exist that contain apoptosis-induced  
acetylated or phosphorylated H2B at,
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respectively, lysine 12 or serine 14. 
Apoptosis-associated acetylation of 
lysine 12 on H2B is a preferred target  
for autoantibodies present before  
onset of the disease as shown by higher 
reactivity of plasma from pre-diseased 
lupus mice, while plasma from dis­
eased lupus mice and patients with 
SLE had similar reactivity. This apop-  
tosis-associated acetylation of lysine 
12 on histone H2B seems therefore  to 
be an im portant initial epitope in the  
developm ent of SLE. Later on during 
the disease also the non-modified  
peptide of H2B is recognized, appar­
ently due to epitope spreading.
In Chapter 6, we describe one of the 
newly generated monoclonal anti­
bodies BT164, that was selected on 
apoptotic nucleosomes (Chapter 3). 
BT164 is an anti-histone antibody  
that recognizes an epitope as deter­
mined by random peptide phage 
display and peptide ELISA's. This 
anti-histone antibody recognizes 
an epitope in the N-terminal tail of 
histone H3 (a.a. 27-32), containing a 
tr i-m ethylated  lysine at position 27. 
Recently, tr i-m ethylated  histone H3 
was also associated with apoptosis 
in another study, which was con­
firmed by our data from immunoblot  
and immunofluorescence staining 
of apoptotic chromatin and cells. 
With the use of siRNA we knocked 
down the histone demethylase spe­
cific for the dem ethylation of H3K27, 
which resulted in hypermethylation  
of chromatin and an increased reac­
tivity of mAb BT164. The significance 
of this tr i-m ethylated  epitope in SLE 
was further analyzed with the use of 
SLE plasma. Autoantibodies present 
in the plasma from lupus mice and 
patients bound to this tri-m ethylated
H3 peptide, which was specific for 
SLE since it was not found in other 
systemic autoim m une diseases, 
such as scleroderma or rheumatoid  
arthritis. Furthermore, this tri-  
methylated histone H3 m otif was 
present in deposits in the glomerular 
basement membranes of lupus mice. 
Importantly, we could detect chro­
matin that contained the epitope of 
BT164 in the circulation of patients  
with lupus nefritis. Also this apoptosis- 
associated H3K27 tri-m ethylation is a 
target for the autoim m une response 
in SLE, leading to the production of 
autoantibodies, which deposit with 
apoptotic chromatin in the glomerular  
basement membranes along the cap­
illary filter.
Fu t u r e  p e r s p e c t ív e s
Future research in Systemic Lupus 
Erythematosus should address the  
role of apoptosis-modified auto ­
antigens, present in apoptotic  
particles, in the stimulation of the  
immune system, with particular 
emphasis on the activation of den ­
dritic cells (DC). This could provide 
insight into the apoptotic struc­
tures and the subsequent pathways 
involved in the activation of DC under 
normal and autoim m une conditions. In 
addition, the possible use of apoptotic  
structures in the induction of to l­
erance in SLE needs to be clarified. If 
successful, these studies could lead to 
the developm ent of novel diagnostic 
and therapeutic options in SLE.
To further address the importance  
of apoptosis-modified autoantigens  
as described in this thesis, their  
presence in apoptotic blebs should
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be evaluated. To this end apoptotic  
particles should be collected from  
apoptotic cell cultures, but also from  
plasma from patients and mice with 
SLE. Characterisation of these apop-  
totic particles could reveal w hether  
apoptotic particles generated in vitro, 
are comparable to those isolated from  
patients with SLE and lupus mice.
The effect of apoptotic blebs or apop-  
tosis-modified autoantigens generated  
in lupus mice and patients on cultured 
myeloid DC (mDC) and plasmacytoid 
DC (pDC) from normal and lupus 
mice, and from patients with SLE and 
controls, has to be evaluated. In this 
system the molecular receptors and 
pathways that mediate DC-activation 
could then be identified, including 
the possible involvement of Toll like 
receptors (TLRs) or other receptors.
The potential T cell stimulatory  
capacity of DCs, challenged with apop-  
totic blebs or apoptosis-modified  
autoantigens, should be determined. 
Finally, the immunogenic or toler- 
izing capacity of apoptotic blebs and 
modified autoantigens should be 
determined in vivo by administrating  
these apoptotic blebs and several 
defined peptides harbouring apop- 
tosis-associated modifications to 
normal and lupus mice, by evaluating 
disease progression in these mice.
The discovery of these apoptosis- 
induced chromatin modifications  
creates exciting novel possibilities for  
fu r ther research.
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Sa m e n v a t t in g
Systemische lupus erythematodes  
(SLE) is een autoimmuunziekte  
waarvan de klinische verschijnselen 
zich manifesteren in meerdere  
organen, onderm eer de nieren. Er 
zijn meerdere oorzaken die een rol 
spelen bij het ontstaan van SLE zoals 
omgevings-, hormonale en genetische 
factoren. Om dat het moeilijk is om 
één specifieke oorzaak voor de ziekte 
te identificeren, is een specifieke 
behandeling voor SLE momenteel niet 
beschikbaar. Als gevolg hiervan, wordt  
als therapie voor patiënten met SLE het 
gehele immuunsysteem onderdrukt. 
Centraal in de ontwikkeling van SLE, 
is de vorming van antilichamen tegen 
een scala van nucleaire antigenen. 
De identificatie en karakterisering  
van deze autoim m uunreactie  tegen 
nucleaire antigenen in SLE zou de 
kennis over het onderliggende  
mechanisme voor het ontstaan van 
de ziekte kunnen vergroten. De kennis 
over "initiërende autoantigenen" kan 
leiden tot de ontwikkeling van meer 
specifieke therapeutische opties voor 
SLE. Het nucleosoom vorm t een van de 
belangrijkste nucleaire autoantigeen  
in SLE. Het nucleosoom bestaat uit 146  
basenparen dubbelstrengs DNA die 
zijn gewikkeld rondom een octam eer  
van histonen. Tijdens apoptose, die 
gedereguleerd is in SLE, worden  
nucleosomen gemodificeerd en 
komen, als gevolg van een verstoorde  
opruiming van apoptotisch materiaal, 
in de circulatie terecht waar zij een 
imm uunreactie kunnen opwekken. In 
dit proefschrift hebben we dan ook 
onderzocht of bij SLE autoantilichamen  
worden gevormd tegen apoptose-  
geïnduceerde histonmodificaties.
Al decennia w ordt er gediscussieerd 
hoe bij SLE autoantilichaam in de nier 
binden en hoe deze ontstekingen  
veroorzaken. Er zijn tw ee  hypotheses 
die proberen te verklaren hoe de 
binding van autoantilichamen in de 
glomerulus kan leiden tot ziekte en 
lupusnefritis. De eerste hypothese 
gaat uit van een kruisreactie van anti-  
nucleosoom en antiDNA antilichamen  
met intrinsieke glomerulaire antigenen 
(mechanisme 1). De andere hypothese  
stelt voor dat de antilichamen via 
nucleosomen aan heparansulfaat 
in de glomerulaire basaalmem-  
braan (GBM) binden (mechanisme  
2). In hoofdstuk 2 worden de argu­
menten voor en tegen deze tw ee  
hypotheses besproken, mede in het 
licht van de recente ontdekkingen in 
Rekvig's laboratorium, die het tw eede  
mechanisme ondersteunen. Deze 
recente bevindingen tonen aan dat 
autoantilichamen colokaliseren met 
chromatine in glomerulaire deposities 
en niet met intrinsieke glomerulaire  
eiwitten, zoals laminine. Hoewel veel 
studies hebben aangetoond dat 
er kruisreactiviteit op treedt van 
autoantilichamen met glomerulaire  
componenten, kunnen deze resultaten 
in twijfel worden getrokken, omdat  
de gebruikte antilichamen niet goed 
gezuiverd waren. Daardoor waren  
deze gebruikte antilichamen nog 
gecomplexeerd met chromatine, zoals 
nucleosomen. Als gevolg hiervan kan 
de waargenomen kruisreactiviteit 
worden verklaard door nucleosoom- 
gemedieerde binding aan glomerulaire  
structuren, met name de GBM.
In hoofdstuk 3 beschrijven we de
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ontwikkeling van monoklonale anti- 
lichamen (mAb) uit lupusmuizen die 
zijn geselecteerd in ELISA op hogere 
reactiviteit met apoptotisch chro­
matine dan met normaal chromatine.
Het doel van deze aanpak was om met 
behulp van lupus autoantilichamen  
apoptose-specifieke targets te 
onthullen. We waren op deze manier  
in staat om verschillende mAbs te 
genereren die specifiek gericht zijn 
tegen apoptotische nucleosomen e n /  
of histonen. Deze antilichamen bleken 
ook bij immunofluorescentie kleuring 
een verhoogde reactiviteit met apop-  
totische cellen en blebs te vertonen. 
Het merendeel van de geselecteerde  
mAbs was nucleosoom-specifiek en 
vertoonden geen reactiviteit met 
alleen histoneiwitten of DNA, zoals 
gemeten in ELISA. De precieze con- 
form ationele  epitopen van deze 
nucleosoom-specifieke antilichamen  
konden we helaas niet bepalen. 
Niettemin, experimenten met trypsine  
en DNAse I, die respectievelijk de 
vrije N-terminale histonstaarten en 
DNA knippen, toonden aan dat zowel 
de N-terminale histonstaarten en het 
DNA cruciaal waren voor de vorming  
van het epitoop. De betrokkenheid van 
de N-terminale staarten in de epitopen  
van deze nucleosoom-specifieke mAbs 
werd bevestigd door het afschermen  
van de N-terminale  histonstaarten  
met behulp van specifieke antihiston 
antilichamen. Tevens vonden we  
een verhoogde reactiviteit van deze 
nucleosoom-specifieke mAbs met 
hypergeacetyleerde nucleosomen, wat  
aangeeft dat acetylgroepen onderdeel 
zijn van het epitoop en dat deze 
optreden tijdens apoptose.
In hoofdstuk 4 w ordt de identificatie
van het epitoop van mAb KM-2, 
afkomstig van lupusmuizen,
beschreven. M e t  de "random peptide  
phage display" techniek hebben we het 
epitoop van KM-2 gelokaliseerd in de 
N-terminale  staart van histon H4. Het 
epitoop van KM-2 bevat drie lysines 
op positie 8, 12 en 16, die worden  
geacetyleerd. Dit tri-geacetyleerde  
epitoop ontstaat al binnen enkele  
uren na inductie van apoptose door 
camptothecine of anti-FAS in verschil­
lende celtypes. Tri-geacetyleerd histon 
H4 bleek ook herkend te worden  
door autoantilichamen van zowel 
lupusmuizen als SLE-patiënten. Het 
tr i-geacetyleerde H4 peptide bleek 
pathogeen te zijn w anneer dit werd  
geïnjecteerd bij lupusmuizen, in tegen­
stelling to t het niet-geacetyleerd H4 
peptide. Het tr i-geacetyleerde H4 
peptide versnelde het ontstaan en 
verhoogde de ernst van de ziekte in 
vergelijking met muizen die behandeld  
werden met het ongemodificeerde  
peptide. Dit bleek uit de meer ernstige 
glomerulaire schade en huidlesies en 
de toenam e van proteïnurie en mor­
talite it  in de groep behandeld met het 
geacetyleerde peptide. Ook konden 
we laten zien dat in een gemengde  
lymfocyt reactie hypergeacetyleerde  
nucleosomen dendritische cellen veel 
effic iënter konden laten matureren  
dan normale nucleosomen en 
daardoor syngene T cellen konden 
stimuleren.
In hoofdstuk 5 beschrijven we de 
identificatie van een andere apoptose-  
geassocieerde histonmodificatie, zoals 
gedefinieerd door het antihiston H2B 
antilichaam LG11-2. Al eerder werd het 
epitoop van LG11-2 in kaart gebracht 
op histon H2B (aminozuren 6-18). 
Binnen dit epitoop bevindt zich serine
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14, dat gefosforyleerd kan worden. 
Gefosforyleerd H2B op serine 14 wordt  
beschouwd als een kenmerk voor 
apoptose. Echter, voor LG11-2 hebben  
we vastgesteld dat geacetyleerd  
lysine 12 w ordt herkend, terwijl de 
fosforylering van serine 14 de binding 
aan H2B remt zoals blijkt uit peptide  
inhibitie ELISA. Bij immunoblotting-  
studies vonden we dat acetylering  
van lysine 12 plaats vindt op een 
vergelijkbaar tijdstip na apoptose-  
inductie als fosforylering van serine 14. 
Het kan zijn dat na apoptose-inductie  
er afzonderlijke chromatinedomeinen  
zijn die geacetyleerd of gefosforyleerd  
worden op respectievelijk, lysine 12 
of serine 14. Apoptose-geassocieerde  
acetylering van lysine 12 is een epitoop  
voor autoantilichamen die gevormd  
worden vóór het ontstaan van de 
ziekte. Dit hebben we aan kunnen 
tonen in ELISA, waarin plasma's van 
lupusmuizen die nog geen ziektesymp-  
tom en hadden een hogere reactiviteit  
gaven met het peptide geacetyleerd  
op lysine 12 dan met een ongem odi­
ficeerd peptide. Dit terwijl plasma's 
van zieke lupusmuizen patiënten  
met SLE geen verschil in reactiviteit  
toonden met beide peptiden. De 
apoptose-gerelateerde acetylering  
van lysine 12 op histon H2B lijkt een 
belangrijke initiërend epitoop voor 
de ontwikkeling van SLE. Later tijdens 
de ziekte worden ook ongem odifi­
ceerde peptiden van H2B herkend, wat  
waarschijnlijk veroorzaakt word door 
"epitope spreading".
In hoofdstuk 6 beschrijven we de 
karakterisering van één van de nieuwe  
monoklonale antilichamen, BT164, 
die geselecteerd is op apoptotische  
nucleosomen (hoofdstuk 3). BT164 is 
een antihiston-antilichaam die een
lineair epitoop herkent. Dit epitoop kon 
daardoor worden geïdentificeerd met 
de "random peptide phage display" 
techniek en een peptide ELISA. BT164 
herkent een epitoop in de N-terminale  
staart van histon H3 (aminozuren 27 
tot 32), met een tr i-gem ethyleerde  
lysine op positie 27. Vrij recent werd  
in een andere studie dit histon H3 tri-  
gemethyleerd op positie 27 (H3K27) 
ook geassocieerd met apoptose. M et  
im m unoblotting en immunofluores-  
centie van apoptotisch chromatine  
en cellen konden we bevestigen dat 
deze modificatie optreedt tijdens 
apoptose. M e t  behulp van "short 
in terference" RNA (siRNA) konden 
we de histondemethylases specifiek 
voor de dem ethylering van H3K27 
uitschakelen, hetgeen resulteerde  
in hypermethylatie van chromatine  
en een verhoogde reactiviteit van 
mAb BT164. De betekenis van dit 
tr igem ethyleerde epitoop in SLE werd  
verder geanalyseerd met behulp van 
SLE plasma's. Autoantilichamen aan­
wezig in het plasma van lupusmuizen 
en SLE-patiënten bonden specifiek 
aan dit tr igem ethyleerde H3 peptide. 
Deze reactiviteit werd niet gevonden 
bij andere systemische autoimmuun-  
ziekten, zoals reumatoïde artritis en 
systemische sclerodermie. Bovendien 
is dit tr igem ethyleerde histon H3 terug  
te vinden in deposities in glomerulaire  
basaalmembranen van lupusmuizen. 
Van belang is dat we in het chromatine  
in de circulatie van SLE-patiënten 
het epitoop van BT164 konden 
identificeren. Ook deze apoptose-  
geassocieerde H3K27 trim ethylatie  
is een doelwit voor de autoim m uun-  
reactie in SLE, hetgeen leidt tot de 
productie van autoantilichamen, die 
deposities vormen met apopto-  
tische chromatine in glomerulaire
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basaalmembranen langs het capillaire 
filter in de nier.
To e k o m s t p e r s p e c t ie v e n
Toekomstig onderzoek gericht op 
systemische lupus erythematodes  
zal de rol verder moeten analyseren 
van apoptose-gemodificeerde auto ­
antigenen, met name van diegene die 
aanwezig zijn in apoptotische partikels. 
De vraag is hoe deze gemodificeerde  
autoantigenen het immuunsysteem  
stimuleren en dan met name hoe 
de activatie van dendritische cellen 
(DC) plaatsvindt. Dit kan meer inzicht 
geven in de apoptotische structuren  
en de processen die betrokken zijn bij 
de activatie van DCs onder normale  
omstandigheden en bij autoim m uun-  
ziekten. Bovendien moet het mogelijke 
gebruik van apoptotische structuren  
voor de inductie van tolerantie in 
SLE worden onderzocht. Als dit lukt, 
kunnen deze studies leiden tot de 
ontwikkeling van nieuwe diagnostische 
en therapeutische mogelijkheden bij 
SLE.
Om het belang van door apoptose  
gemodificeerde autoantigenen, zoals 
beschreven in dit proefschrift, te 
onderbouwen zou hun aanwezigheid  
in apoptotische blebs moeten worden  
geëvalueerd. Hiertoe dienen apopto-  
tische partikels te worden verzameld  
van apoptotische cellen, maar ook 
uit plasma van patiënten met SLE en 
lupusmuizen. Karakterisering van deze 
apoptotische partikels kan aantonen  
of de apoptotische partikels die in vitro 
gegenereerd worden, vergelijkbaar zijn 
met diegene die geïsoleerd worden  
uit plasma's van patiënten met SLE en 
lupusmuizen.
Tevens moet het effect worden  
geëvalueerd van apoptose-gemodi-  
ficeerde antigenen en apoptotische  
blebs uit lupusmuizen en SLE-patiënten 
op myeloïde DC (mDC) en plasma- 
cytoïde DC (pDC) van normale en 
lupusmuizen, en van SLE- en controle  
patiënten. Op deze wijze kunnen de 
moleculaire receptoren en processen 
die activering van DCs aansturen, 
worden vastgesteld. Ook de mogelijke 
betrokkenheid van "Toll like" recep­
toren (TLR) of eventuele andere  
receptoren moet worden bekeken. 
Bovendien moet de potentiële T cel 
stimulerende capaciteit van DCs, die 
zijn geïncubeerd met apoptotische  
blebs of apoptotisch-gemodificeerde  
autoantigenen, worden bepaald. 
Tenslotte, moet de immunogene of 
tolerantie inducerende capaciteit van 
apoptotische blebs en gemodificeerde  
autoantigenen in vivo worden bepaald. 
Dit kan door deze apoptotische blebs 
en een aantal gedefinieerde peptiden  
die apoptose-geassocieerde modi­
ficaties bevatten, toe te dienen aan 
normale en lupusmuizen en vervolgens 
de progressie van de ziekte in deze 
muizen te analyseren. De ontdekking  
van deze door apoptose geïnduceerde  
chromatine modificaties zorgt voor 
spannende nieuwe mogelijkheden  
voor verder onderzoek.
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l is t  of abbreviations
v
Aa Amino acids
Ac Acetyl
ANA Anti-nuclear antibodies
AnV Annexin V
APC Antigen presenting cell
bp Base pairs
BSA Bovine serum albumin
CPT Camptothecin
DAPI 4',6-diamidino-2-phenylindole
DC Dendritic cell
DIL Drug-induced lupus
dsDNA Double stranded deoxyribonucleic acid
DTH Delayed type hypersensitivity
EDD Electron-dense deposits
ELISA Enzyme-linked immunosorbent assay
FCS Fetal calf serum
GBM Glomerular basement membrane
H1-4 Histone 1-4
HAT Histone acetyl transferase
HDAC Histone deacetylase
HS Heparan sulfate
Ig Immunoglobulin
kDa KiloDalton
mAb Monoclonal antibody
Me Methyl
PBS Phosphate buffered saline
Ph Phosphoryl
PI Propidium iodide
PTM Posttranslational modification
RA Rheumatoid arthritis
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
SLE Systemic lupus erythematosus
SLEDAI Systemic Lupus Erythematosus Disease Activity Index
SSc Systemic scleroderma
TLR Toll like receptor
TNF-a Tumor necrosis factor a
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end labelling
TSA Trichostatin A
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Chapter 1: figure 1
H1
H2A H2B
Figure 1. The nucleosome.
Double stranded DNA (grey) is wrapped around the core histones H2A, H2B, H3 and H4, two copies of each) with the 
linker histone H1 attached on the outside of the nucleosome. The N-terminal tails are protruding from the core particle6.
Chapter 1: figure- 2
Figure 2. Schematic representation on the hypothesis of the development of systemic lupus erythematosus29.
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. GBM
Capillary lumen
Figure 1.
A) Schematic representation of the localization of glomerular targets for nephritogenic autoantibodies. Antibodies 
against laminin and type IV collagen bind in the glomerular basement membrane (GBM). In vivo-bound Ig and TUNEL 
staining colocalize in electron-dense deposits (EDD; gray area) in the GBM with probing antibodies for histone H1, histone 
H3, DNA, and TATA binding protein (TBP).
B) Colocalization immunoelectron microscopy of electron-dense deposits in a kidney section from an (NZW x NZB)F1 
mouse, with TUNEL staining. In electron-dense deposits, there is colocalization of in vivo-bound antibodies (5 nm gold 
particles) (green) with TUNEL staining (10 nm gold particles) (orange). Notably, TUNEL did not stain glomerular struc­
tures outside electron-dense deposits, which indicates that there was no cross-reactive binding to intrinsic glomerular 
structures.
C) Colocalization immunoelectron microscopy of electron-dense deposits in a kidney section from an (NZW x NZB)F1 
mouse, with anti-laminin staining. In electron-dense deposits, there is no colocalization of in vivo-bound antibodies (5 
nm gold particles) (green) and anti-laminin probes (10 nm gold particles) (red), whereas the GBM stained positively 
for laminin outside electron-dense deposits (adapted, with permission, from the American Society for Investigative 
Pathology9)
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Chapter 3: figure 1
Figure 1. Hypothesis for the sequence of events in lupus graphically depicted.
Autoantibodies are formed against nucleosomes containing apoptosis-induced modifications. These initiating antigens 
are not cleared sufficiently in systemic lupus erythematosus. This leads to uptake by antigen presenting cells (APC), and 
to immunogenic presentation to autoreactive T cells, which stimulate B cells to produce autoantibodies with subse­
quently broadening of the autoantibody repertoire by epitope spreading. The produced antibodies in complex with 
chromatin deposit in basement membranes, causing inflammations as illustrated here for the kidney.
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Figure 4. Influence of the nucleosome structure and composition on the reactivity of monoclonal antibodies.
A) Cleavage sites of trypsin are depicted in the protein structure of the individual histones H2A, H2B, H3 and H4. The 
pink parts are removed after trypsin-treatment. On the right is a representation of the 3D structure of the nucleosome, 
either untreated or treated with trypsin, which leads to the removal of the C-and N-terminal tails protruding from the 
nucleosome.
B) Treatment of nucleosomes with trypsin or DNase I leads to a decreased reactivity of the anti-apoptotic-nucleosome 
antibodies (expressed as relative reactivity) compared to untreated nucleosomes (set at 1, dotted line). Anti-histone 
antibody #34 was used as a positive control for the removal of the N-terminal tails. Anti-DNA antibody #36 was used as 
a control for equal loading after trypsin treatment and as a positive control for DNasel treatment. These results show 
that the histone tails and DNA play an important role in the formation of the epitope of the anti-nucleosome antibodies, 
either direct as being part of the epitope or indirectly by their impact on the conformation of the epitope.
C) Anti-apoptotic nucleosome antibodies show the highest reactivity with reconstituted nucleosomal complexes 
containing all nucleosome components (H2A/H2B/H3/H4)DNA. Reactivity with subnucleosomal complexes (H2A/H2B) 
DNA or (H3/H4)DNA is lower.
D) The binding of the anti-apoptotic nucleosome antibodies to the nucleosome can be inhibited by specific anti-histone 
antibodies. Apparently, the histone tails of H2A and/or H4 are important for the epitope of antibodies BT116 and BT124, 
whereas the tail of histone H3 plays a role in the epitope of antibody BT131. Binding of BT162 is not inhibited by any of 
the used anti-histone antibodies.
Colour figures 119
Co
lo
ur
 f
ig
ur
es
Chapter 4: figure 2
camptothecin 
-  + B
KM-2
H4K5ac
H4K8ac
H4K12ac
H4K16ac
H4K5,8,12,16ac
H2AK5ac
H2AK9ac
H2BS14p
H3.1
actin
0 1 2  3 4 0 4 24 (hrs)
Chapter '4: figure 3  
A
-4^ -
B T S A C P T - T S A C P T
« « • 6
0 • 1 7  •  • m
m «
— • 8 1 ■ i
9 «  # •
*  - c
x .-& 
I I  1ili Mia
Figure 2. Recognition of apoptosis-induced hyper- 
acetylation of H4 and H2A by the lupus mouse-derived 
autoantibody KM-2.
A) Enhanced reactivity of KM-2, anti-H4-AcK5, anti- 
H4-AcK8, anti-H4-AcK12, anti-H4-AcK16, anti-H2A-AcK5, 
anti-H2A-AcK9, and an antibody to H2B phosphorylated at 
serine 14 (anti-H2B-PhS14) with sodium dodecyl sulfate­
polyacrylamide gel electrophoresis (SDS-PAGE)-resolved 
histones that were acid-extracted from Jurkat cells that 
had been induced to undergo apoptosis by 4 hours of 
incubation with camptothecin (CPT). An antibody specific 
for actin was used as an internal loading control.
B) Recognition by KM-2 of apoptotic blebs of Jurkat 
cells that stain positively by TUNEL. Staining with 
4',6-diamidino-2-phenylindole (DAPI) reveals fragmen­
tation of the nucleus. (Original magnification x 400.)
C) Concomitant cleavage of poly(ADP-ribose) polymerase 
2 (PARP-2) with enhanced reactivity of KM-2 with 
SDS-PAGE-resolved H4 and H2A extracted from Jurkat 
cells induced to undergo apoptosis by CPT and anti-Fas 
antibody for the indicated time periods. The progress 
of apoptosis was analyzed by measuring the percentage 
of cells that stained positive for annexin V-fluorescein 
isothiocyanate (AN) and propidium iodide (PI).
D) Relative histone acetyltransferase (HAT) and histone 
deacetylase (HDA) activity in non-apoptotic Jurkat cells 
and Jurkat cells in early apoptosis induced by CPT or 
anti-Fas antibody. Activities in untreated cells are set at 1. 
Values are the mean and SD. P values indicate significant 
differences compared with untreated cells. See figure 1 
for other definitions.
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Figure 3. Recognition of apoptotic histones and 
acetylated histones by lupus-derived plasma samples.
A) Reactivity of plasma samples (given in absolute 
optical density [OD] values measured at 450 nm) from 
6-9-week-old (before disease onset) MRL/lpr lupus mice 
(n=11), >20-week-old diseased MRL/lpr lupus mice 
(n=13), and systemic lupus erythematosus (SLE) patients 
(n=35) with non-acetylated H4 peptide (residues 1-22) 
and the corresponding H4 peptide tri-acetylated at K8, 
K12, and K16. Horizontal lines indicate the mean. P values 
were obtained by Student's paired t-test.
B) Reactivity of plasma from 9 SLE patients with resolved 
histones extracted from Jurkat cells cultured without 
addition or with TSA or camptothecin (CPT).
C) Immunofluorescence staining of Jurkat cells cultured 
without addition or with TSA or CPT by plasma from 9 
SLE patients. Note that apoptotic blebs are intensely 
stained after induction of apoptosis. A pool of plasma 
samples from healthy individuals was used as a control 
(C). Semi-quantitative scoring of the blots and immuno­
fluorescence staining is summarized in table 1. (Original 
magnification x 400.) DAPI= 4',6-diamidino-2-phenylindole 
(see figure 1 for other definitions).
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Figure 1. The lupus-derived autoantibody LG11-2 preferably binds to H2B acetylated at K12.
A) Reactivity of the lupus-derived antibody LG11-2 with different H2B peptides. The reactivity was measured in a peptide 
competition ELISA in which unmodified H2B (aa 1-18) peptide was coated. LG11-2 was pre-incubated with unmodified 
or modified H2B peptides, after which its reactivity to the coated unmodified H2B peptide was determined. Binding 
of LG11-2 to unmodified H2B peptide (1-18) is most efficiently inhibited by a H2B peptide acetylated at K12. Peptides 
phosphorylated at S14 and/or acetylated at K5 and K15 are far less efficient competitors compared to unmodified H2B 
peptide and the peptide acetylated at K12. IC50 values are defined as the amount (expressed in nM) of competitor 
peptide required to inhibit the maximal LG11-2 binding to coated unmodified H2B peptide by 50%.
B) Immunofluorescence double staining of LG11-2 (green) and anti-H2BS14p (red) on apoptotic (induced by CPT) Jurkat 
cells did not reveal a significant co-localization as depicted in the merge by yellow. These in situ data confirm the peptide 
ELISA data in panel A. The images are representative for numerous observations.
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Figure 2. The lupus-derived autoantibody LG11-2 preferably recognizes hyperacetylated and apoptotic histones.
A) LG11-2 shows on western immunoblot an enhanced binding to histones extracted from cells treated with trichostatin 
A (TSA) or camptothecin (CPT) compared to normal (control) cells. Antibody-antigen concentrations were optimalized to 
maximally visualize differences in reactivity between control, hyperacetylated and apoptotic histones.
B) LG11-2 shows an enhanced binding to apoptotic (CPT) and hyperacetylated (TSA) Jurkat cells compared to normal 
(control) cells. LG11-2 staining is visualized in green and DAPI in the pseudo-colour red in the merged images. Antibody 
concentration was optimalized to maximally visualize differences in reactivity between control, hyperacetylated and 
apoptotic histones.
C) Immunofluorescence double staining of LG11-2 (green) and anti-H2BK12ac (red) on TSA treated cells revealed a signif­
icant co-localization as indicated by yellow in the merge.
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Figure 1. Higher reactivity of lupus-derived mAb BT164 
with apoptotic chromatin.
A) BT164 shows a higher reactivity with apoptotic 
nucleosomes (dashed line) in ELISA compared to control 
nucleosomes (continuous line).
B) BT164 shows an increased immunofluorescent 
staining with apoptotic cells compared to control cells. 
DAPI = blue, BT164 = green and anti-H2BS14p = red. 
Furthermore, the epitope of BT164 appears to be translo­
cated to the surface of apoptotic blebs as most staining in 
the apoptotic cell is observed in the blebs. Apoptosis was 
induced by camptothecin.
C) An enhanced reactivity of BT164 with apoptotic 
histone H3 on western blot is observed already 4 hours 
after induction of apoptosis. As a control, #34 recognizing 
non-modified histone H3, is used as a probe. With #34 
no difference between control and apoptotic histones is 
observed, and equal loading is demonstrated. Apoptosis- 
associated tri-acetylation of H4 as probed by KM-2 also 
increases in apoptotic extracts as reported previously.8 
The rate of apoptosis is measured by staining with 
Annexin V (AnV) and Propidium Iodide (PI). AnV-positive/ 
PI-negative cells represent early apoptotic cells; 
AnV-positive/PI-positive cells represent late apoptotic 
cells.
Figure 3. BT164 specifically stains and precipitates 
H3K27me3.
A) BT164 (green) immunofluorescence staining colocalizes 
(yellow) only with antibodies against methylated H3K27 
(red). No colocalization is observed with antibodies (red) 
directed against other possible modifications present in 
the epitope of BT164. Also antibody #34 that recognizes 
unmodified H3, does not show colocalization with bT164.
B) BT164 immunoprecipitates apoptotic tri-methylated 
histone H3K27. Apoptotic chromatin immunoprecipi- 
tated with BT164 is recognized by BT164, as expected, 
and by the anti-H3K27me3 antibody, while precipitated 
chromatin does not contain acetylated H3K27 since no 
staining is observed with anti-H3K27ac.
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Figure 4. H3K27me3 is present in glomerular deposits, in plasma and is recognized by lupus autoantibodies.
A) Extracellular glomerular staining of kidney sections of MRL/lpr lupus mice by BT 164. In MRL+/+ mice is only a nuclear 
staining of the glomerular cells is observed. In MRL/lpr mice extracellular staining is observed, which colocalizes with 
anti-laminin-1 staining expressed in the glomerular basement membrane. In the merge the colocalization of BT164 
(green) with the nuclei (DAPI) and laminin-1 (red) is visualized.
B) Tri-methylated H3 (15 kDa) is present in the plasma form SLE patients, but not in controls. Plasma from a SLE patient 
or control (C) was affinity purified with a BT164 column. The eluate was resolved by SDS-PAGE, blotted and probed with 
BT164. Molecular weight is indicated in kDa.
C) Higher reactivity with the H3 peptide tri-methylated on K27 compared to non-modified H3 peptide of 13/18 plasma 
from pre-diseased lupus mice, 24/28 plasma from diseased lupus mice, 17/24 plasma from SLE patients with lupus 
nephritis, and 13/16 plasma from SLE patients without lupus nephritis . Plasma from control patients with rheumatic 
arthritis (RA) or systemic scleroderma (SSc) do not show (enhanced) reactivity with the tri-methylated peptide H3 
peptide. Plasma from healthy control humans and mice do not show any reactivity with either peptide (data not shown). 
*P< 0.05; **P <0.01; ***P<0.001
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